{ "version": "2.2", "instance": { "irwd-20241231x10k.htm": { "nsprefix": "irwd", "nsuri": "http://www.ironwoodpharma.com/20241231", "dts": { "schema": { "local": [ "irwd-20241231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd", "https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd", "https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "calculationLink": { "local": [ "irwd-20241231_cal.xml" ] }, "definitionLink": { "local": [ "irwd-20241231_def.xml" ] }, "labelLink": { "local": [ "irwd-20241231_lab.xml" ] }, "presentationLink": { "local": [ "irwd-20241231_pre.xml" ] }, "inline": { "local": [ "irwd-20241231x10k.htm" ] } }, "keyStandard": 448, "keyCustom": 136, "axisStandard": 34, "axisCustom": 0, "memberStandard": 53, "memberCustom": 52, "hidden": { "total": 31, "http://fasb.org/us-gaap/2024": 28, "http://xbrl.sec.gov/dei/2024": 3 }, "contextCount": 354, "entityCount": 1, "segmentCount": 112, "elementCount": 1049, "unitCount": 11, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 1219, "http://xbrl.sec.gov/dei/2024": 39, "http://xbrl.sec.gov/cyd/2024": 15, "http://xbrl.sec.gov/ecd/2024": 5, "http://fasb.org/srt/2024": 1 }, "report": { "R1": { "role": "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation", "longName": "995200090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets", "longName": "995200100 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "As_Of_12_31_2024_JibFf-avkkWf6yqBT8Gysw", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_JibFf-avkkWf6yqBT8Gysw", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "unique": true } }, "R3": { "role": "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheetsParenthetical", "longName": "995200105 - Statement - Consolidated Balance Sheets (Parenthetical)", "shortName": "Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "As_Of_12_31_2024_JibFf-avkkWf6yqBT8Gysw", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_-u5k1rPZgUmkGeZWt8Lylg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_JibFf-avkkWf6yqBT8Gysw", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_-u5k1rPZgUmkGeZWt8Lylg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfIncomeLoss", "longName": "995200200 - Statement - Consolidated Statements of Income (Loss)", "shortName": "Consolidated Statements of Income (Loss)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "irwd:RestructuringExpenseBenefit", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "unique": true } }, "R5": { "role": "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss", "longName": "995200300 - Statement - Consolidated Statements of Comprehensive Income (Loss)", "shortName": "Consolidated Statements of Comprehensive Income (Loss)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "unique": true } }, "R6": { "role": "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit", "longName": "995200400 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)", "shortName": "Consolidated Statements of Stockholders' Equity (Deficit)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "As_Of_12_31_2021_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_jHowgtp25EO2xfo3iGOBHw", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2021_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember_jHowgtp25EO2xfo3iGOBHw", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows", "longName": "995200500 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:Depreciation", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "unique": true } }, "R8": { "role": "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical", "longName": "995200505 - Statement - Consolidated Statements of Cash Flows (Parenthetical)", "shortName": "Consolidated Statements of Cash Flows (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "As_Of_12_31_2024_JibFf-avkkWf6yqBT8Gysw", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2022_Ac7j1kCQREKu06YlCrn_8w", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "unique": true } }, "R9": { "role": "http://www.ironwoodpharma.com/role/DisclosureNatureOfBusiness", "longName": "995210101 - Disclosure - Nature of Business", "shortName": "Nature of Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "longName": "995210201 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.ironwoodpharma.com/role/DisclosureAcquisitions", "longName": "995210301 - Disclosure - Acquisitions", "shortName": "Acquisitions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:AssetAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:AssetAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerShare", "longName": "995210401 - Disclosure - Net Income (Loss) Per Share", "shortName": "Net Income (Loss) Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreements", "longName": "995210501 - Disclosure - Collaboration, License, and Other Agreements", "shortName": "Collaboration, License, and Other Agreements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstruments", "longName": "995210601 - Disclosure - Fair Value of Financial Instruments", "shortName": "Fair Value of Financial Instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.ironwoodpharma.com/role/DisclosureLeases", "longName": "995210701 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.ironwoodpharma.com/role/DisclosurePropertyAndEquipment", "longName": "995210801 - Disclosure - Property and Equipment", "shortName": "Property and Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.ironwoodpharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities", "longName": "995210901 - Disclosure - Accrued Expenses and Other Current Liabilities", "shortName": "Accrued Expenses and Other Current Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.ironwoodpharma.com/role/DisclosureDebt", "longName": "995211001 - Disclosure - Debt", "shortName": "Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.ironwoodpharma.com/role/DisclosureCommitmentsAndContingencies", "longName": "995211101 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:CommitmentsContingenciesAndGuaranteesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:CommitmentsContingenciesAndGuaranteesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.ironwoodpharma.com/role/DisclosureStockholdersEquity", "longName": "995211201 - Disclosure - Stockholders' Equity", "shortName": "Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlans", "longName": "995211301 - Disclosure - Employee Stock Benefit Plans", "shortName": "Employee Stock Benefit Plans", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxes", "longName": "995211401 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.ironwoodpharma.com/role/DisclosureRetirementPlans", "longName": "995211501 - Disclosure - Retirement Plans", "shortName": "Retirement Plans", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.ironwoodpharma.com/role/DisclosureWorkforceReductionAndRestructuring", "longName": "995211601 - Disclosure - Workforce Reduction and Restructuring", "shortName": "Workforce Reduction and Restructuring", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.ironwoodpharma.com/role/DisclosureSegmentReporting", "longName": "995211701 - Disclosure - Segment Reporting", "shortName": "Segment Reporting", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.ironwoodpharma.com/role/DisclosureSelectedQuarterlyFinancialDataUnaudited", "longName": "995211801 - Disclosure - Selected Quarterly Financial Data (Unaudited)", "shortName": "Selected Quarterly Financial Data (Unaudited)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R27": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "Duration_10_1_2023_To_12_31_2023_mdYduDgAnUOMY8vNriFJKw", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "us-gaap:QuarterlyFinancialInformationTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": null }, "R28": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "Duration_10_1_2024_To_12_31_2024_8wbb371dtUeMP02yO8NnJg", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_10_1_2024_To_12_31_2024_8wbb371dtUeMP02yO8NnJg", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R29": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "longName": "995447 - Disclosure - Insider Trading Policies and Procedures", "shortName": "Insider Trading Policies and Procedures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "29", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R30": { "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure", "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure", "shortName": "Cybersecurity Risk Management and Strategy Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "30", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "longName": "99920202 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "31", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "longName": "99930203 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsTables", "longName": "99930303 - Disclosure - Acquisitions (Tables)", "shortName": "Acquisitions (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:AssetAcquisitionTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AssetAcquisitionTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:AssetAcquisitionTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AssetAcquisitionTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerShareTables", "longName": "99930403 - Disclosure - Net Income (Loss) Per Share (Tables)", "shortName": "Net Income (Loss) Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsTables", "longName": "99930503 - Disclosure - Collaboration, License, and Other Agreements (Tables)", "shortName": "Collaboration, License, and Other Agreements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsTables", "longName": "99930603 - Disclosure - Fair Value of Financial Instruments (Tables)", "shortName": "Fair Value of Financial Instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.ironwoodpharma.com/role/DisclosureLeasesTables", "longName": "99930703 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.ironwoodpharma.com/role/DisclosurePropertyAndEquipmentTables", "longName": "99930803 - Disclosure - Property and Equipment (Tables)", "shortName": "Property and Equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": null }, "R39": { "role": "http://www.ironwoodpharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables", "longName": "99930903 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)", "shortName": "Accrued Expenses and Other Current Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.ironwoodpharma.com/role/DisclosureDebtTables", "longName": "99931003 - Disclosure - Debt (Tables)", "shortName": "Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTables", "longName": "99931303 - Disclosure - Employee Stock Benefit Plans (Tables)", "shortName": "Employee Stock Benefit Plans (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesTables", "longName": "99931403 - Disclosure - Income Taxes (Tables)", "shortName": "Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "irwd:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignAndComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "irwd:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignAndComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansTables", "longName": "99931503 - Disclosure - Retirement Plans (Tables)", "shortName": "Retirement Plans (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "43", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.ironwoodpharma.com/role/DisclosureWorkforceReductionAndRestructuringTables", "longName": "99931603 - Disclosure - Workforce Reduction and Restructuring (Tables)", "shortName": "Workforce Reduction and Restructuring (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "44", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.ironwoodpharma.com/role/DisclosureSelectedQuarterlyFinancialDataUnauditedTables", "longName": "99931803 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Tables)", "shortName": "Selected Quarterly Financial Data (Unaudited) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "45", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:QuarterlyFinancialInformationTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:QuarterlyFinancialInformationTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentInformationDetails", "longName": "99940201 - Disclosure - Summary of Significant Accounting Policies - Segment Information (Details)", "shortName": "Summary of Significant Accounting Policies - Segment Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "Unit_Standard_segment_UPliYGwpvUacsA7Qw8zaYg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:NumberOfReportableSegments", "us-gaap:NumberOfReportableSegments", "p", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": null }, "R47": { "role": "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails", "longName": "99940202 - Disclosure - Summary of Significant Accounting Policies - Cash and Cash Equivalents (Details)", "shortName": "Summary of Significant Accounting Policies - Cash and Cash Equivalents (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "As_Of_12_31_2024_JibFf-avkkWf6yqBT8Gysw", "name": "us-gaap:CashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_JibFf-avkkWf6yqBT8Gysw", "name": "us-gaap:CashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashDetails", "longName": "99940203 - Disclosure - Summary of Significant Accounting Policies - Restricted Cash (Details)", "shortName": "Summary of Significant Accounting Policies - Restricted Cash (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "As_Of_12_31_2024_JibFf-avkkWf6yqBT8Gysw", "name": "us-gaap:RestrictedCash", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "us-gaap:RestrictedCash", "p", "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": null }, "R49": { "role": "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableDetails", "longName": "99940204 - Disclosure - Summary of Significant Accounting Policies - Accounts Receivable (Details)", "shortName": "Summary of Significant Accounting Policies - Accounts Receivable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "As_Of_12_31_2024_JibFf-avkkWf6yqBT8Gysw", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "us-gaap:AllowanceForDoubtfulAccountsReceivable", "p", "us-gaap:TradeAndOtherAccountsReceivablePolicy", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_JibFf-avkkWf6yqBT8Gysw", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "us-gaap:AllowanceForDoubtfulAccountsReceivable", "p", "us-gaap:TradeAndOtherAccountsReceivablePolicy", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails", "longName": "99940205 - Disclosure - Summary of Significant Accounting Policies - Concentrations of Credit Risk (Details)", "shortName": "Summary of Significant Accounting Policies - Concentrations of Credit Risk (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_srt_MajorCustomersAxis_irwd_AbbviePlcMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_KcA1osKcokmtYBCRA_I-xA", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "Unit_Standard_pure_o_LvPScFJEyjZOySCfKmrA", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "td", "tr", "table", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_srt_MajorCustomersAxis_irwd_AbbviePlcMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_KcA1osKcokmtYBCRA_I-xA", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "Unit_Standard_pure_o_LvPScFJEyjZOySCfKmrA", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "td", "tr", "table", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails", "longName": "99940206 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)", "shortName": "Summary of Significant Accounting Policies - Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_EXgZ2GpPgkqjKYRUGP79uQ", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_EXgZ2GpPgkqjKYRUGP79uQ", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesIntangibleAssetsDetails", "longName": "99940207 - Disclosure - Summary of Significant Accounting Policies - Intangible Assets (Details)", "shortName": "Summary of Significant Accounting Policies - Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "As_Of_12_31_2024_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_irwd_AssembledWorkforceMember_w6R_O7cJq0uBN2Pulj43mg", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:IntangibleAssetsFiniteLivedPolicy", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": null }, "R53": { "role": "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDerivativeAssetsAndLiabilitiesDetails", "longName": "99940208 - Disclosure - Summary of Significant Accounting Policies - Derivative Assets and Liabilities (Details)", "shortName": "Summary of Significant Accounting Policies - Derivative Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "As_Of_9_16_2019_us-gaap_DebtInstrumentAxis_irwd_ConvertibleSeniorNotes225PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_VRX_TYkQqkWig0HjI0kTGA", "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "unitRef": "Unit_Standard_pure_o_LvPScFJEyjZOySCfKmrA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "i", "p", "us-gaap:DebtDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": null }, "R54": { "role": "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails", "longName": "99940209 - Disclosure - Summary of Significant Accounting Policies - Revenue Recognition (Details)", "shortName": "Summary of Significant Accounting Policies - Revenue Recognition (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_irwd_AbbviePlcMember_srt_StatementGeographicalAxis_country_US_NNyOgoYm30CHUbyu4V_CPQ", "name": "irwd:CollaborativeArrangementPercentageOfPreTaxNetProfitLoss", "unitRef": "Unit_Standard_pure_o_LvPScFJEyjZOySCfKmrA", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_irwd_AbbviePlcMember_srt_StatementGeographicalAxis_country_US_NNyOgoYm30CHUbyu4V_CPQ", "name": "irwd:CollaborativeArrangementPercentageOfPreTaxNetProfitLoss", "unitRef": "Unit_Standard_pure_o_LvPScFJEyjZOySCfKmrA", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPatentCostsDetails", "longName": "99940210 - Disclosure - Summary of Significant Accounting Policies - Patent Costs (Details)", "shortName": "Summary of Significant Accounting Policies - Patent Costs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_3zLifOjqSEyiF99KCQe2oQ", "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "irwd:PatentCostsPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "unique": true } }, "R56": { "role": "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails", "longName": "99940211 - Disclosure - Summary of Significant Accounting Policies - New Accounting Pronouncements (Details)", "shortName": "Summary of Significant Accounting Policies - New Accounting Pronouncements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "As_Of_12_31_2024_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202307Member_B6eQd0aCk06_w218gupnCA", "name": "us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202307Member_B6eQd0aCk06_w218gupnCA", "name": "us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCumulativeEffectAdjustmentTabularDisclosureDetails", "longName": "99940212 - Disclosure - Summary of Significant Accounting Policies - Cumulative-effect Adjustment - Tabular Disclosure (Details)", "shortName": "Summary of Significant Accounting Policies - Cumulative-effect Adjustment - Tabular Disclosure (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "As_Of_12_31_2024_JibFf-avkkWf6yqBT8Gysw", "name": "us-gaap:DeferredIncomeTaxAssetsNet", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2021_QYcSCfNIo0ChQVuvdUbPLA", "name": "us-gaap:DeferredIncomeTaxAssetsNet", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "unique": true } }, "R58": { "role": "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCumulativeEffectAdjustmentAdditionalInformationDetails", "longName": "99940213 - Disclosure - Summary of Significant Accounting Policies - Cumulative-effect Adjustment - Additional Information (Details)", "shortName": "Summary of Significant Accounting Policies - Cumulative-effect Adjustment - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_C9d6dFAK8Em5nwarGrxbZg", "name": "irwd:InterestExpenseNoncashExpectedIncreaseDecreaseDuringPeriod", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_C9d6dFAK8Em5nwarGrxbZg", "name": "irwd:InterestExpenseNoncashExpectedIncreaseDecreaseDuringPeriod", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsGeneralInformationDetails", "longName": "99940301 - Disclosure - Acquisitions - General Information (Details)", "shortName": "Acquisitions - General Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "As_Of_6_29_2023_us-gaap_AssetAcquisitionAxis_irwd_VectivbioHoldingAgAndItsSubsidiariesMember_c4J0WCC9QE2JwvStJzd70A", "name": "irwd:AssetAcquisitionOwnershipInterestPercentage", "unitRef": "Unit_Standard_pure_o_LvPScFJEyjZOySCfKmrA", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "us-gaap:AssetAcquisitionTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_29_2023_us-gaap_AssetAcquisitionAxis_irwd_VectivbioHoldingAgAndItsSubsidiariesMember_c4J0WCC9QE2JwvStJzd70A", "name": "irwd:AssetAcquisitionOwnershipInterestPercentage", "unitRef": "Unit_Standard_pure_o_LvPScFJEyjZOySCfKmrA", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "us-gaap:AssetAcquisitionTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsNoncontrollingInterestDetails", "longName": "99940302 - Disclosure - Acquisitions - Noncontrolling Interest (Details)", "shortName": "Acquisitions - Noncontrolling Interest (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_fCHdzTjoQEWzMV7M6Z6FLg", "name": "us-gaap:PaymentsToMinorityShareholders", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_12_12_2023_To_12_12_2023_srt_OwnershipAxis_irwd_VectivbioHoldingAgAndItsSubsidiariesMember_6iP7Ti0dC0ydkwdtd2vL2g", "name": "us-gaap:PaymentsToMinorityShareholders", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:AssetAcquisitionTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "unique": true } }, "R61": { "role": "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsTotalConsiderationPaidTabularDisclosureDetails", "longName": "99940303 - Disclosure - Acquisitions - Total Consideration Paid - Tabular Disclosure (Details)", "shortName": "Acquisitions - Total Consideration Paid - Tabular Disclosure (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "Duration_6_29_2023_To_6_29_2023_us-gaap_AssetAcquisitionAxis_irwd_VectivbioHoldingAgAndItsSubsidiariesMember_qtjAeyo7rE2QYmZqzaPuUQ", "name": "irwd:AssetAcquisitionConsiderationTransferredCashConsiderationPaidSellingShareholders", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:AssetAcquisitionTableTextBlock", "us-gaap:AssetAcquisitionTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_6_29_2023_To_6_29_2023_us-gaap_AssetAcquisitionAxis_irwd_VectivbioHoldingAgAndItsSubsidiariesMember_qtjAeyo7rE2QYmZqzaPuUQ", "name": "irwd:AssetAcquisitionConsiderationTransferredCashConsiderationPaidSellingShareholders", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:AssetAcquisitionTableTextBlock", "us-gaap:AssetAcquisitionTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsTotalConsiderationPaidAdditionalInformationDetails", "longName": "99940304 - Disclosure - Acquisitions - Total Consideration Paid - Additional Information (Details)", "shortName": "Acquisitions - Total Consideration Paid - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "As_Of_6_29_2023_us-gaap_AssetAcquisitionAxis_irwd_VectivbioHoldingAgAndItsSubsidiariesMember_c4J0WCC9QE2JwvStJzd70A", "name": "irwd:AssetAcquisitionConsiderationTransferredCashConsiderationPaidSellingShareholdersSharesTenderedShares", "unitRef": "Unit_Standard_shares_40V2pP1iRE64oUYSuAdgzA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_29_2023_us-gaap_AssetAcquisitionAxis_irwd_VectivbioHoldingAgAndItsSubsidiariesMember_c4J0WCC9QE2JwvStJzd70A", "name": "irwd:AssetAcquisitionConsiderationTransferredCashConsiderationPaidSellingShareholdersSharesTenderedShares", "unitRef": "Unit_Standard_shares_40V2pP1iRE64oUYSuAdgzA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsAcquiredInProcessResearchAndDevelopmentDetails", "longName": "99940305 - Disclosure - Acquisitions - Acquired In-process Research and Development (Details)", "shortName": "Acquisitions - Acquired In-process Research and Development (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_fCHdzTjoQEWzMV7M6Z6FLg", "name": "irwd:AssetAcquisitionAcquiredInProcessResearchAndDevelopmentExpense", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2023_To_6_30_2023_us-gaap_AssetAcquisitionAxis_irwd_VectivbioHoldingAgAndItsSubsidiariesMember_g8H31IJGX0CwnLt-bIr4Zg", "name": "irwd:AssetAcquisitionAcquiredInProcessResearchAndDevelopmentExpense", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-8", "ancestors": [ "span", "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "unique": true } }, "R64": { "role": "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails", "longName": "99940306 - Disclosure - Acquisitions - Assets Acquired and Liabilities Assumed (Details)", "shortName": "Acquisitions - Assets Acquired and Liabilities Assumed (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "As_Of_6_29_2023_us-gaap_AssetAcquisitionAxis_irwd_VectivbioHoldingAgAndItsSubsidiariesMember_c4J0WCC9QE2JwvStJzd70A", "name": "irwd:AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_29_2023_us-gaap_AssetAcquisitionAxis_irwd_VectivbioHoldingAgAndItsSubsidiariesMember_c4J0WCC9QE2JwvStJzd70A", "name": "irwd:AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsExpensesDetails", "longName": "99940307 - Disclosure - Acquisitions - Expenses (Details)", "shortName": "Acquisitions - Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_AssetAcquisitionAxis_irwd_VectivbioHoldingAgAndItsSubsidiariesMember_i0721E_As0qgLQwtDRHgeQ", "name": "irwd:AssetAcquisitionAcquisitionRelatedCosts", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_AssetAcquisitionAxis_irwd_VectivbioHoldingAgAndItsSubsidiariesMember_i0721E_As0qgLQwtDRHgeQ", "name": "irwd:AssetAcquisitionAcquisitionRelatedCosts", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsFiniteLivedIntangibleAssetsDetails", "longName": "99940308 - Disclosure - Acquisitions - Finite-lived Intangible Assets (Details)", "shortName": "Acquisitions - Finite-lived Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "As_Of_12_31_2023_EQuWQ5Sps0uzLFqYTj9Hhw", "name": "us-gaap:FiniteLivedIntangibleAssetsNet", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_12_31_2023_To_12_31_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_irwd_AssembledWorkforceMember_FuNyNcUVLkW_EGE6Qa8r_w", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "us-gaap:AmortizationOfIntangibleAssets", "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "unique": true } }, "R67": { "role": "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsFutureAmortizationExpenseDetails", "longName": "99940309 - Disclosure - Acquisitions - Future Amortization Expense (Details)", "shortName": "Acquisitions - Future Amortization Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "As_Of_12_31_2024_JibFf-avkkWf6yqBT8Gysw", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_JibFf-avkkWf6yqBT8Gysw", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerShareComputationDetails", "longName": "99940401 - Disclosure - Net Income (Loss) Per Share - Computation (Details)", "shortName": "Net Income (Loss) Per Share - Computation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "Duration_10_1_2024_To_12_31_2024_8wbb371dtUeMP02yO8NnJg", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "us-gaap:QuarterlyFinancialInformationTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "unique": true } }, "R69": { "role": "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerSharePotentiallyDilutiveSecuritiesDetails", "longName": "99940402 - Disclosure - Net Income (Loss) Per Share - Potentially Dilutive Securities (Details)", "shortName": "Net Income (Loss) Per Share - Potentially Dilutive Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_40V2pP1iRE64oUYSuAdgzA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_40V2pP1iRE64oUYSuAdgzA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsSummaryDetails", "longName": "99940501 - Disclosure - Collaboration, License, and Other Agreements - Summary (Details)", "shortName": "Collaboration, License, and Other Agreements - Summary (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "Duration_10_1_2024_To_12_31_2024_8wbb371dtUeMP02yO8NnJg", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "us-gaap:QuarterlyFinancialInformationTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_irwd_CollaborativeArrangementOtherAgreementsMember_DxPMG6Z270WO-MIBcuRC3w", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "unique": true } }, "R71": { "role": "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsAccountsReceivableDetails", "longName": "99940502 - Disclosure - Collaboration, License, and Other Agreements - Accounts Receivable (Details)", "shortName": "Collaboration, License, and Other Agreements - Accounts Receivable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "As_Of_12_31_2024_JibFf-avkkWf6yqBT8Gysw", "name": "us-gaap:AccountsReceivableNet", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_JibFf-avkkWf6yqBT8Gysw", "name": "us-gaap:AccountsReceivableNet", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R72": { "role": "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaGeneralInformationDetails", "longName": "99940503 - Disclosure - Collaboration, License, and Other Agreements - North America - General Information (Details)", "shortName": "Collaboration, License, and Other Agreements - North America - General Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_irwd_AbbviePlcMember_iB6pTVYzKEyM7aKG0ZEZOw", "name": "irwd:NumberOfRemainingCommercialPeriodPerformanceObligations", "unitRef": "Unit_Standard_item_yUx8Prdc60iAItiRmpEYkA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "unique": true } }, "R73": { "role": "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCollaborativeArrangementsRevenueDetails", "longName": "99940504 - Disclosure - Collaboration, License, and Other Agreements - North America - Collaborative Arrangements Revenue (Details)", "shortName": "Collaboration, License, and Other Agreements - North America - Collaborative Arrangements Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "Duration_10_1_2024_To_12_31_2024_8wbb371dtUeMP02yO8NnJg", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "us-gaap:QuarterlyFinancialInformationTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_irwd_AbbviePlcMember_srt_ProductOrServiceAxis_irwd_CollaborativeArrangementsLinzessMember_srt_StatementGeographicalAxis_srt_NorthAmericaMember_L_PeRGoyvEesi8kXn8mLRA", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "unique": true } }, "R74": { "role": "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCommercialEffortsDetails", "longName": "99940505 - Disclosure - Collaboration, License, and Other Agreements - North America - Commercial Efforts (Details)", "shortName": "Collaboration, License, and Other Agreements - North America - Commercial Efforts (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "Duration_10_1_2024_To_12_31_2024_8wbb371dtUeMP02yO8NnJg", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "us-gaap:QuarterlyFinancialInformationTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_irwd_AbbviePlcMember_srt_ProductOrServiceAxis_irwd_CollaborativeArrangementsLinzessMember_srt_StatementGeographicalAxis_country_US_uuiIS-xXqkyBzBmnBJsfKQ", "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "unique": true } }, "R75": { "role": "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaRoyaltyRevenueDetails", "longName": "99940506 - Disclosure - Collaboration, License, and Other Agreements - North America - Royalty Revenue (Details)", "shortName": "Collaboration, License, and Other Agreements - North America - Royalty Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "Duration_10_1_2024_To_12_31_2024_8wbb371dtUeMP02yO8NnJg", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "us-gaap:QuarterlyFinancialInformationTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_irwd_AbbviePlcMember_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_srt_StatementGeographicalAxis_irwd_CanadaAndMexicoMember_HGXMrQVDHUSvgjFYXB7irQ", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "unique": true } }, "R76": { "role": "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsEuropeanAndOtherTerritoriesDetails", "longName": "99940507 - Disclosure - Collaboration, License, and Other Agreements - European and Other Territories (Details)", "shortName": "Collaboration, License, and Other Agreements - European and Other Territories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "Duration_10_1_2024_To_12_31_2024_8wbb371dtUeMP02yO8NnJg", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "us-gaap:QuarterlyFinancialInformationTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_irwd_AbbviePlcMember_iB6pTVYzKEyM7aKG0ZEZOw", "name": "irwd:CollaborativeArrangementRoyaltyNetSalesOfProductsContainingActiveIngredientPeriodFollowingFirstCommercialSale", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "unique": true } }, "R77": { "role": "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsJapanDetails", "longName": "99940508 - Disclosure - Collaboration, License, and Other Agreements - Japan (Details)", "shortName": "Collaboration, License, and Other Agreements - Japan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "Duration_10_1_2024_To_12_31_2024_8wbb371dtUeMP02yO8NnJg", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "us-gaap:QuarterlyFinancialInformationTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_irwd_AstellasPharmaInc2009LicenseAgreementAmended2019Member_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_Se-mZmMjjk-26PoecnmxjA", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "unique": true } }, "R78": { "role": "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsChinaHongKongAndMacauDetails", "longName": "99940509 - Disclosure - Collaboration, License, and Other Agreements - China, Hong Kong and Macau (Details)", "shortName": "Collaboration, License, and Other Agreements - China, Hong Kong and Macau (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "Duration_10_1_2024_To_12_31_2024_8wbb371dtUeMP02yO8NnJg", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "us-gaap:QuarterlyFinancialInformationTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_irwd_AstraZenecaMember_ZCt1l2n6zkqbdoa4vqQ65Q", "name": "irwd:MilestonePaymentToBeReceivedByCompanyUponMilestoneAchievement", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "unique": true } }, "R79": { "role": "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsOtherCollaborationAndLicenseAgreementsDetails", "longName": "99940510 - Disclosure - Collaboration, License, and Other Agreements - Other Collaboration and License Agreements (Details)", "shortName": "Collaboration, License, and Other Agreements - Other Collaboration and License Agreements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "Duration_10_1_2024_To_12_31_2024_8wbb371dtUeMP02yO8NnJg", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "us-gaap:QuarterlyFinancialInformationTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2023_To_4_30_2023_srt_CounterpartyNameAxis_irwd_CourPharmaceuticalsDevelopmentCompanyIncMember_Qn6-gIADfESvK87hu0lvaw", "name": "irwd:CollaborativeArrangementUpfrontPayment", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "unique": true } }, "R80": { "role": "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsGeneralInformationDetails", "longName": "99940601 - Disclosure - Fair Value of Financial Instruments - General Information (Details)", "shortName": "Fair Value of Financial Instruments - General Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "As_Of_12_31_2024_JibFf-avkkWf6yqBT8Gysw", "name": "irwd:ThresholdPercentageOfCollateralizedValue", "unitRef": "Unit_Standard_pure_o_LvPScFJEyjZOySCfKmrA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_JibFf-avkkWf6yqBT8Gysw", "name": "irwd:ThresholdPercentageOfCollateralizedValue", "unitRef": "Unit_Standard_pure_o_LvPScFJEyjZOySCfKmrA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R81": { "role": "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails", "longName": "99940602 - Disclosure - Fair Value of Financial Instruments - Measured on Recurring Basis (Details)", "shortName": "Fair Value of Financial Instruments - Measured on Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "As_Of_12_31_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Ym_6shN9OEKXPnByscS-Ow", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Ym_6shN9OEKXPnByscS-Ow", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R82": { "role": "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsConvertibleSeniorNotesDetails", "longName": "99940603 - Disclosure - Fair Value of Financial Instruments - Convertible Senior Notes (Details)", "shortName": "Fair Value of Financial Instruments - Convertible Senior Notes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "As_Of_6_30_2015_us-gaap_DebtInstrumentAxis_irwd_ConvertibleSeniorNotes225PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_uhxPFI2FukqikfH34IGSkQ", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_irwd_ConvertibleSeniorNotes075PercentDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_GjL4cCcLYEOX_MtIaOlQyw", "name": "us-gaap:LongTermDebtFairValue", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "unique": true } }, "R83": { "role": "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsCappedCallsDetails", "longName": "99940604 - Disclosure - Fair Value of Financial Instruments - Capped Calls (Details)", "shortName": "Fair Value of Financial Instruments - Capped Calls (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "Duration_8_1_2019_To_8_31_2019_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_CallOptionMember_6zOWd_zd0UuVhk3zce22hA", "name": "us-gaap:OptionIndexedToIssuersEquityStrikePrice1", "unitRef": "Unit_Divide_USD_shares_-u5k1rPZgUmkGeZWt8Lylg", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": null }, "R84": { "role": "http://www.ironwoodpharma.com/role/DisclosureLeasesLettersOfCreditDetails", "longName": "99940701 - Disclosure - Leases - Letters of Credit (Details)", "shortName": "Leases - Letters of Credit (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "As_Of_12_31_2024_srt_CounterpartyNameAxis_irwd_SummerStreetLeaseAndVehicleLeaseMember_tebgDJAxC0SD2tInPCYLNA", "name": "us-gaap:LettersOfCreditOutstandingAmount", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "us-gaap:LettersOfCreditOutstandingAmount", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_srt_CounterpartyNameAxis_irwd_SummerStreetLeaseAndVehicleLeaseMember_tebgDJAxC0SD2tInPCYLNA", "name": "us-gaap:LettersOfCreditOutstandingAmount", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "us-gaap:LettersOfCreditOutstandingAmount", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R85": { "role": "http://www.ironwoodpharma.com/role/DisclosureLeasesLeaseCostDetails", "longName": "99940702 - Disclosure - Leases - Lease Cost (Details)", "shortName": "Leases - Lease Cost (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:OperatingLeaseCost", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:ShortTermLeaseCost", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "unique": true } }, "R86": { "role": "http://www.ironwoodpharma.com/role/DisclosureLeasesSupplementalInformationDetails", "longName": "99940703 - Disclosure - Leases - Supplemental Information (Details)", "shortName": "Leases - Supplemental Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:OperatingLeasePayments", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:OperatingLeasePayments", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R87": { "role": "http://www.ironwoodpharma.com/role/DisclosureLeasesSummerStreetLeaseDetails", "longName": "99940704 - Disclosure - Leases - Summer Street Lease (Details)", "shortName": "Leases - Summer Street Lease (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "As_Of_12_31_2024_JibFf-avkkWf6yqBT8Gysw", "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent", "unitRef": "Unit_Standard_pure_o_LvPScFJEyjZOySCfKmrA", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2019_srt_CounterpartyNameAxis_irwd_SummerStreetLeaseMember__bfxI06r8UCpi75X0y6yGg", "name": "us-gaap:AreaOfRealEstateProperty", "unitRef": "Unit_Standard_sqft_tG-Cyw-MS0u7HdjqRP0Rmg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "unique": true } }, "R88": { "role": "http://www.ironwoodpharma.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails", "longName": "99940705 - Disclosure - Leases - Future Minimum Lease Payments (Details)", "shortName": "Leases - Future Minimum Lease Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "As_Of_12_31_2024_JibFf-avkkWf6yqBT8Gysw", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_JibFf-avkkWf6yqBT8Gysw", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R89": { "role": "http://www.ironwoodpharma.com/role/DisclosureLeasesOperatingLeaseObligationsDetails", "longName": "99940706 - Disclosure - Leases - Operating Lease Obligations (Details)", "shortName": "Leases - Operating Lease Obligations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "89", "firstAnchor": { "contextRef": "As_Of_12_31_2024_JibFf-avkkWf6yqBT8Gysw", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_JibFf-avkkWf6yqBT8Gysw", "name": "us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "unique": true } }, "R90": { "role": "http://www.ironwoodpharma.com/role/DisclosurePropertyAndEquipmentTabularDisclosureDetails", "longName": "99940801 - Disclosure - Property and Equipment - Tabular Disclosure (Details)", "shortName": "Property and Equipment - Tabular Disclosure (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "90", "firstAnchor": { "contextRef": "As_Of_12_31_2024_JibFf-avkkWf6yqBT8Gysw", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_JibFf-avkkWf6yqBT8Gysw", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R91": { "role": "http://www.ironwoodpharma.com/role/DisclosurePropertyAndEquipmentDepreciationExpenseDetails", "longName": "99940802 - Disclosure - Property and Equipment - Depreciation Expense (Details)", "shortName": "Property and Equipment - Depreciation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "91", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R92": { "role": "http://www.ironwoodpharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTabularDisclosureDetails", "longName": "99940901 - Disclosure - Accrued Expenses and Other Current Liabilities - Tabular Disclosure (Details)", "shortName": "Accrued Expenses and Other Current Liabilities - Tabular Disclosure (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "92", "firstAnchor": { "contextRef": "As_Of_12_31_2024_JibFf-avkkWf6yqBT8Gysw", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_JibFf-avkkWf6yqBT8Gysw", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R93": { "role": "http://www.ironwoodpharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesAdditionalInformationDetails", "longName": "99940902 - Disclosure - Accrued Expenses and Other Current Liabilities - Additional Information (Details)", "shortName": "Accrued Expenses and Other Current Liabilities - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "93", "firstAnchor": { "contextRef": "As_Of_12_31_2024_JibFf-avkkWf6yqBT8Gysw", "name": "us-gaap:OtherAccruedLiabilitiesCurrent", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_JibFf-avkkWf6yqBT8Gysw", "name": "irwd:OtherAccruedLiabilitiesCurrentUninvoicedVendorLiabilities", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "unique": true } }, "R94": { "role": "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails", "longName": "99941001 - Disclosure - Debt - General Information (Details)", "shortName": "Debt - General Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "94", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:ProceedsFromLongTermLinesOfCredit", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_6_1_2015_To_6_30_2015_Je48eqbF1k-i8uad5jL0cg", "name": "us-gaap:PaymentsForHedgeFinancingActivities", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "unique": true } }, "R95": { "role": "http://www.ironwoodpharma.com/role/DisclosureDebtInterestExpenseDetails", "longName": "99941002 - Disclosure - Debt - Interest Expense (Details)", "shortName": "Debt - Interest Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "95", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember_luStjQ5tiE6RpLIYPxky3A", "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "irwd:InterestExpenseDebtTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember_luStjQ5tiE6RpLIYPxky3A", "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "irwd:InterestExpenseDebtTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R96": { "role": "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesBalancesDetails", "longName": "99941003 - Disclosure - Debt - Convertible Senior Notes - Balances (Details)", "shortName": "Debt - Convertible Senior Notes - Balances (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "96", "firstAnchor": { "contextRef": "As_Of_12_31_2024_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_veU21CnvXEeEE9ZA5gOGbA", "name": "us-gaap:UnamortizedDebtIssuanceExpense", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": null }, "R97": { "role": "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesFutureMinimumPaymentsDetails", "longName": "99941004 - Disclosure - Debt - Convertible Senior Notes - Future Minimum Payments (Details)", "shortName": "Debt - Convertible Senior Notes - Future Minimum Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "97", "firstAnchor": { "contextRef": "As_Of_12_31_2024_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_veU21CnvXEeEE9ZA5gOGbA", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_veU21CnvXEeEE9ZA5gOGbA", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R98": { "role": "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "longName": "99941005 - Disclosure - Debt - Convertible Senior Notes Due 2024 and Convertible Senior Notes Due 2026 (Details)", "shortName": "Debt - Convertible Senior Notes Due 2024 and Convertible Senior Notes Due 2026 (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "98", "firstAnchor": { "contextRef": "As_Of_6_30_2015_us-gaap_DebtInstrumentAxis_irwd_ConvertibleSeniorNotes225PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_uhxPFI2FukqikfH34IGSkQ", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_8_1_2019_To_8_31_2019_us-gaap_DebtInstrumentAxis_irwd_ConvertibleSeniorNotes075PercentDue2024AndConvertibleSeniorNotes150PercentDue2026Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_uP4iUWrTGUeQfTQU8IS6sw", "name": "us-gaap:ProceedsFromIssuanceOfLongTermDebt", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "unique": true } }, "R99": { "role": "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesDue2022ConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "longName": "99941006 - Disclosure - Debt - Convertible Senior Notes Due 2022, Convertible Senior Notes Due 2024 and Convertible Senior Notes Due 2026 (Details)", "shortName": "Debt - Convertible Senior Notes Due 2022, Convertible Senior Notes Due 2024 and Convertible Senior Notes Due 2026 (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "99", "firstAnchor": { "contextRef": "Duration_8_1_2019_To_8_31_2019_us-gaap_DebtInstrumentAxis_irwd_ConvertibleSeniorNotes075PercentDue2024AndConvertibleSeniorNotes150PercentDue2026Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_uP4iUWrTGUeQfTQU8IS6sw", "name": "irwd:DebtInstrumentDebtIssuanceCostsIncurred", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_8_1_2019_To_8_31_2019_us-gaap_DebtInstrumentAxis_irwd_ConvertibleSeniorNotes075PercentDue2024AndConvertibleSeniorNotes150PercentDue2026Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_uP4iUWrTGUeQfTQU8IS6sw", "name": "irwd:DebtInstrumentDebtIssuanceCostsIncurred", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R100": { "role": "http://www.ironwoodpharma.com/role/DisclosureDebtCappedCallsWithRespectTo2024ConvertibleNotesAnd2026ConvertibleNotesDetails", "longName": "99941007 - Disclosure - Debt - Capped Calls with Respect to 2024 Convertible Notes and 2026 Convertible Notes (Details)", "shortName": "Debt - Capped Calls with Respect to 2024 Convertible Notes and 2026 Convertible Notes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "100", "firstAnchor": { "contextRef": "Duration_8_1_2019_To_8_31_2019_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_CallOptionMember_6zOWd_zd0UuVhk3zce22hA", "name": "irwd:PaymentMadeForInvestingInCappedCalls", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_8_1_2019_To_8_31_2019_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_CallOptionMember_6zOWd_zd0UuVhk3zce22hA", "name": "irwd:PaymentMadeForInvestingInCappedCalls", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R101": { "role": "http://www.ironwoodpharma.com/role/DisclosureCommitmentsAndContingenciesDetails", "longName": "99941101 - Disclosure - Commitments and Contingencies (Details)", "shortName": "Commitments and Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "101", "firstAnchor": { "contextRef": "As_Of_12_31_2024_us-gaap_GuaranteeObligationsByNatureAxis_us-gaap_IndemnificationGuaranteeMember_K1R4oXHH-0CP9wfBsEJTmg", "name": "us-gaap:GuaranteeObligationsCurrentCarryingValue", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "us-gaap:GuaranteeObligationsCurrentCarryingValue", "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_us-gaap_GuaranteeObligationsByNatureAxis_us-gaap_IndemnificationGuaranteeMember_K1R4oXHH-0CP9wfBsEJTmg", "name": "us-gaap:GuaranteeObligationsCurrentCarryingValue", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "us-gaap:GuaranteeObligationsCurrentCarryingValue", "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R102": { "role": "http://www.ironwoodpharma.com/role/DisclosureStockholdersEquityCommonStockDetails", "longName": "99941201 - Disclosure - Stockholders' Equity - Common Stock (Details)", "shortName": "Stockholders' Equity - Common Stock (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "102", "firstAnchor": { "contextRef": "As_Of_12_31_2024_JibFf-avkkWf6yqBT8Gysw", "name": "irwd:CommonStockVotingRightsPerShare", "unitRef": "Unit_Standard_Vote_J_2aDcK1wkGf9XaLkEDThQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:CommonStockVotingRights", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_JibFf-avkkWf6yqBT8Gysw", "name": "irwd:CommonStockVotingRightsPerShare", "unitRef": "Unit_Standard_Vote_J_2aDcK1wkGf9XaLkEDThQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:CommonStockVotingRights", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R103": { "role": "http://www.ironwoodpharma.com/role/DisclosureStockholdersEquityStockRepurchaseProgramDetails", "longName": "99941202 - Disclosure - Stockholders' Equity - Stock Repurchase Program (Details)", "shortName": "Stockholders' Equity - Stock Repurchase Program (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "103", "firstAnchor": { "contextRef": "As_Of_5_31_2021_ZEvDLHMzgkqn0UWBFd3S5w", "name": "srt:StockRepurchaseProgramAuthorizedAmount1", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_5_31_2021_ZEvDLHMzgkqn0UWBFd3S5w", "name": "srt:StockRepurchaseProgramAuthorizedAmount1", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R104": { "role": "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansSummaryOfExpenseRecognizedByShareBasedCompensationArrangementDetails", "longName": "99941301 - Disclosure - Employee Stock Benefit Plans - Summary of Expense Recognized by Share-based Compensation Arrangement (Details)", "shortName": "Employee Stock Benefit Plans - Summary of Expense Recognized by Share-based Compensation Arrangement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "104", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_W48xbRJNnkm_bthchZWDkw", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "unique": true } }, "R105": { "role": "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansShareBasedCompensationExpenseTabularDisclosureDetails", "longName": "99941302 - Disclosure - Employee Stock Benefit Plans - Share-based Compensation Expense - Tabular Disclosure (Details)", "shortName": "Employee Stock Benefit Plans - Share-based Compensation Expense - Tabular Disclosure (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "105", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "unique": true } }, "R106": { "role": "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansShareBasedCompensationExpenseAdditionalInformationDetails", "longName": "99941303 - Disclosure - Employee Stock Benefit Plans - Share-based Compensation Expense - Additional Information (Details)", "shortName": "Employee Stock Benefit Plans - Share-based Compensation Expense - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "106", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2023_To_6_30_2023_us-gaap_AssetAcquisitionAxis_irwd_VectivbioHoldingAgAndItsSubsidiariesMember_g8H31IJGX0CwnLt-bIr4Zg", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "unique": true } }, "R107": { "role": "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansStockBenefitPlansDetails", "longName": "99941304 - Disclosure - Employee Stock Benefit Plans - Stock Benefit Plans (Details)", "shortName": "Employee Stock Benefit Plans - Stock Benefit Plans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "107", "firstAnchor": { "contextRef": "As_Of_12_31_2024_JibFf-avkkWf6yqBT8Gysw", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "unitRef": "Unit_Standard_shares_40V2pP1iRE64oUYSuAdgzA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_JibFf-avkkWf6yqBT8Gysw", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "unitRef": "Unit_Standard_shares_40V2pP1iRE64oUYSuAdgzA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R108": { "role": "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansRestrictedStockAwardsGeneralInformationDetails", "longName": "99941305 - Disclosure - Employee Stock Benefit Plans - Restricted Stock Awards - General Information (Details)", "shortName": "Employee Stock Benefit Plans - Restricted Stock Awards - General Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "108", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_BsQlBItn_EGPKo1f7X-xfw", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_BsQlBItn_EGPKo1f7X-xfw", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R109": { "role": "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansRestrictedStockAwardsActivityDetails", "longName": "99941306 - Disclosure - Employee Stock Benefit Plans - Restricted Stock Awards - Activity (Details)", "shortName": "Employee Stock Benefit Plans - Restricted Stock Awards - Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "109", "firstAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_ZJjJ8eqxbkONMwushGWuDA", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Unit_Standard_shares_40V2pP1iRE64oUYSuAdgzA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_5qjJ7QeIJESrkpmyQdUWdQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "Unit_Standard_shares_40V2pP1iRE64oUYSuAdgzA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "unique": true } }, "R110": { "role": "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansRestrictedStockAwardsAdditionalInformationDetails", "longName": "99941307 - Disclosure - Employee Stock Benefit Plans - Restricted Stock Awards - Additional Information (Details)", "shortName": "Employee Stock Benefit Plans - Restricted Stock Awards - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "110", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_5qjJ7QeIJESrkpmyQdUWdQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "unitRef": "Unit_Divide_USD_shares_-u5k1rPZgUmkGeZWt8Lylg", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "td", "tr", "table", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_5qjJ7QeIJESrkpmyQdUWdQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "unique": true } }, "R111": { "role": "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansRestrictedStockUnitsDetails", "longName": "99941308 - Disclosure - Employee Stock Benefit Plans - Restricted Stock Units (Details)", "shortName": "Employee Stock Benefit Plans - Restricted Stock Units (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "111", "firstAnchor": { "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_EZOXjREWRkmtTQHJDyDfBQ", "name": "irwd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNumberOfSharesPerOptionExercised", "unitRef": "Unit_Standard_shares_40V2pP1iRE64oUYSuAdgzA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_EZOXjREWRkmtTQHJDyDfBQ", "name": "irwd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNumberOfSharesPerOptionExercised", "unitRef": "Unit_Standard_shares_40V2pP1iRE64oUYSuAdgzA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R112": { "role": "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTimeBasedRsusVestingDetails", "longName": "99941309 - Disclosure - Employee Stock Benefit Plans - Time-based RSUs - Vesting (Details)", "shortName": "Employee Stock Benefit Plans - Time-based RSUs - Vesting (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "112", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_irwd_TimeBasedRestrictedStockUnitsMember_zZTZgE2ocUGUUpHE0D7hLg", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_irwd_TimeBasedRestrictedStockUnitsMember_zZTZgE2ocUGUUpHE0D7hLg", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R113": { "role": "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTimeBasedRsusActivityDetails", "longName": "99941310 - Disclosure - Employee Stock Benefit Plans - Time-based RSUs - Activity (Details)", "shortName": "Employee Stock Benefit Plans - Time-based RSUs - Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "113", "firstAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_irwd_TimeBasedRestrictedStockUnitsMember_BiNPT2SxMkKkkVsSCi5Zwg", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Unit_Standard_shares_40V2pP1iRE64oUYSuAdgzA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_irwd_TimeBasedRestrictedStockUnitsMember_WxMBv2K8eUqBZnJQvXOo1A", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "Unit_Standard_shares_40V2pP1iRE64oUYSuAdgzA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "unique": true } }, "R114": { "role": "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTimeBasedRsusAdditionalInformationDetails", "longName": "99941311 - Disclosure - Employee Stock Benefit Plans - Time-based RSUs - Additional Information (Details)", "shortName": "Employee Stock Benefit Plans - Time-based RSUs - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "114", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_irwd_TimeBasedRestrictedStockUnitsMember_WxMBv2K8eUqBZnJQvXOo1A", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "unitRef": "Unit_Divide_USD_shares_-u5k1rPZgUmkGeZWt8Lylg", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_irwd_TimeBasedRestrictedStockUnitsMember_WxMBv2K8eUqBZnJQvXOo1A", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "unique": true } }, "R115": { "role": "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansPerformanceBasedRsusVestingDetails", "longName": "99941312 - Disclosure - Employee Stock Benefit Plans - Performance-based RSUs - Vesting (Details)", "shortName": "Employee Stock Benefit Plans - Performance-based RSUs - Vesting (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "115", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_irwd_PerformanceBasedRestrictedStockUnitsMember_XM7t86bBrkC5FdrUMNVzAw", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_irwd_PerformanceBasedRestrictedStockUnitsMember_XM7t86bBrkC5FdrUMNVzAw", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R116": { "role": "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansPerformanceBasedRsusAssumptionsDetails", "longName": "99941313 - Disclosure - Employee Stock Benefit Plans - Performance-based RSUs - Assumptions (Details)", "shortName": "Employee Stock Benefit Plans - Performance-based RSUs - Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "116", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_irwd_PerformanceBasedRestrictedStockUnitsRelativeTotalShareholderReturnMember_GKBtqy2q1UiTMOQlT3Nhsw", "name": "irwd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageCommonStockFairValue", "unitRef": "Unit_Divide_USD_shares_-u5k1rPZgUmkGeZWt8Lylg", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "td", "tr", "table", "irwd:ScheduleOfShareBasedPaymentAwardPerformanceBasedRestrictedStockUnitsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_irwd_PerformanceBasedRestrictedStockUnitsRelativeTotalShareholderReturnMember_GKBtqy2q1UiTMOQlT3Nhsw", "name": "irwd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageCommonStockFairValue", "unitRef": "Unit_Divide_USD_shares_-u5k1rPZgUmkGeZWt8Lylg", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "td", "tr", "table", "irwd:ScheduleOfShareBasedPaymentAwardPerformanceBasedRestrictedStockUnitsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R117": { "role": "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansPerformanceBasedRsusActivityDetails", "longName": "99941314 - Disclosure - Employee Stock Benefit Plans - Performance-based RSUs - Activity (Details)", "shortName": "Employee Stock Benefit Plans - Performance-based RSUs - Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "117", "firstAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_irwd_PerformanceBasedRestrictedStockUnitsMember_GA-799w0EUW4dPO0T3xr-A", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Unit_Standard_shares_40V2pP1iRE64oUYSuAdgzA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_irwd_PerformanceBasedRestrictedStockUnitsMember_XM7t86bBrkC5FdrUMNVzAw", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "Unit_Standard_shares_40V2pP1iRE64oUYSuAdgzA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "unique": true } }, "R118": { "role": "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansPerformanceBasedRsusAdditionalInformationDetails", "longName": "99941315 - Disclosure - Employee Stock Benefit Plans - Performance-based RSUs - Additional Information (Details)", "shortName": "Employee Stock Benefit Plans - Performance-based RSUs - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "118", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_irwd_PerformanceBasedRestrictedStockUnitsMember_XM7t86bBrkC5FdrUMNVzAw", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_irwd_PerformanceBasedRestrictedStockUnitsMember_XM7t86bBrkC5FdrUMNVzAw", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R119": { "role": "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansStockOptionsGeneralInformationDetails", "longName": "99941316 - Disclosure - Employee Stock Benefit Plans - Stock Options - General Information (Details)", "shortName": "Employee Stock Benefit Plans - Stock Options - General Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "119", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "irwd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "irwd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R120": { "role": "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansStockOptionsActivityDetails", "longName": "99941317 - Disclosure - Employee Stock Benefit Plans - Stock Options - Activity (Details)", "shortName": "Employee Stock Benefit Plans - Stock Options - Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "120", "firstAnchor": { "contextRef": "As_Of_12_31_2023_EQuWQ5Sps0uzLFqYTj9Hhw", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Unit_Standard_shares_40V2pP1iRE64oUYSuAdgzA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "unitRef": "Unit_Standard_shares_40V2pP1iRE64oUYSuAdgzA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "unique": true } }, "R121": { "role": "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansStockOptionsTotalIntrinsicValueDetails", "longName": "99941318 - Disclosure - Employee Stock Benefit Plans - Stock Options - Total Intrinsic Value (Details)", "shortName": "Employee Stock Benefit Plans - Stock Options - Total Intrinsic Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "121", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R122": { "role": "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansUnrecognizedShareBasedCompensationDetails", "longName": "99941319 - Disclosure - Employee Stock Benefit Plans - Unrecognized Share-based Compensation (Details)", "shortName": "Employee Stock Benefit Plans - Unrecognized Share-based Compensation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "122", "firstAnchor": { "contextRef": "As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_0Y1lAjCK60-YgN1eJ69FUw", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_0Y1lAjCK60-YgN1eJ69FUw", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R123": { "role": "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesComponentsOfIncomeBeforeIncomeTaxesDetails", "longName": "99941401 - Disclosure - Income Taxes - Components of Income before Income Taxes (Details)", "shortName": "Income Taxes - Components of Income before Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "123", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "irwd:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignAndComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "irwd:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignAndComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R124": { "role": "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesProvisionForBenefitFromIncomeTaxesTabularDisclosureDetails", "longName": "99941402 - Disclosure - Income Taxes - Provision for (Benefit from) Income Taxes - Tabular Disclosure (Details)", "shortName": "Income Taxes - Provision for (Benefit from) Income Taxes - Tabular Disclosure (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "124", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:CurrentForeignTaxExpenseBenefit", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "unique": true } }, "R125": { "role": "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesProvisionForBenefitFromIncomeTaxesAdditionalInformationDetails", "longName": "99941403 - Disclosure - Income Taxes - Provision for (Benefit from) Income Taxes - Additional Information (Details)", "shortName": "Income Taxes - Provision for (Benefit from) Income Taxes - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "125", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "irwd:IncomeTaxExpenseBenefitNonCash", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "unique": true } }, "R126": { "role": "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesFederalStatutoryRateDetails", "longName": "99941404 - Disclosure - Income Taxes - Federal Statutory Rate (Details)", "shortName": "Income Taxes - Federal Statutory Rate (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "126", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "Unit_Standard_pure_o_LvPScFJEyjZOySCfKmrA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "Unit_Standard_pure_o_LvPScFJEyjZOySCfKmrA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R127": { "role": "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails", "longName": "99941405 - Disclosure - Income Taxes - Reconciliation of Income Taxes (Details)", "shortName": "Income Taxes - Reconciliation of Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "127", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R128": { "role": "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails", "longName": "99941406 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)", "shortName": "Income Taxes - Deferred Tax Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "128", "firstAnchor": { "contextRef": "As_Of_12_31_2024_JibFf-avkkWf6yqBT8Gysw", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_JibFf-avkkWf6yqBT8Gysw", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R129": { "role": "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesValuationAllowanceDetails", "longName": "99941407 - Disclosure - Income Taxes - Valuation Allowance (Details)", "shortName": "Income Taxes - Valuation Allowance (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "129", "firstAnchor": { "contextRef": "As_Of_12_31_2024_JibFf-avkkWf6yqBT8Gysw", "name": "us-gaap:DeferredTaxAssetsValuationAllowance", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "unique": true } }, "R130": { "role": "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesAcquisitionsDetails", "longName": "99941408 - Disclosure - Income Taxes - Acquisitions (Details)", "shortName": "Income Taxes - Acquisitions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "130", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_fCHdzTjoQEWzMV7M6Z6FLg", "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2023_To_6_30_2023_us-gaap_AssetAcquisitionAxis_irwd_VectivbioHoldingAgAndItsSubsidiariesMember_g8H31IJGX0CwnLt-bIr4Zg", "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "unique": true } }, "R131": { "role": "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails", "longName": "99941409 - Disclosure - Income Taxes - Net Operating Loss Carryforwards (Details)", "shortName": "Income Taxes - Net Operating Loss Carryforwards (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "131", "firstAnchor": { "contextRef": "As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_DZXbO-qcAEmbLqFZLGspVg", "name": "us-gaap:OperatingLossCarryforwards", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_DZXbO-qcAEmbLqFZLGspVg", "name": "us-gaap:OperatingLossCarryforwards", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R132": { "role": "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardsDetails", "longName": "99941410 - Disclosure - Income Taxes - Tax Credit Carryforwards (Details)", "shortName": "Income Taxes - Tax Credit Carryforwards (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "132", "firstAnchor": { "contextRef": "As_Of_12_31_2024_JibFf-avkkWf6yqBT8Gysw", "name": "us-gaap:TaxCreditCarryforwardAmount", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_JibFf-avkkWf6yqBT8Gysw", "name": "us-gaap:TaxCreditCarryforwardAmount", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R133": { "role": "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesUnrecognizedIncomeTaxBenefitsTabularDisclosureDetails", "longName": "99941411 - Disclosure - Income Taxes - Unrecognized Income Tax Benefits - Tabular Disclosure (Details)", "shortName": "Income Taxes - Unrecognized Income Tax Benefits - Tabular Disclosure (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "133", "firstAnchor": { "contextRef": "As_Of_12_31_2023_EQuWQ5Sps0uzLFqYTj9Hhw", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "unique": true } }, "R134": { "role": "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesUnrecognizedIncomeTaxBenefitsAdditionalInformationDetails", "longName": "99941412 - Disclosure - Income Taxes - Unrecognized Income Tax Benefits - Additional Information (Details)", "shortName": "Income Taxes - Unrecognized Income Tax Benefits - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "134", "firstAnchor": { "contextRef": "As_Of_12_31_2024_JibFf-avkkWf6yqBT8Gysw", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_JibFf-avkkWf6yqBT8Gysw", "name": "us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "unique": true } }, "R135": { "role": "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedContributionRetirementPlansDetails", "longName": "99941501 - Disclosure - Retirement Plans - Defined Contribution Retirement Plans (Details)", "shortName": "Retirement Plans - Defined Contribution Retirement Plans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "135", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:DefinedContributionPlanCostRecognized", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:DefinedContributionPlanCostRecognized", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R136": { "role": "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansGeneralInformationDetails", "longName": "99941502 - Disclosure - Retirement Plans - Defined Benefit Retirement Plans - General Information (Details)", "shortName": "Retirement Plans - Defined Benefit Retirement Plans - General Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "136", "firstAnchor": null, "uniqueAnchor": null }, "R137": { "role": "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansNetPeriodicBenefitCostCreditDetails", "longName": "99941503 - Disclosure - Retirement Plans - Defined Benefit Retirement Plans - Net Periodic Benefit Cost (Credit) (Details)", "shortName": "Retirement Plans - Defined Benefit Retirement Plans - Net Periodic Benefit Cost (Credit) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "137", "firstAnchor": { "contextRef": "Duration_6_29_2023_To_12_31_2023_tZfqBo9UhUeQ1JL4nwcnzQ", "name": "us-gaap:DefinedBenefitPlanServiceCost", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_6_29_2023_To_12_31_2023_tZfqBo9UhUeQ1JL4nwcnzQ", "name": "us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "unique": true } }, "R138": { "role": "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansOtherComprehensiveIncomeLossDetails", "longName": "99941504 - Disclosure - Retirement Plans - Defined Benefit Retirement Plans - Other Comprehensive Income (Loss) (Details)", "shortName": "Retirement Plans - Defined Benefit Retirement Plans - Other Comprehensive Income (Loss) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "138", "firstAnchor": { "contextRef": "Duration_6_29_2023_To_12_31_2023_tZfqBo9UhUeQ1JL4nwcnzQ", "name": "us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_6_29_2023_To_12_31_2023_tZfqBo9UhUeQ1JL4nwcnzQ", "name": "us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R139": { "role": "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansFundedUnfundedStatusDetails", "longName": "99941505 - Disclosure - Retirement Plans - Defined Benefit Retirement Plans - Funded (Unfunded) Status (Details)", "shortName": "Retirement Plans - Defined Benefit Retirement Plans - Funded (Unfunded) Status (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "139", "firstAnchor": { "contextRef": "As_Of_12_31_2024_JibFf-avkkWf6yqBT8Gysw", "name": "us-gaap:DefinedBenefitPlanBenefitObligation", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfNetFundedStatusTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_JibFf-avkkWf6yqBT8Gysw", "name": "us-gaap:DefinedBenefitPlanFundedStatusOfPlan", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfNetFundedStatusTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "unique": true } }, "R140": { "role": "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansChangeInDefinedBenefitObligationDetails", "longName": "99941506 - Disclosure - Retirement Plans - Defined Benefit Retirement Plans - Change in Defined Benefit Obligation (Details)", "shortName": "Retirement Plans - Defined Benefit Retirement Plans - Change in Defined Benefit Obligation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "140", "firstAnchor": { "contextRef": "As_Of_6_28_2023_noNJTuDkMUqvYzUfEyj3xg", "name": "us-gaap:DefinedBenefitPlanBenefitObligation", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_6_29_2023_To_12_31_2023_tZfqBo9UhUeQ1JL4nwcnzQ", "name": "us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "unique": true } }, "R141": { "role": "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansChangeInFairValueOfPlanAssetsDetails", "longName": "99941507 - Disclosure - Retirement Plans - Defined Benefit Retirement Plans - Change in Fair Value of Plan Assets (Details)", "shortName": "Retirement Plans - Defined Benefit Retirement Plans - Change in Fair Value of Plan Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "141", "firstAnchor": { "contextRef": "As_Of_6_28_2023_noNJTuDkMUqvYzUfEyj3xg", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_6_29_2023_To_12_31_2023_tZfqBo9UhUeQ1JL4nwcnzQ", "name": "us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "unique": true } }, "R142": { "role": "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansAllocationOfPlanAssetsDetails", "longName": "99941508 - Disclosure - Retirement Plans - Defined Benefit Retirement Plans - Allocation of Plan Assets (Details)", "shortName": "Retirement Plans - Defined Benefit Retirement Plans - Allocation of Plan Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "142", "firstAnchor": { "contextRef": "As_Of_12_31_2024_JibFf-avkkWf6yqBT8Gysw", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfNetFundedStatusTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_JibFf-avkkWf6yqBT8Gysw", "name": "us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations", "unitRef": "Unit_Standard_pure_o_LvPScFJEyjZOySCfKmrA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "unique": true } }, "R143": { "role": "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansFairValueOfPlanAssetsDetails", "longName": "99941509 - Disclosure - Retirement Plans - Defined Benefit Retirement Plans - Fair Value of Plan Assets (Details)", "shortName": "Retirement Plans - Defined Benefit Retirement Plans - Fair Value of Plan Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "143", "firstAnchor": { "contextRef": "As_Of_12_31_2024_JibFf-avkkWf6yqBT8Gysw", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfNetFundedStatusTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_2Oci8VMfdUWWv2QGBy4zrw", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "unique": true } }, "R144": { "role": "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansAssumptionsDetails", "longName": "99941510 - Disclosure - Retirement Plans - Defined Benefit Retirement Plans - Assumptions (Details)", "shortName": "Retirement Plans - Defined Benefit Retirement Plans - Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "144", "firstAnchor": { "contextRef": "Duration_6_29_2023_To_12_31_2023_tZfqBo9UhUeQ1JL4nwcnzQ", "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "unitRef": "Unit_Standard_pure_o_LvPScFJEyjZOySCfKmrA", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_6_29_2023_To_12_31_2023_tZfqBo9UhUeQ1JL4nwcnzQ", "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "unitRef": "Unit_Standard_pure_o_LvPScFJEyjZOySCfKmrA", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R145": { "role": "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansFutureMinimumPaymentsDetails", "longName": "99941511 - Disclosure - Retirement Plans - Defined Benefit Retirement Plans - Future Minimum Payments (Details)", "shortName": "Retirement Plans - Defined Benefit Retirement Plans - Future Minimum Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "145", "firstAnchor": { "contextRef": "As_Of_12_31_2024_JibFf-avkkWf6yqBT8Gysw", "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_JibFf-avkkWf6yqBT8Gysw", "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true, "unique": true } }, "R146": { "role": "http://www.ironwoodpharma.com/role/DisclosureWorkforceReductionAndRestructuringGeneralInformationDetails", "longName": "99941601 - Disclosure - Workforce Reduction and Restructuring - General Information (Details)", "shortName": "Workforce Reduction and Restructuring - General Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "146", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:RestructuringCharges", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2023_To_4_30_2023_us-gaap_RestructuringPlanAxis_irwd_ReductionInHeadquarterBasedWorkforceApril2023Member_7oRc50le4kqUijubHanOjw", "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent", "unitRef": "Unit_Standard_pure_o_LvPScFJEyjZOySCfKmrA", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "unique": true } }, "R147": { "role": "http://www.ironwoodpharma.com/role/DisclosureWorkforceReductionAndRestructuringTabularDisclosureDetails", "longName": "99941602 - Disclosure - Workforce Reduction and Restructuring - Tabular Disclosure (Details)", "shortName": "Workforce Reduction and Restructuring - Tabular Disclosure (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "147", "firstAnchor": { "contextRef": "As_Of_12_31_2023_EQuWQ5Sps0uzLFqYTj9Hhw", "name": "us-gaap:RestructuringReserve", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:PaymentsForRestructuring", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "unique": true } }, "R148": { "role": "http://www.ironwoodpharma.com/role/DisclosureSegmentReportingDetails", "longName": "99941701 - Disclosure - Segment Reporting (Details)", "shortName": "Segment Reporting (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "148", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_ks8LkKImQ0ub7DzcSRzfiQ", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "Unit_Standard_segment_UPliYGwpvUacsA7Qw8zaYg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:NumberOfReportableSegments", "us-gaap:NumberOfReportableSegments", "p", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": null }, "R149": { "role": "http://www.ironwoodpharma.com/role/DisclosureSelectedQuarterlyFinancialDataUnauditedDetails", "longName": "99941801 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Details)", "shortName": "Selected Quarterly Financial Data (Unaudited) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "149", "firstAnchor": { "contextRef": "Duration_10_1_2024_To_12_31_2024_8wbb371dtUeMP02yO8NnJg", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "us-gaap:QuarterlyFinancialInformationTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_10_1_2024_To_12_31_2024_8wbb371dtUeMP02yO8NnJg", "name": "us-gaap:CostsAndExpenses", "unitRef": "Unit_Standard_USD_orXLopNMmEabYMx6F-ppkA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "us-gaap:QuarterlyFinancialInformationTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irwd-20241231x10k.htm", "unique": true } } }, "tag": { "irwd_AbbviePlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "AbbviePlcMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsAccountsReceivableDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsEuropeanAndOtherTerritoriesDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCollaborativeArrangementsRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCommercialEffortsDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaRoyaltyRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsSummaryDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsTables", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "documentation": "AbbVie Plc [Member]", "label": "AbbVie Plc [Member]", "terseLabel": "AbbVie Plc" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountingStandardsUpdate202006Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingStandardsUpdate202006Member", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCumulativeEffectAdjustmentAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCumulativeEffectAdjustmentTabularDisclosureDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update 2020-06 [Member]", "terseLabel": "Accounting Standards Update 2020-06", "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity." } } }, "auth_ref": [ "r724", "r725", "r726", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735" ] }, "us-gaap_AccountingStandardsUpdate202307Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingStandardsUpdate202307Member", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update 2023-07 [Member]", "terseLabel": "Accounting Standards Update 2023-07", "documentation": "Accounting Standards Update 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures." } } }, "auth_ref": [ "r370", "r371" ] }, "us-gaap_AccountingStandardsUpdate202309Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingStandardsUpdate202309Member", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update 2023-09 [Member]", "terseLabel": "Accounting Standards Update 2023-09", "documentation": "Accounting Standards Update 2023-09 Income Taxes (Topic 740): Improvements to Income Tax Disclosures." } } }, "auth_ref": [ "r677", "r678", "r679" ] }, "us-gaap_AccountsNotesAndLoansReceivableLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsNotesAndLoansReceivableLineItems", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsAccountsReceivableDetails" ], "lang": { "en-us": { "role": { "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r373", "r1247" ] }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" ], "lang": { "en-us": { "role": { "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "terseLabel": "Accrued Expenses and Other Current Liabilities", "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period." } } }, "auth_ref": [ "r633" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts Payable, Current", "verboseLabel": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r91", "r1059" ] }, "us-gaap_AccountsPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsAccountsReceivableDetails" ], "lang": { "en-us": { "role": { "label": "Accounts Payable", "terseLabel": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r174", "r1417" ] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable [Member]", "terseLabel": "Accounts receivable", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": [ "r986" ] }, "us-gaap_AccountsReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNet", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsAccountsReceivableDetails" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable, after Allowance for Credit Loss", "terseLabel": "Accounts receivable, net", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business." } } }, "auth_ref": [ "r935", "r985", "r1079", "r1420", "r1421" ] }, "us-gaap_AccountsReceivableNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsAccountsReceivableDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableDetails" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable, after Allowance for Credit Loss [Abstract]", "terseLabel": "Accounts receivable, net", "verboseLabel": "Accounts Receivable" } } }, "auth_ref": [] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r1244" ] }, "irwd_AccountsReceivableNetOfAccountsPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "AccountsReceivableNetOfAccountsPayableCurrentAndNoncurrent", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsAccountsReceivableDetails" ], "lang": { "en-us": { "role": { "documentation": "Accounts Receivable, Net of Accounts Payable, Current and Noncurrent", "label": "Accounts Receivable, Net of Accounts Payable, Current and Noncurrent", "terseLabel": "Accounts receivable, net of accounts payable" } } }, "auth_ref": [] }, "irwd_AccruedExpensesAndOtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "AccruedExpensesAndOtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 }, "http://www.ironwoodpharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTabularDisclosureDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTabularDisclosureDetails", "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of accrued expenses and as well as used to reflect the other current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Expenses and Other Liabilities, Current", "totalLabel": "Total accrued expenses and other current liabilities", "verboseLabel": "Accrued expenses and other current liabilities" } } }, "auth_ref": [] }, "us-gaap_AccruedIncomeTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedIncomeTaxesCurrent", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTabularDisclosureDetails": { "parentTag": "irwd_AccruedExpensesAndOtherLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Income Taxes, Current", "terseLabel": "Accrued taxes", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations." } } }, "auth_ref": [ "r94", "r172" ] }, "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Liabilities and Other Liabilities [Abstract]", "terseLabel": "Accrued Expenses" } } }, "auth_ref": [] }, "irwd_AccruedResearchAndDevelopmentExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "AccruedResearchAndDevelopmentExpenseCurrent", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsOtherCollaborationAndLicenseAgreementsDetails", "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "This element represents the carrying value as of the balance sheet date of obligations incurred and payable, pertaining to research and development costs, that are statutory in nature, which are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Research and Development Expense Current", "terseLabel": "Accrued research and development costs" } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosurePropertyAndEquipmentTabularDisclosureDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosurePropertyAndEquipmentTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less accumulated depreciation and amortization", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r51", "r251", "r867" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r28", "r29", "r114", "r254", "r862", "r897", "r901" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated other comprehensive loss", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r3", "r16", "r29", "r717", "r720", "r801", "r892", "r893", "r1220", "r1221", "r1222", "r1231", "r1232", "r1233", "r1236" ] }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Acquired Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r392", "r393", "r394", "r396", "r998" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r1136" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCumulativeEffectAdjustmentTabularDisclosureDetails", "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r107" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional paid-in capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r913", "r1231", "r1232", "r1233", "r1236", "r1387", "r1453" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r1149" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r1149" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r1149" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r1149" ] }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCumulativeEffectAdjustmentAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCumulativeEffectAdjustmentTabularDisclosureDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update [Axis]", "documentation": "Information by amendment to accounting standards." } } }, "auth_ref": [ "r240", "r241", "r242", "r243", "r244", "r245", "r295", "r296", "r297", "r298", "r308", "r370", "r371", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r403", "r404", "r412", "r675", "r676", "r677", "r678", "r679", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r724", "r725", "r726", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r758", "r759", "r772", "r775", "r778", "r796", "r797", "r798", "r799", "r800", "r801", "r816", "r817", "r818", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901" ] }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "negatedLabel": "Taxes paid related to net share settlement of share-based awards", "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Share-based compensation expense related to share-based awards and employee stock purchase plan", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r69", "r70", "r589" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash provided by operating activities:" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": [ "r1194" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r1107", "r1118", "r1128", "r1161" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r1110", "r1121", "r1131", "r1164" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": [ "r1195" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r1149" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r1156" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r1111", "r1122", "r1132", "r1156", "r1165", "r1169", "r1177" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r1175" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansShareBasedCompensationExpenseTabularDisclosureDetails": { "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansShareBasedCompensationExpenseAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansShareBasedCompensationExpenseTabularDisclosureDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansSummaryOfExpenseRecognizedByShareBasedCompensationArrangementDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Share-based compensation expense", "verboseLabel": "Total share-based compensation expense included in operating expenses", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r622", "r631" ] }, "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpenseNetOfTax", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansShareBasedCompensationExpenseTabularDisclosureDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansShareBasedCompensationExpenseTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expense, after Tax", "totalLabel": "Total share-based compensation expense, net of tax", "documentation": "Amount, after tax, of expense for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableDetails" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable, Allowance for Credit Loss", "terseLabel": "Allowance for credit losses", "documentation": "Amount of allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r255", "r374", "r387", "r388", "r389", "r1421" ] }, "irwd_AlnylamMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "AlnylamMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsOtherCollaborationAndLicenseAgreementsDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsSummaryDetails" ], "lang": { "en-us": { "role": { "documentation": "Alnylam [Member]", "label": "Alnylam" } } }, "auth_ref": [] }, "irwd_AmendedAndRestated2010EmployeeDirectorAndConsultantEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "AmendedAndRestated2010EmployeeDirectorAndConsultantEquityIncentivePlanMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansStockBenefitPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Amended and Restated 2010 Employee Director and Consultant Equity Incentive Plan [Member]", "label": "Amended and Restated 2010 Employee Director and Consultant Equity Incentive Plan [Member]", "terseLabel": "2010 Equity Plan" } } }, "auth_ref": [] }, "irwd_AmendedAndRestated2019EquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "AmendedAndRestated2019EquityIncentivePlanMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansStockBenefitPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Amended and Restated 2019 Equity Incentive Plan [Member]", "label": "Amended and Restated 2019 Equity Incentive Plan [Member]", "terseLabel": "A&R 2019 Equity Plan" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfFinancingCosts", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureDebtInterestExpenseDetails": { "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtInterestExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of debt issuance costs", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref": [ "r123", "r466", "r1226", "r1400" ] }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Non-cash interest expense", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r466", "r1029", "r1030", "r1226", "r1400" ] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Amortization of Intangible Assets", "terseLabel": "Amortization expense", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r10", "r391", "r398", "r1025" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerSharePotentiallyDilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Total potentially dilutive securities excluded from the computation of diluted weighted average shares outstanding (in shares)", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r328" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerSharePotentiallyDilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r39" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerSharePotentiallyDilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerSharePotentiallyDilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r39" ] }, "irwd_ApplicableRateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "ApplicableRateMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Applicable Rate [Member]", "label": "Applicable Rate [Member]", "terseLabel": "Applicable Rate" } } }, "auth_ref": [] }, "us-gaap_AreaOfRealEstateProperty": { "xbrltype": "areaItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AreaOfRealEstateProperty", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesSummerStreetLeaseDetails" ], "lang": { "en-us": { "role": { "label": "Area of Real Estate Property", "terseLabel": "Rentable area leased (in square feet)", "documentation": "Area of a real estate property." } } }, "auth_ref": [] }, "irwd_AsahiKaseiPharmaCorporationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "AsahiKaseiPharmaCorporationMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsOtherCollaborationAndLicenseAgreementsDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsSummaryDetails" ], "lang": { "en-us": { "role": { "documentation": "Asahi Kasei Pharma Corporation [Member]", "label": "Asahi Kasei Pharma Corporation [Member]", "terseLabel": "Asahi Kasei Pharma Corporation" } } }, "auth_ref": [] }, "irwd_AssembledWorkforceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "AssembledWorkforceMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsFiniteLivedIntangibleAssetsDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Assembled Workforce [Member]", "label": "Assembled Workforce [Member]", "terseLabel": "Assembled Workforce" } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Asset Acquisition [Abstract]" } } }, "auth_ref": [] }, "irwd_AssetAcquisitionAcquiredInProcessResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "AssetAcquisitionAcquiredInProcessResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfIncomeLoss": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 4.0 }, "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsAcquiredInProcessResearchAndDevelopmentDetails", "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Acquired In-process Research and Development Expense", "label": "Asset Acquisition, Acquired In-process Research and Development Expense", "terseLabel": "Acquired in-process research and development", "verboseLabel": "Asset acquisition, acquired in-process research and development expense" } } }, "auth_ref": [] }, "irwd_AssetAcquisitionAcquisitionRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "AssetAcquisitionAcquisitionRelatedCosts", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Acquisition Related Costs", "label": "Asset Acquisition, Acquisition Related Costs", "terseLabel": "Asset acquisition, acquisition related costs" } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionAxis", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsAcquiredInProcessResearchAndDevelopmentDetails", "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsExpensesDetails", "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsTotalConsiderationPaidAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsTotalConsiderationPaidTabularDisclosureDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansShareBasedCompensationExpenseAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesAcquisitionsDetails" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Axis]", "documentation": "Information by asset acquisition." } } }, "auth_ref": [ "r392", "r393", "r394", "r395", "r396", "r1380" ] }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionConsiderationTransferred", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsTotalConsiderationPaidTabularDisclosureDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsTotalConsiderationPaidTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition, Consideration Transferred", "totalLabel": "Total purchase consideration", "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer." } } }, "auth_ref": [ "r1048", "r1381", "r1382", "r1383" ] }, "us-gaap_AssetAcquisitionConsiderationTransferredAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionConsiderationTransferredAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsTotalConsiderationPaidTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition, Consideration Transferred [Abstract]", "terseLabel": "Asset Acquisition, Consideration Transferred" } } }, "auth_ref": [] }, "irwd_AssetAcquisitionConsiderationTransferredCashConsiderationPaidSellingShareholders": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "AssetAcquisitionConsiderationTransferredCashConsiderationPaidSellingShareholders", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsTotalConsiderationPaidTabularDisclosureDetails": { "parentTag": "us-gaap_AssetAcquisitionConsiderationTransferred", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsTotalConsiderationPaidTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Consideration Transferred, Cash Consideration Paid, Selling Shareholders", "label": "Asset Acquisition, Consideration Transferred, Cash Consideration Paid, Selling Shareholders", "terseLabel": "Cash consideration paid to selling shareholders" } } }, "auth_ref": [] }, "irwd_AssetAcquisitionConsiderationTransferredCashConsiderationPaidSellingShareholdersSharesTenderedSharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "AssetAcquisitionConsiderationTransferredCashConsiderationPaidSellingShareholdersSharesTenderedSharePrice", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsTotalConsiderationPaidAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Consideration Transferred, Cash Consideration Paid, Selling Shareholders, Shares Tendered, Share Price", "label": "Asset Acquisition, Consideration Transferred, Cash Consideration Paid, Selling Shareholders, Shares Tendered, Share Price", "terseLabel": "Asset acquisition, consideration transferred, cash consideration paid, selling shareholders, shares tendered, share price (in dollars per share)" } } }, "auth_ref": [] }, "irwd_AssetAcquisitionConsiderationTransferredCashConsiderationPaidSellingShareholdersSharesTenderedShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "AssetAcquisitionConsiderationTransferredCashConsiderationPaidSellingShareholdersSharesTenderedShares", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsTotalConsiderationPaidAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Consideration Transferred, Cash Consideration Paid, Selling Shareholders, Shares Tendered, Shares", "label": "Asset Acquisition, Consideration Transferred, Cash Consideration Paid, Selling Shareholders, Shares Tendered, Shares", "terseLabel": "Asset acquisition, consideration transferred, cash consideration paid, selling shareholders, shares tendered, shares (in shares)" } } }, "auth_ref": [] }, "irwd_AssetAcquisitionConsiderationTransferredCashConsiderationPaidSettleRestrictedStockUnitsAndStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "AssetAcquisitionConsiderationTransferredCashConsiderationPaidSettleRestrictedStockUnitsAndStockOptions", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsTotalConsiderationPaidTabularDisclosureDetails": { "parentTag": "us-gaap_AssetAcquisitionConsiderationTransferred", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsTotalConsiderationPaidTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Consideration Transferred, Cash Consideration Paid, Settle Restricted Stock Units and Stock Options", "label": "Asset Acquisition, Consideration Transferred, Cash Consideration Paid, Settle Restricted Stock Units and Stock Options", "terseLabel": "Cash consideration paid to settle VectivBio RSUs and stock options" } } }, "auth_ref": [] }, "irwd_AssetAcquisitionConsiderationTransferredCashConsiderationPaidSettleRestrictedStockUnitsAndStockOptionsSharesSettledSharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "AssetAcquisitionConsiderationTransferredCashConsiderationPaidSettleRestrictedStockUnitsAndStockOptionsSharesSettledSharePrice", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsTotalConsiderationPaidAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Consideration Transferred, Cash Consideration Paid, Settle Restricted Stock Units and Stock Options, Shares Settled, Share Price", "label": "Asset Acquisition, Consideration Transferred, Cash Consideration Paid, Settle Restricted Stock Units and Stock Options, Shares Settled, Share Price", "terseLabel": "Asset acquisition, consideration transferred, cash consideration paid, settle restricted stock units and stock options, shares settled, share price (in dollars per share)" } } }, "auth_ref": [] }, "irwd_AssetAcquisitionConsiderationTransferredCashConsiderationPaidSettleRestrictedStockUnitsAndStockOptionsSharesSettledShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "AssetAcquisitionConsiderationTransferredCashConsiderationPaidSettleRestrictedStockUnitsAndStockOptionsSharesSettledShares", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsTotalConsiderationPaidAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Consideration Transferred, Cash Consideration Paid, Settle Restricted Stock Units and Stock Options, Shares Settled, Shares", "label": "Asset Acquisition, Consideration Transferred, Cash Consideration Paid, Settle Restricted Stock Units and Stock Options, Shares Settled, Shares", "terseLabel": "Asset acquisition, consideration transferred, cash consideration paid, settle restricted stock units and stock options, shares settled, shares (in shares)" } } }, "auth_ref": [] }, "irwd_AssetAcquisitionConsiderationTransferredCashConsiderationPaidSettleWarrantLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "AssetAcquisitionConsiderationTransferredCashConsiderationPaidSettleWarrantLiabilities", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsTotalConsiderationPaidTabularDisclosureDetails": { "parentTag": "us-gaap_AssetAcquisitionConsiderationTransferred", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsTotalConsiderationPaidTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Consideration Transferred, Cash Consideration Paid, Settle Warrant Liabilities", "label": "Asset Acquisition, Consideration Transferred, Cash Consideration Paid, Settle Warrant Liabilities", "terseLabel": "Cash consideration paid to settle VectivBio warrant liabilities" } } }, "auth_ref": [] }, "irwd_AssetAcquisitionConsiderationTransferredCashConsiderationPaidSettleWarrantLiabilitiesWarrantsOutstandingPricePerWarrant": { "xbrltype": "perShareItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "AssetAcquisitionConsiderationTransferredCashConsiderationPaidSettleWarrantLiabilitiesWarrantsOutstandingPricePerWarrant", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsTotalConsiderationPaidAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Consideration Transferred, Cash Consideration Paid, Settle Warrant Liabilities, Warrants Outstanding, Price Per Warrant", "label": "Asset Acquisition, Consideration Transferred, Cash Consideration Paid, Settle Warrant Liabilities, Warrants Outstanding, Price Per Warrant", "terseLabel": "Asset acquisition, consideration transferred, cash consideration paid, settle warrant liabilities, warrants outstanding, price per warrant (in dollars per share)" } } }, "auth_ref": [] }, "irwd_AssetAcquisitionConsiderationTransferredCashConsiderationPaidSettleWarrantLiabilitiesWarrantsOutstandingSharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "AssetAcquisitionConsiderationTransferredCashConsiderationPaidSettleWarrantLiabilitiesWarrantsOutstandingSharePrice", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsTotalConsiderationPaidAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Consideration Transferred, Cash Consideration Paid, Settle Warrant Liabilities, Warrants Outstanding, Share Price", "label": "Asset Acquisition, Consideration Transferred, Cash Consideration Paid, Settle Warrant Liabilities, Warrants Outstanding, Share Price", "terseLabel": "Asset acquisition, consideration transferred, cash consideration paid, settle warrant liabilities, warrants outstanding, share price (in dollars per share)" } } }, "auth_ref": [] }, "irwd_AssetAcquisitionConsiderationTransferredCashConsiderationPaidSettleWarrantLiabilitiesWarrantsOutstandingShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "AssetAcquisitionConsiderationTransferredCashConsiderationPaidSettleWarrantLiabilitiesWarrantsOutstandingShares", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsTotalConsiderationPaidAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Consideration Transferred, Cash Consideration Paid, Settle Warrant Liabilities, Warrants Outstanding, Shares", "label": "Asset Acquisition, Consideration Transferred, Cash Consideration Paid, Settle Warrant Liabilities, Warrants Outstanding, Shares", "terseLabel": "Asset acquisition, consideration transferred, cash consideration paid, settle warrant liabilities, warrants outstanding, shares (in shares)" } } }, "auth_ref": [] }, "irwd_AssetAcquisitionConsiderationTransferredCashConsiderationPaidSettleWarrantLiabilitiesWarrantsOutstandingStrikePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "AssetAcquisitionConsiderationTransferredCashConsiderationPaidSettleWarrantLiabilitiesWarrantsOutstandingStrikePrice", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsTotalConsiderationPaidAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Consideration Transferred, Cash Consideration Paid, Settle Warrant Liabilities, Warrants Outstanding, Strike Price", "label": "Asset Acquisition, Consideration Transferred, Cash Consideration Paid, Settle Warrant Liabilities, Warrants Outstanding, Strike Price", "terseLabel": "Asset acquisition, consideration transferred, cash consideration paid, settle warrant liabilities, warrants outstanding, strike price (in dollars per share)" } } }, "auth_ref": [] }, "irwd_AssetAcquisitionConsiderationTransferredFairValueOfNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "AssetAcquisitionConsiderationTransferredFairValueOfNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsTotalConsiderationPaidTabularDisclosureDetails": { "parentTag": "us-gaap_AssetAcquisitionConsiderationTransferred", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsTotalConsiderationPaidTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Consideration Transferred, Fair Value of Noncontrolling Interest", "label": "Asset Acquisition, Consideration Transferred, Fair Value of Noncontrolling Interest", "terseLabel": "Fair value of non-controlling interest" } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionConsiderationTransferredTransactionCost", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsTotalConsiderationPaidTabularDisclosureDetails": { "parentTag": "us-gaap_AssetAcquisitionConsiderationTransferred", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsTotalConsiderationPaidTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition, Consideration Transferred, Transaction Cost", "terseLabel": "Transaction costs", "documentation": "Amount of transaction cost incurred as part of consideration transferred in asset acquisition." } } }, "auth_ref": [ "r1048", "r1381", "r1382", "r1383" ] }, "us-gaap_AssetAcquisitionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionDomain", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsAcquiredInProcessResearchAndDevelopmentDetails", "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsExpensesDetails", "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsTotalConsiderationPaidAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsTotalConsiderationPaidTabularDisclosureDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansShareBasedCompensationExpenseAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesAcquisitionsDetails" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Domain]", "documentation": "Asset acquisition." } } }, "auth_ref": [ "r392", "r393", "r394", "r395", "r396", "r1380" ] }, "us-gaap_AssetAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionLineItems", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsAcquiredInProcessResearchAndDevelopmentDetails", "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsExpensesDetails", "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsTotalConsiderationPaidAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsTotalConsiderationPaidTabularDisclosureDetails", "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesAcquisitionsDetails" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Line Items]", "terseLabel": "Acquisitions", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r1380" ] }, "irwd_AssetAcquisitionOwnershipInterestPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "AssetAcquisitionOwnershipInterestPercentage", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsGeneralInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Ownership Interest, Percentage", "label": "Asset Acquisition, Ownership Interest, Percentage", "terseLabel": "Asset acquisition, ownership interest, percentage (as a percent)" } } }, "auth_ref": [] }, "irwd_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails": { "parentTag": "irwd_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Acquired In-process Research and Development", "label": "Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Acquired In-process Research and Development", "terseLabel": "Acquired in-process research and development" } } }, "auth_ref": [] }, "irwd_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails": { "parentTag": "irwd_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets", "label": "Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets", "totalLabel": "Total assets acquired" } } }, "auth_ref": [] }, "irwd_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails": { "parentTag": "irwd_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "label": "Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash and cash equivalents" } } }, "auth_ref": [] }, "irwd_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails": { "parentTag": "irwd_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities", "label": "Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities", "terseLabel": "Current liabilities" } } }, "auth_ref": [] }, "irwd_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails": { "parentTag": "irwd_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets", "label": "Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets", "terseLabel": "Intangible assets" } } }, "auth_ref": [] }, "irwd_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails": { "parentTag": "irwd_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "label": "Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "totalLabel": "Total liabilities assumed" } } }, "auth_ref": [] }, "irwd_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "label": "Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "totalLabel": "Net assets acquired" } } }, "auth_ref": [] }, "irwd_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails": { "parentTag": "irwd_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Liabilities, Noncurrent", "label": "Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Liabilities, Noncurrent", "terseLabel": "Other liabilities" } } }, "auth_ref": [] }, "irwd_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPrepaidExpensesAndOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPrepaidExpensesAndOtherCurrentAssets", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails": { "parentTag": "irwd_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Prepaid Expenses and Other Current Assets", "label": "Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Prepaid Expenses and Other Current Assets", "terseLabel": "Prepaid expenses and other current assets" } } }, "auth_ref": [] }, "irwd_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyAndEquipment", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails": { "parentTag": "irwd_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property and Equipment", "label": "Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property and Equipment", "terseLabel": "Property and equipment" } } }, "auth_ref": [] }, "irwd_AssetAcquisitionSharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "AssetAcquisitionSharePrice", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsGeneralInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Share Price", "label": "Asset Acquisition, Share Price", "terseLabel": "Asset acquisition, share price (in dollars per share)" } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionTable", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsAcquiredInProcessResearchAndDevelopmentDetails", "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsExpensesDetails", "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsTotalConsiderationPaidAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsTotalConsiderationPaidTabularDisclosureDetails", "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesAcquisitionsDetails" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Table]", "documentation": "Disclosure of information about asset acquisition." } } }, "auth_ref": [ "r1380" ] }, "us-gaap_AssetAcquisitionTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionTableTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsTables" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Table Text Block]", "terseLabel": "Schedule of asset acquisition", "documentation": "Tabular disclosure of asset acquisition." } } }, "auth_ref": [ "r1380" ] }, "us-gaap_AssetAcquisitionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitions" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Text Block]", "terseLabel": "Acquisitions", "documentation": "The entire disclosure for asset acquisition." } } }, "auth_ref": [ "r1380" ] }, "irwd_AssetAcquisitionsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "AssetAcquisitionsPolicyPolicyTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for asset acquisitions.", "label": "Asset Acquisitions Policy [Policy Text Block]", "terseLabel": "Acquisitions" } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r170", "r184", "r253", "r283", "r333", "r341", "r358", "r361", "r375", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r705", "r709", "r760", "r858", "r940", "r1017", "r1018", "r1059", "r1086", "r1273", "r1274", "r1406" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r247", "r256", "r283", "r375", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r705", "r709", "r760", "r1059", "r1273", "r1274", "r1406" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure", "totalLabel": "Total assets measured at fair value", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r737", "r738", "r1051" ] }, "us-gaap_AssetsFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosureAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "auth_ref": [] }, "irwd_AstellasPharmaInc2009LicenseAgreementAmended2019Member": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "AstellasPharmaInc2009LicenseAgreementAmended2019Member", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsJapanDetails" ], "lang": { "en-us": { "role": { "documentation": "Astellas Pharma Inc, 2009 License Agreement, Amended 2019 [Member]", "label": "Astellas Pharma Inc., 2009 License Agreement, Amended 2019" } } }, "auth_ref": [] }, "irwd_AstellasPharmaIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "AstellasPharmaIncMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsJapanDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsSummaryDetails" ], "lang": { "en-us": { "role": { "documentation": "Astellas Pharma Inc [Member]", "label": "Astellas Pharma Inc." } } }, "auth_ref": [] }, "irwd_AstraZenecaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "AstraZenecaMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsChinaHongKongAndMacauDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsSummaryDetails" ], "lang": { "en-us": { "role": { "documentation": "AstraZeneca [Member]", "label": "AstraZeneca" } } }, "auth_ref": [] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorFirmId", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r1090", "r1091", "r1114" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorLocation", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r1090", "r1091", "r1114" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorName", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r1090", "r1091", "r1114" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r1172" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r1173" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r1168" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r1168" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r1168" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r1168" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r1168" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r1168" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansPerformanceBasedRsusActivityDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansPerformanceBasedRsusAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansPerformanceBasedRsusAssumptionsDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansPerformanceBasedRsusVestingDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansRestrictedStockAwardsActivityDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansRestrictedStockAwardsAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansRestrictedStockAwardsGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansRestrictedStockUnitsDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansStockBenefitPlansDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansStockOptionsGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansSummaryOfExpenseRecognizedByShareBasedCompensationArrangementDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTables", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTimeBasedRsusActivityDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTimeBasedRsusAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTimeBasedRsusVestingDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansUnrecognizedShareBasedCompensationDetails", "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerShareComputationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r593", "r594", "r595", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r617", "r618", "r619", "r620", "r621" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r1171" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r1170" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r1169" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r1169" ] }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r132" ] }, "irwd_CalendarQuarterCommencingAfterDecember312019Member": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "CalendarQuarterCommencingAfterDecember312019Member", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to calendar quarter commencing after calendar quarter ending December 31, 2019.", "label": "Calendar quarter commencing after December 31, 2019" } } }, "auth_ref": [] }, "us-gaap_CallOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CallOptionMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtCappedCallsWithRespectTo2024ConvertibleNotesAnd2026ConvertibleNotesDetails", "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsCappedCallsDetails" ], "lang": { "en-us": { "role": { "label": "Call Option [Member]", "terseLabel": "Capped Calls with Respect to 2024 Convertible Notes and 2026 Convertible Notes", "documentation": "Financial contract between two parties, the buyer and the seller of the option, where the buyer has the right but not the obligation to buy an agreed quantity of a particular commodity or financial instrument (the underlying instrument) from the seller of the option for a certain price (the strike price). Seller is obligated to sell the asset to the buyer, if the buyer exercises the option." } } }, "auth_ref": [ "r978", "r979" ] }, "irwd_CanadaAndMexicoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "CanadaAndMexicoMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaRoyaltyRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Canada and Mexico [Member]", "label": "Canada and Mexico", "terseLabel": "Canada and Mexico" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets", "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r34", "r249", "r1002" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValueAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value [Abstract]", "terseLabel": "Cash and Cash Equivalents" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAxis", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": [ "r249" ] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash and cash equivalents", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1389", "r1390" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r35" ] }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Restricted Cash", "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits." } } }, "auth_ref": [ "r35", "r169" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period", "totalLabel": "Total cash, cash equivalents, and restricted cash", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r34", "r129", "r280" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r2", "r129" ] }, "us-gaap_CashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "Cash Equivalents, at Carrying Value", "terseLabel": "Cash Equivalent included in cash and cash equivalent", "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r1217", "r1419" ] }, "us-gaap_CashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashEquivalentsMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Cash Equivalents [Member]", "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r249" ] }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" ], "lang": { "en-us": { "role": { "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]", "verboseLabel": "Change in Accounting Principle, Accounting Standards Update, Adopted", "documentation": "Indicates (true false) whether accounting standards update was adopted." } } }, "auth_ref": [ "r203", "r204", "r245", "r294", "r370", "r376", "r377", "r378", "r383", "r384", "r403", "r412", "r677", "r686", "r687", "r695", "r696", "r698", "r712", "r713", "r724", "r725", "r758", "r759", "r775", "r796", "r797", "r816", "r817", "r890", "r891" ] }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" ], "lang": { "en-us": { "role": { "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date", "verboseLabel": "Change in Accounting Principle, Accounting Standards Update, Adoption Date", "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format." } } }, "auth_ref": [ "r203", "r204", "r245", "r370", "r376", "r377", "r378", "r383", "r384", "r385", "r403", "r412", "r677", "r686", "r687", "r695", "r696", "r697", "r698", "r699", "r711", "r712", "r713", "r714", "r724", "r725", "r726", "r730", "r758", "r759", "r775", "r796", "r797", "r816", "r817", "r890", "r891", "r1207" ] }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" ], "lang": { "en-us": { "role": { "label": "Change in Accounting Principle, Accounting Standards Update, Transition Option Elected [Extensible Enumeration]", "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Transition Option Elected", "documentation": "Indicates transition method applied for adoption of amendment to accounting standards." } } }, "auth_ref": [ "r386", "r679", "r691", "r692", "r698", "r699", "r700", "r716", "r727", "r732", "r772", "r773", "r774", "r776", "r777", "r778", "r798", "r892", "r902" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r1147" ] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": [ "r1144" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": [ "r1142" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDisclosuresAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureStockholdersEquityStockRepurchaseProgramDetails" ], "lang": { "en-us": { "role": { "label": "Class of Stock Disclosures [Abstract]", "terseLabel": "Stock Repurchase Program" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r1148" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r1148" ] }, "irwd_CollaborationAndLicenseAgreementsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "CollaborationAndLicenseAgreementsDisclosureAbstract", "lang": { "en-us": { "role": { "documentation": "Collaboration and License Agreements Disclosure [Abstract]", "label": "Collaboration and License Agreements Disclosure [Abstract]" } } }, "auth_ref": [] }, "irwd_CollaborativeArrangementCoPromotionAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "CollaborativeArrangementCoPromotionAgreementMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsOtherCollaborationAndLicenseAgreementsDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsSummaryDetails" ], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Co-promotion Agreement [Member]", "label": "Collaborative arrangement, co-promotion agreements" } } }, "auth_ref": [] }, "irwd_CollaborativeArrangementCoPromotionAndOtherAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "CollaborativeArrangementCoPromotionAndOtherAgreementsMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsOtherCollaborationAndLicenseAgreementsDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsSummaryDetails" ], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Co-promotion and Other Agreements [Member]", "label": "Collaborative arrangement, co-promotion and other agreements" } } }, "auth_ref": [] }, "irwd_CollaborativeArrangementCollaborationAndLicenseAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "CollaborativeArrangementCollaborationAndLicenseAgreementsMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsChinaHongKongAndMacauDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsEuropeanAndOtherTerritoriesDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsJapanDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCollaborativeArrangementsRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaRoyaltyRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsSummaryDetails" ], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Collaboration and License Agreements [Member]", "label": "Collaborative arrangement, collaboration and license agreements" } } }, "auth_ref": [] }, "irwd_CollaborativeArrangementCommercialAndSalesBasedMilestonePaymentsEligibleToReceive": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "CollaborativeArrangementCommercialAndSalesBasedMilestonePaymentsEligibleToReceive", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsOtherCollaborationAndLicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Commercial and Sales-based Milestone Payments, Eligible to Receive", "label": "Collaborative Arrangement, Commercial and Sales-based Milestone Payments, Eligible to Receive", "terseLabel": "Collaborative arrangement, commercial and sales-based milestone payments, eligible to receive" } } }, "auth_ref": [] }, "irwd_CollaborativeArrangementDevelopmentAndCommercializationAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "CollaborativeArrangementDevelopmentAndCommercializationAgreementsMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsOtherCollaborationAndLicenseAgreementsDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsSummaryDetails" ], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Development and Commercialization Agreements [Member]", "label": "Collaborative Arrangement, Development and Commercialization Agreements [Member]", "terseLabel": "Collaborative arrangement, development and commercialization agreements" } } }, "auth_ref": [] }, "irwd_CollaborativeArrangementDevelopmentMilestonesEligibleToReceive": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "CollaborativeArrangementDevelopmentMilestonesEligibleToReceive", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsOtherCollaborationAndLicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Development Milestones, Eligible to Receive", "label": "Collaborative Arrangement, Development Milestones, Eligible to Receive", "terseLabel": "Collaborative arrangement, development milestones, eligible to receive" } } }, "auth_ref": [] }, "irwd_CollaborativeArrangementDevelopmentMilestonesReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "CollaborativeArrangementDevelopmentMilestonesReceived", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsOtherCollaborationAndLicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Development Milestones, Received", "label": "Collaborative Arrangement, Development Milestones, Received", "terseLabel": "Collaborative arrangement, development milestones, received" } } }, "auth_ref": [] }, "irwd_CollaborativeArrangementDevelopmentRelatedPaymentEligibleToReceive": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "CollaborativeArrangementDevelopmentRelatedPaymentEligibleToReceive", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsOtherCollaborationAndLicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Development Related Payment, Eligible to Receive", "label": "Collaborative Arrangement, Development Related Payment, Eligible to Receive", "terseLabel": "Collaborative arrangement, development related payment, eligible to receive" } } }, "auth_ref": [] }, "irwd_CollaborativeArrangementDevelopmentRelatedPaymentReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "CollaborativeArrangementDevelopmentRelatedPaymentReceived", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsOtherCollaborationAndLicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Development Related Payment, Received", "label": "Collaborative Arrangement, Development Related Payment, Received", "terseLabel": "Collaborative arrangement, development related payment, received" } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementDisclosureTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreements" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Collaboration, License, and Other Agreements", "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants." } } }, "auth_ref": [ "r192", "r194", "r208" ] }, "irwd_CollaborativeArrangementNoncontingentReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "CollaborativeArrangementNoncontingentReceivableCurrent", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsChinaHongKongAndMacauDetails" ], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Noncontingent Receivable, Current", "label": "Collaborative Arrangement, Noncontingent Receivable, Current", "terseLabel": "Collaborative arrangement, non-contingent receivable, current" } } }, "auth_ref": [] }, "irwd_CollaborativeArrangementOptionToAcquireLicenseExercisePricePayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "CollaborativeArrangementOptionToAcquireLicenseExercisePricePayable", "crdr": "credit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsOtherCollaborationAndLicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Option to Acquire License, Exercise Price, Payable", "label": "Collaborative Arrangement, Option to Acquire License, Exercise Price, Payable", "terseLabel": "Collaborative arrangement, option to acquire license, exercise price, payable" } } }, "auth_ref": [] }, "irwd_CollaborativeArrangementOtherAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "CollaborativeArrangementOtherAgreementsMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsSummaryDetails" ], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Other Agreements [Member]", "label": "Collaborative arrangement, other agreements" } } }, "auth_ref": [] }, "irwd_CollaborativeArrangementPercentageOfNetLoss": { "xbrltype": "percentItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "CollaborativeArrangementPercentageOfNetLoss", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaGeneralInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of net loss from commercialization.", "label": "Collaborative Arrangement Percentage of Net Loss", "terseLabel": "Percentage of net loss from commercialization (as a percent)" } } }, "auth_ref": [] }, "irwd_CollaborativeArrangementPercentageOfNetProfit": { "xbrltype": "percentItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "CollaborativeArrangementPercentageOfNetProfit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaGeneralInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of net profit from commercialization.", "label": "Collaborative Arrangement Percentage of Net Profit", "terseLabel": "Percentage of net profit from commercialization (as a percent)" } } }, "auth_ref": [] }, "irwd_CollaborativeArrangementPercentageOfObligationOfDevelopmentCostsIncurred": { "xbrltype": "percentItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "CollaborativeArrangementPercentageOfObligationOfDevelopmentCostsIncurred", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaGeneralInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Percentage of Obligation of Development Costs Incurred", "label": "Collaborative Arrangement, Percentage of Obligation of Development Costs Incurred", "terseLabel": "Collaborative arrangement, percentage of obligation of development costs incurred" } } }, "auth_ref": [] }, "irwd_CollaborativeArrangementPercentageOfPreTaxNetProfitLoss": { "xbrltype": "percentItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "CollaborativeArrangementPercentageOfPreTaxNetProfitLoss", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of pre-tax net profit or loss from commercialization.", "label": "Collaborative Arrangement Percentage of Pre Tax Net Profit (Loss)", "terseLabel": "Percentage of the pre-tax net profit or loss (as a percent)" } } }, "auth_ref": [] }, "irwd_CollaborativeArrangementPerformanceObligationsNumber": { "xbrltype": "integerItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "CollaborativeArrangementPerformanceObligationsNumber", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsOtherCollaborationAndLicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Performance Obligations, Number", "label": "Collaborative Arrangement, Performance Obligations, Number", "terseLabel": "Collaborative arrangement, performance obligations, number" } } }, "auth_ref": [] }, "irwd_CollaborativeArrangementRightToApplyCreditAgainstFutureAmountsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "CollaborativeArrangementRightToApplyCreditAgainstFutureAmountsDue", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsOtherCollaborationAndLicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Right to Apply Credit Against Future Amounts Due", "label": "Collaborative Arrangement, Right to Apply Credit Against Future Amounts Due", "terseLabel": "Collaborative arrangement, right to apply credit against future amounts due" } } }, "auth_ref": [] }, "irwd_CollaborativeArrangementRoyaltyNetSalesOfProductsContainingActiveIngredientPeriodFollowingFirstCommercialSale": { "xbrltype": "durationItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "CollaborativeArrangementRoyaltyNetSalesOfProductsContainingActiveIngredientPeriodFollowingFirstCommercialSale", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsEuropeanAndOtherTerritoriesDetails" ], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Royalty, Net Sales of Products Containing Active Ingredient, Period Following First Commercial Sale", "label": "Collaborative Arrangement, Royalty, Net Sales of Products Containing Active Ingredient, Period Following First Commercial Sale", "terseLabel": "Collaborative arrangement, royalty, net sales of products containing active ingredient, period following first commercial sale" } } }, "auth_ref": [] }, "irwd_CollaborativeArrangementRoyaltyPercentageAggregateAnnualNetProductSalesMaximum": { "xbrltype": "percentItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "CollaborativeArrangementRoyaltyPercentageAggregateAnnualNetProductSalesMaximum", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsChinaHongKongAndMacauDetails" ], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Royalty Percentage, Aggregate Annual Net Product Sales, Maximum", "label": "Collaborative Arrangement, Royalty Percentage, Aggregate Annual Net Product Sales, Maximum", "terseLabel": "Collaborative arrangement, royalty percentage, aggregate annual net product sales, maximum (as a percent)" } } }, "auth_ref": [] }, "irwd_CollaborativeArrangementUpfrontPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "CollaborativeArrangementUpfrontPayment", "crdr": "credit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsOtherCollaborationAndLicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Upfront Payment", "label": "Collaborative Arrangement, Upfront Payment", "terseLabel": "Collaborative arrangement, upfront payment" } } }, "auth_ref": [] }, "irwd_CollaborativeArrangementUpfrontPaymentReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "CollaborativeArrangementUpfrontPaymentReceived", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsOtherCollaborationAndLicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Upfront Payment Received", "label": "Collaborative Arrangement, Upfront Payment Received", "terseLabel": "Collaborative arrangement, upfront payment received" } } }, "auth_ref": [] }, "irwd_CollaborativeArrangementsAndActivePharmaceuticalIngredientMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "CollaborativeArrangementsAndActivePharmaceuticalIngredientMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsChinaHongKongAndMacauDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsEuropeanAndOtherTerritoriesDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsJapanDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCollaborativeArrangementsRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCommercialEffortsDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaRoyaltyRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsOtherCollaborationAndLicenseAgreementsDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsSummaryDetails" ], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangements and Active Pharmaceutical Ingredient [Member]", "label": "Collaborative arrangements and active pharmaceutical ingredient" } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsChinaHongKongAndMacauDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsEuropeanAndOtherTerritoriesDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsJapanDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCollaborativeArrangementsRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCommercialEffortsDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaRoyaltyRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsOtherCollaborationAndLicenseAgreementsDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsTables", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Collaboration agreements", "verboseLabel": "Collaboration, License, Promotion and Other Commercial Agreements", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r703" ] }, "irwd_CollaborativeArrangementsLinzessMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "CollaborativeArrangementsLinzessMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCollaborativeArrangementsRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCommercialEffortsDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaGeneralInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangements, LINZESS [Member]", "label": "Collaborative arrangements, LINZESS" } } }, "auth_ref": [] }, "irwd_CollaborativeArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "CollaborativeArrangementsMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsChinaHongKongAndMacauDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsEuropeanAndOtherTerritoriesDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsJapanDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCollaborativeArrangementsRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCommercialEffortsDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaRoyaltyRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsOtherCollaborationAndLicenseAgreementsDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsSummaryDetails" ], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangements [Member]", "label": "Collaborative arrangements revenue" } } }, "auth_ref": [] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommercialPaperMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": [ "r146", "r434", "r1080", "r1081", "r1082", "r1083" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r101", "r176", "r859", "r926" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsContingenciesAndGuaranteesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsContingenciesAndGuaranteesTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "Commitments Contingencies and Guarantees [Text Block]", "terseLabel": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments, contingencies, and guarantees." } } }, "auth_ref": [ "r143", "r144", "r1269" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r1076", "r1077", "r1078", "r1080", "r1081", "r1082", "r1083", "r1231", "r1232", "r1236", "r1387", "r1452", "r1453" ] }, "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureStockholdersEquityCommonStockDetails", "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]", "terseLabel": "Common stock" } } }, "auth_ref": [] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r105" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r105", "r927" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheetsParenthetical", "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)", "terseLabel": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r105" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r17", "r105", "r927", "r946", "r1453", "r1454" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common Stock, Value, Issued", "terseLabel": "Class A Common Stock, $0.001 par value, 500,000,000 shares authorized and 160,205,899 shares issued and outstanding at December 31, 2024 and 500,000,000 shares authorized and 156,354,238 shares issued and outstanding at December 31, 2023", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r105", "r861", "r1059" ] }, "us-gaap_CommonStockVotingRights": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockVotingRights", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureStockholdersEquityCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Common Stock, Voting Rights", "terseLabel": "Description of the number of voting rights per share", "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights." } } }, "auth_ref": [ "r57" ] }, "irwd_CommonStockVotingRightsPerShare": { "xbrltype": "integerItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "CommonStockVotingRightsPerShare", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureStockholdersEquityCommonStockDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of voting rights per share of common stock.", "label": "Common Stock, Voting Rights Per Share", "terseLabel": "Number of voting rights per share" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r1153" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r1152" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r1154" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r1151" ] }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CompensationAndRetirementDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesProvisionForBenefitFromIncomeTaxesTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSelectedQuarterlyFinancialDataUnauditedDetails", "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "terseLabel": "Comprehensive income (loss) attributable to Ironwood Pharmaceuticals, Inc.", "totalLabel": "Comprehensive income (loss) attributable to Ironwood Pharmaceuticals, Inc.", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r30", "r260", "r262", "r269", "r853", "r874", "r876" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive income (loss), net of tax:" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "terseLabel": "Less: Other comprehensive loss attributable to noncontrolling interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r8", "r74", "r79", "r260", "r262", "r268", "r852", "r874", "r875" ] }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Income (Loss)", "documentation": "Disclosure of accounting policy for comprehensive income." } } }, "auth_ref": [] }, "irwd_ComputerAndOfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "ComputerAndOfficeEquipmentMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosurePropertyAndEquipmentTabularDisclosureDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "documentation": "Computer and Office Equipment [Member]", "label": "Computer and Office Equipment [Member]", "terseLabel": "Computer and office equipment" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r44", "r45", "r87", "r88", "r369", "r986" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r44", "r45", "r87", "r88", "r369", "r904", "r986" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r44", "r45", "r87", "r88", "r369", "r986", "r1206" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentrations of Credit Risk", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r90", "r196" ] }, "us-gaap_ConcentrationRiskLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskLineItems", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk [Line Items]", "terseLabel": "Concentrations", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r986" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk percentage (as a percent)", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r44", "r45", "r87", "r88", "r369" ] }, "us-gaap_ConcentrationRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTable", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk [Table]", "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk." } } }, "auth_ref": [ "r43", "r44", "r45", "r46", "r87", "r168", "r986" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r44", "r45", "r87", "r88", "r369", "r986" ] }, "irwd_ConcentrationsOfSuppliersPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "ConcentrationsOfSuppliersPolicyTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of the entity's accounting policy for concentrations of suppliers.", "label": "Concentrations of Suppliers [Policy Text Block]", "terseLabel": "Concentrations of Suppliers" } } }, "auth_ref": [] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r75", "r1006" ] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsOtherCollaborationAndLicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability", "terseLabel": "Deferred revenue", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r490", "r491", "r502" ] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTabularDisclosureDetails": { "parentTag": "irwd_AccruedExpensesAndOtherLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTabularDisclosureDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsOtherCollaborationAndLicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred revenue, current", "verboseLabel": "Deferred revenue", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r490", "r491", "r502" ] }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityNoncurrent", "crdr": "credit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsOtherCollaborationAndLicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability, Noncurrent", "terseLabel": "Deferred revenue, noncurrent", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": [ "r490", "r491", "r502" ] }, "us-gaap_ConvertibleDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebtCurrent", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCumulativeEffectAdjustmentTabularDisclosureDetails", "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Convertible Debt, Current", "terseLabel": "Current portion of convertible senior notes", "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r93" ] }, "us-gaap_ConvertibleDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCumulativeEffectAdjustmentTabularDisclosureDetails", "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Convertible Debt, Noncurrent", "terseLabel": "Convertible senior notes, net of current portion", "verboseLabel": "Long-term portion of convertible senior notes", "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock." } } }, "auth_ref": [ "r27" ] }, "us-gaap_ConvertibleDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebtSecuritiesMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerSharePotentiallyDilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Debt Securities [Member]", "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder." } } }, "auth_ref": [ "r1302" ] }, "us-gaap_ConvertibleNotesPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleNotesPayableMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesBalancesDetails", "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesDue2022ConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesFutureMinimumPaymentsDetails", "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureDebtInterestExpenseDetails", "http://www.ironwoodpharma.com/role/DisclosureDebtTables", "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsConvertibleSeniorNotesDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDerivativeAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable [Member]", "terseLabel": "Convertible Senior Notes", "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder." } } }, "auth_ref": [ "r93", "r171" ] }, "irwd_ConvertibleSeniorNotes0.75PercentDue2024AndConvertibleSeniorNotes1.50PercentDue2026Member": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "ConvertibleSeniorNotes0.75PercentDue2024AndConvertibleSeniorNotes1.50PercentDue2026Member", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtCappedCallsWithRespectTo2024ConvertibleNotesAnd2026ConvertibleNotesDetails", "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesDue2022ConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerShareComputationDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDerivativeAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "0.75% Convertible Senior Notes due 2024 and 1.50% Convertible Senior Notes due 2026", "label": "0.75% Convertible Senior Notes due 2024 and 1.50% Convertible Senior Notes due 2026" } } }, "auth_ref": [] }, "irwd_ConvertibleSeniorNotes0.75PercentDue2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "ConvertibleSeniorNotes0.75PercentDue2024Member", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtCappedCallsWithRespectTo2024ConvertibleNotesAnd2026ConvertibleNotesDetails", "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesBalancesDetails", "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesDue2022ConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsConvertibleSeniorNotesDetails", "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerShareComputationDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDerivativeAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "0.75% Convertible Senior Notes due 2024", "label": "0.75% Convertible Senior Notes due 2024" } } }, "auth_ref": [] }, "irwd_ConvertibleSeniorNotes1.50PercentDue2026Member": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "ConvertibleSeniorNotes1.50PercentDue2026Member", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtCappedCallsWithRespectTo2024ConvertibleNotesAnd2026ConvertibleNotesDetails", "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesBalancesDetails", "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesDue2022ConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsConvertibleSeniorNotesDetails", "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerShareComputationDetails", "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerSharePotentiallyDilutiveSecuritiesDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDerivativeAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "1.50% Convertible Senior Notes due 2026", "label": "1.50% Convertible Senior Notes due 2026" } } }, "auth_ref": [] }, "irwd_ConvertibleSeniorNotes2.25PercentDue2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "ConvertibleSeniorNotes2.25PercentDue2022Member", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsConvertibleSeniorNotesDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDerivativeAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "2.25% Convertible Senior Notes due 2022", "label": "2.25% Convertible Senior Notes due 2022" } } }, "auth_ref": [] }, "irwd_CostSharingArrangementReductionToResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "CostSharingArrangementReductionToResearchAndDevelopmentExpense", "crdr": "credit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaGeneralInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the reduction to research and development expense for the amount received from the collaboration partner under cost sharing provisions.", "label": "Cost Sharing Arrangement Reduction to Research and Development Expense", "terseLabel": "Cost sharing amount, reduction to research and development" } } }, "auth_ref": [] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfIncomeLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSelectedQuarterlyFinancialDataUnauditedDetails", "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Costs and Expenses", "terseLabel": "Total cost and expenses", "totalLabel": "Total costs and expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r125" ] }, "us-gaap_CostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpensesAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Costs and expenses:" } } }, "auth_ref": [] }, "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Costs Associated with Exit or Disposal Activity or Restructuring [Policy Text Block]", "terseLabel": "Restructuring Expenses", "documentation": "Disclosure of accounting policy for cost associated with exit or disposal activity or restructuring. Excludes entity newly acquired in business combination and discontinued operation." } } }, "auth_ref": [ "r139", "r140" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsAccountsReceivableDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsChinaHongKongAndMacauDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsEuropeanAndOtherTerritoriesDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsJapanDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCollaborativeArrangementsRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCommercialEffortsDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaRoyaltyRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsOtherCollaborationAndLicenseAgreementsDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsSummaryDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsTables", "http://www.ironwoodpharma.com/role/DisclosureLeasesLettersOfCreditDetails", "http://www.ironwoodpharma.com/role/DisclosureLeasesSummerStreetLeaseDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "auth_ref": [ "r234", "r235", "r286", "r287", "r448", "r478", "r802", "r809", "r857", "r1003", "r1005" ] }, "irwd_CourPharmaceuticalsDevelopmentCompanyIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "CourPharmaceuticalsDevelopmentCompanyIncMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsOtherCollaborationAndLicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "COUR Pharmaceuticals Development Company, Inc. [Member]", "label": "COUR Pharmaceuticals Development Company, Inc.", "terseLabel": "COUR Pharmaceuticals Development Company, Inc." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditConcentrationRiskMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" ], "lang": { "en-us": { "role": { "label": "Credit Concentration Risk [Member]", "terseLabel": "Credit Concentration Risk", "documentation": "Reflects the percentage that a specified receivable or amount at risk from a counterparty under a contractual arrangement is to a specified benchmark, such as total receivables, net revenues, pretax results. Risk is the materially adverse effects of loss attributable to (a) the failure to collect a significant receivable from a major customer or group of homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a contractual arrangement." } } }, "auth_ref": [ "r168" ] }, "srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCumulativeEffectAdjustmentTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption, Adjusted Balance [Member]", "terseLabel": "Cumulative Effect, Period of Adoption, Adjusted Balance", "documentation": "Represents amount after cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards." } } }, "auth_ref": [ "r1207", "r1215", "r1234", "r1250", "r1251", "r1261", "r1375", "r1376", "r1378", "r1379", "r1386", "r1387", "r1388", "r1405" ] }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCumulativeEffectAdjustmentTabularDisclosureDetails", "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]", "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment", "documentation": "Increase (decrease) to financial statements for cumulative-effect adjustment in period of adoption of amendment to accounting standards." } } }, "auth_ref": [ "r237", "r242", "r293", "r301", "r308", "r380", "r386", "r404", "r675", "r676", "r689", "r691", "r715", "r717", "r718", "r720", "r721", "r722", "r728", "r731", "r733", "r734", "r799" ] }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CumulativeEffectPeriodOfAdoptionAxis", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCumulativeEffectAdjustmentTabularDisclosureDetails", "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Axis]", "documentation": "Information by cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards." } } }, "auth_ref": [ "r237", "r242", "r293", "r301", "r308", "r380", "r386", "r404", "r675", "r676", "r689", "r691", "r715", "r717", "r718", "r720", "r721", "r722", "r728", "r731", "r733", "r734", "r799" ] }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CumulativeEffectPeriodOfAdoptionDomain", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCumulativeEffectAdjustmentTabularDisclosureDetails", "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Domain]", "documentation": "Cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards." } } }, "auth_ref": [ "r237", "r242", "r293", "r301", "r308", "r380", "r386", "r404", "r675", "r676", "r689", "r691", "r715", "r717", "r718", "r720", "r721", "r722", "r728", "r731", "r733", "r734", "r799" ] }, "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesProvisionForBenefitFromIncomeTaxesAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesProvisionForBenefitFromIncomeTaxesTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]", "terseLabel": "Current taxes:" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentForeignTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesProvisionForBenefitFromIncomeTaxesTabularDisclosureDetails": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesProvisionForBenefitFromIncomeTaxesTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Current Foreign Tax Expense (Benefit)", "terseLabel": "Foreign", "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r1209", "r1230" ] }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesProvisionForBenefitFromIncomeTaxesTabularDisclosureDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesProvisionForBenefitFromIncomeTaxesTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Current Income Tax Expense (Benefit)", "totalLabel": "Total current taxes", "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations." } } }, "auth_ref": [ "r674", "r1230" ] }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesProvisionForBenefitFromIncomeTaxesTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentStateAndLocalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesProvisionForBenefitFromIncomeTaxesTabularDisclosureDetails": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesProvisionForBenefitFromIncomeTaxesAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesProvisionForBenefitFromIncomeTaxesTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Current State and Local Tax Expense (Benefit)", "terseLabel": "State", "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1209", "r1230", "r1377" ] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" ], "lang": { "en-us": { "role": { "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r134", "r369" ] }, "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r1099", "r1188" ] }, "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]" } } }, "auth_ref": [ "r1099", "r1188" ] }, "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]" } } }, "auth_ref": [ "r1101", "r1190" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]" } } }, "auth_ref": [ "r1101", "r1190" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]" } } }, "auth_ref": [ "r1103", "r1192" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r1101", "r1190" ] }, "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]" } } }, "auth_ref": [ "r1094", "r1183" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementProcessesIntegratedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Flag]" } } }, "auth_ref": [ "r1095", "r1184" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Text Block]" } } }, "auth_ref": [ "r1095", "r1184" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract", "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]" } } }, "auth_ref": [ "r1093", "r1182" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]" } } }, "auth_ref": [ "r1093", "r1182" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]" } } }, "auth_ref": [ "r1093", "r1182" ] }, "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Third Party Engaged [Flag]" } } }, "auth_ref": [ "r1096", "r1185" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]" } } }, "auth_ref": [ "r1098", "r1187" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]" } } }, "auth_ref": [ "r1098", "r1187" ] }, "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r1099", "r1188" ] }, "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r1102", "r1191" ] }, "cyd_CybersecurityRiskRoleOfManagementTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskRoleOfManagementTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Role of Management [Text Block]" } } }, "auth_ref": [ "r1100", "r1189" ] }, "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]" } } }, "auth_ref": [ "r1097", "r1186" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebt" ], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r145", "r281", "r406", "r407", "r408", "r409", "r410", "r433", "r434", "r444", "r450", "r451", "r452", "r453", "r454", "r455", "r460", "r467", "r468", "r470", "r770" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtCappedCallsWithRespectTo2024ConvertibleNotesAnd2026ConvertibleNotesDetails", "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesBalancesDetails", "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesDue2022ConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsConvertibleSeniorNotesDetails", "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerShareComputationDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDerivativeAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r27", "r93", "r94", "r171", "r175", "r289", "r445", "r446", "r447", "r448", "r449", "r451", "r456", "r457", "r458", "r459", "r461", "r462", "r463", "r464", "r465", "r466", "r1026", "r1027", "r1028", "r1029", "r1030", "r1057", "r1228", "r1262", "r1263", "r1264", "r1399", "r1401" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Debt instrument, basis spread on variable rate (as a percent)", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesFutureMinimumPaymentsDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Gross", "totalLabel": "Total future minimum payments under the convertible senior notes", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r27", "r175", "r471" ] }, "irwd_DebtInstrumentConditionalConversionRepurchasePricePrincipalPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "DebtInstrumentConditionalConversionRepurchasePricePrincipalPercentage", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details" ], "lang": { "en-us": { "role": { "documentation": "The percentage of principal amount of debt arrived at as the repurchase price under the debt conversion arrangement.", "label": "Debt Instrument Conditional Conversion, Repurchase Price Principal Percentage", "terseLabel": "Repurchase price" } } }, "auth_ref": [] }, "irwd_DebtInstrumentConversionObligationNumberOfBusinessDaysAfterConsecutiveTradingDayPeriod": { "xbrltype": "integerItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "DebtInstrumentConversionObligationNumberOfBusinessDaysAfterConsecutiveTradingDayPeriod", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of business days immediately after any five consecutive trading day period during the debt instrument measurement period.", "label": "Debt Instrument Conversion Obligation Number Of Business Days After Consecutive Trading Day Period", "terseLabel": "Number of business days immediately after any five consecutive trading day period during the measurement period" } } }, "auth_ref": [] }, "irwd_DebtInstrumentConversionObligationPeriodOfConsecutiveTradingDays": { "xbrltype": "integerItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "DebtInstrumentConversionObligationPeriodOfConsecutiveTradingDays", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details" ], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Conversion Obligation, Period of Consecutive Trading Days", "label": "Debt Instrument, Conversion Obligation, Period of Consecutive Trading Days", "terseLabel": "Number of consecutive trading days before five business days during the measurement period" } } }, "auth_ref": [] }, "irwd_DebtInstrumentConversionPremium": { "xbrltype": "percentItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "DebtInstrumentConversionPremium", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details" ], "lang": { "en-us": { "role": { "documentation": "The percentage of conversion premium above the last reported sale price of common stock.", "label": "Debt Instrument, Conversion Premium", "terseLabel": "Conversion premium percentage on sale price of common stock" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Convertible, Conversion Price", "verboseLabel": "Initial conversion price (in dollars per share)", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } } }, "auth_ref": [ "r147", "r447" ] }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleConversionRatio1", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Convertible, Conversion Ratio", "verboseLabel": "Conversion rate, number of shares to be issued per", "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount." } } }, "auth_ref": [ "r57", "r98", "r150", "r151", "r447" ] }, "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days", "terseLabel": "Consecutive trading days", "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger", "terseLabel": "Minimum percentage of stock price", "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleThresholdTradingDays", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Convertible, Threshold Trading Days", "terseLabel": "Number of trading days", "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature." } } }, "auth_ref": [] }, "irwd_DebtInstrumentCovenantMaximumConsolidatedSecuredNetLeverageRatioAfterInterimPeriod": { "xbrltype": "pureItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "DebtInstrumentCovenantMaximumConsolidatedSecuredNetLeverageRatioAfterInterimPeriod", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant, Maximum Consolidated Secured Net Leverage Ratio, after Interim Period", "label": "Debt Instrument, Covenant, Maximum Consolidated Secured Net Leverage Ratio, after Interim Period", "terseLabel": "Debt instrument, covenant, maximum consolidated secured net leverage ratio, after interim period" } } }, "auth_ref": [] }, "irwd_DebtInstrumentCovenantMaximumConsolidatedSecuredNetLeverageRatioAfterInterimPeriodConsummatesAcquisitionAfterElectedIncrease": { "xbrltype": "pureItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "DebtInstrumentCovenantMaximumConsolidatedSecuredNetLeverageRatioAfterInterimPeriodConsummatesAcquisitionAfterElectedIncrease", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant, Maximum Consolidated Secured Net Leverage Ratio, after Interim Period, Consummates Acquisition, after Elected Increase", "label": "Debt Instrument, Covenant, Maximum Consolidated Secured Net Leverage Ratio, after Interim Period, Consummates Acquisition, after Elected Increase", "terseLabel": "Debt instrument, covenant, maximum consolidated secured net leverage ratio, after interim period, consummates acquisition, after elected increase" } } }, "auth_ref": [] }, "irwd_DebtInstrumentCovenantMaximumConsolidatedSecuredNetLeverageRatioConsummatesAcquisitionMinimumConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "DebtInstrumentCovenantMaximumConsolidatedSecuredNetLeverageRatioConsummatesAcquisitionMinimumConsideration", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant, Maximum Consolidated Secured Net Leverage Ratio, Consummates Acquisition, Minimum Consideration", "label": "Debt Instrument, Covenant, Maximum Consolidated Secured Net Leverage Ratio, Consummates Acquisition, Minimum Consideration", "terseLabel": "Debt instrument, covenant, maximum consolidated secured net leverage ratio, consummates acquisition, minimum consideration" } } }, "auth_ref": [] }, "irwd_DebtInstrumentCovenantMaximumConsolidatedSecuredNetLeverageRatioConsummatesAcquisitionNumberOfFiscalQuarters": { "xbrltype": "integerItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "DebtInstrumentCovenantMaximumConsolidatedSecuredNetLeverageRatioConsummatesAcquisitionNumberOfFiscalQuarters", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant, Maximum Consolidated Secured Net Leverage Ratio, Consummates Acquisition, Number of Fiscal Quarters", "label": "Debt Instrument, Covenant, Maximum Consolidated Secured Net Leverage Ratio, Consummates Acquisition, Number of Fiscal Quarters", "terseLabel": "Debt instrument, covenant, maximum consolidated secured net leverage ratio, consummates acquisition, number of fiscal quarters" } } }, "auth_ref": [] }, "irwd_DebtInstrumentCovenantMaximumConsolidatedSecuredNetLeverageRatioInitialPeriod": { "xbrltype": "pureItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "DebtInstrumentCovenantMaximumConsolidatedSecuredNetLeverageRatioInitialPeriod", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant, Maximum Consolidated Secured Net Leverage Ratio, Initial Period", "label": "Debt Instrument, Covenant, Maximum Consolidated Secured Net Leverage Ratio, Initial Period", "terseLabel": "Debt instrument, covenant, maximum consolidated secured net leverage ratio, initial period" } } }, "auth_ref": [] }, "irwd_DebtInstrumentCovenantMaximumConsolidatedSecuredNetLeverageRatioInitialPeriodConsummatesAcquisitionAfterElectedIncrease": { "xbrltype": "pureItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "DebtInstrumentCovenantMaximumConsolidatedSecuredNetLeverageRatioInitialPeriodConsummatesAcquisitionAfterElectedIncrease", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant, Maximum Consolidated Secured Net Leverage Ratio, Initial Period, Consummates Acquisition, after Elected Increase", "label": "Debt Instrument, Covenant, Maximum Consolidated Secured Net Leverage Ratio, Initial Period, Consummates Acquisition, after Elected Increase", "terseLabel": "Debt instrument, covenant, maximum consolidated secured net leverage ratio, initial period, consummates acquisition, after elected increase" } } }, "auth_ref": [] }, "irwd_DebtInstrumentCovenantMaximumConsolidatedSecuredNetLeverageRatioInterimPeriod": { "xbrltype": "pureItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "DebtInstrumentCovenantMaximumConsolidatedSecuredNetLeverageRatioInterimPeriod", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant, Maximum Consolidated Secured Net Leverage Ratio, Interim Period", "label": "Debt Instrument, Covenant, Maximum Consolidated Secured Net Leverage Ratio, Interim Period", "terseLabel": "Debt instrument, covenant, maximum consolidated secured net leverage ratio, interim period" } } }, "auth_ref": [] }, "irwd_DebtInstrumentCovenantMaximumConsolidatedSecuredNetLeverageRatioInterimPeriodConsummatesAcquisitionAfterElectedIncrease": { "xbrltype": "pureItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "DebtInstrumentCovenantMaximumConsolidatedSecuredNetLeverageRatioInterimPeriodConsummatesAcquisitionAfterElectedIncrease", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant, Maximum Consolidated Secured Net Leverage Ratio, Interim Period, Consummates Acquisition, after Elected Increase", "label": "Debt Instrument, Covenant, Maximum Consolidated Secured Net Leverage Ratio, Interim Period, Consummates Acquisition, after Elected Increase", "terseLabel": "Debt instrument, covenant, maximum consolidated secured net leverage ratio, interim period, consummates acquisition, after elected increase" } } }, "auth_ref": [] }, "irwd_DebtInstrumentCovenantMinimumInterestCoverageRatio": { "xbrltype": "pureItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "DebtInstrumentCovenantMinimumInterestCoverageRatio", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant, Minimum Interest Coverage Ratio", "label": "Debt Instrument, Covenant, Minimum Interest Coverage Ratio", "terseLabel": "Debt instrument, covenant, minimum interest coverage ratio" } } }, "auth_ref": [] }, "irwd_DebtInstrumentDebtIssuanceCostsIncurred": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "DebtInstrumentDebtIssuanceCostsIncurred", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesDue2022ConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details" ], "lang": { "en-us": { "role": { "documentation": "Debt issuance costs incurred.", "label": "Debt Instrument, Debt Issuance Costs Incurred", "terseLabel": "Debt issuance costs incurred" } } }, "auth_ref": [] }, "irwd_DebtInstrumentDefaultPaymentPercentageOfPrincipalAmountOfNotesOutstanding": { "xbrltype": "percentItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "DebtInstrumentDefaultPaymentPercentageOfPrincipalAmountOfNotesOutstanding", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details" ], "lang": { "en-us": { "role": { "documentation": "Debt Instrument Default Payment, Percentage of Principal Amount of Notes Outstanding", "label": "Debt Instrument Default Payment, Percentage of Principal Amount of Notes Outstanding", "terseLabel": "Percentage of aggregate principal amount of notes outstanding and payable in case of event of default under the agreement" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesBalancesDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesBalancesDetails", "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsConvertibleSeniorNotesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Face Amount", "terseLabel": "Debt instrument, face amount", "verboseLabel": "Debt instrument, face amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r445", "r770", "r771", "r1027", "r1028", "r1057" ] }, "us-gaap_DebtInstrumentFeeAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFeeAmount", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Fee Amount", "terseLabel": "Fees and expenses", "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument." } } }, "auth_ref": [ "r99" ] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesDue2022ConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Effective interest rate on liability components (as a percent)", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r96", "r473", "r770", "r771", "r1057" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsConvertibleSeniorNotesDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDerivativeAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Stated interest rate (as a percent)", "verboseLabel": "Stated interest rate (as a percent)", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r96", "r446" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesBalancesDetails", "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesDue2022ConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesFutureMinimumPaymentsDetails", "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureDebtInterestExpenseDetails", "http://www.ironwoodpharma.com/role/DisclosureDebtTables", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDerivativeAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r289", "r445", "r446", "r447", "r448", "r449", "r451", "r456", "r457", "r458", "r459", "r461", "r462", "r463", "r464", "r465", "r466", "r469", "r1026", "r1027", "r1028", "r1029", "r1030", "r1057", "r1228", "r1399", "r1401" ] }, "irwd_DebtInstrumentMaturityDateRangeEndPeriodPriorToStatedMaturityDateExistingConvertibleNotesThenOutstandingUnlessCaseOfClause": { "xbrltype": "durationItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "DebtInstrumentMaturityDateRangeEndPeriodPriorToStatedMaturityDateExistingConvertibleNotesThenOutstandingUnlessCaseOfClause", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Maturity Date Range, End, Period Prior to Stated Maturity Date, Existing Convertible Notes then Outstanding, Unless Case of Clause", "label": "Debt Instrument, Maturity Date Range, End, Period Prior to Stated Maturity Date, Existing Convertible Notes then Outstanding, Unless Case of Clause", "terseLabel": "Debt instrument, maturity date range, end, period prior to stated maturity date, existing convertible notes then outstanding, unless case of clause" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentMaturityDateRangeStart1": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentMaturityDateRangeStart1", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Maturity Date Range, Start", "terseLabel": "Debt instrument, maturity date range, start", "documentation": "Earliest date the outstanding debt instruments are required to be repaid, in YYYY-MM-DD format." } } }, "auth_ref": [ "r97" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtCappedCallsWithRespectTo2024ConvertibleNotesAnd2026ConvertibleNotesDetails", "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesBalancesDetails", "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesDue2022ConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsConvertibleSeniorNotesDetails", "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerShareComputationDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDerivativeAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r27", "r289", "r445", "r446", "r447", "r448", "r449", "r451", "r456", "r457", "r458", "r459", "r461", "r462", "r463", "r464", "r465", "r466", "r1026", "r1027", "r1028", "r1029", "r1030", "r1057", "r1228", "r1262", "r1263", "r1264", "r1399", "r1401" ] }, "irwd_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details" ], "lang": { "en-us": { "role": { "documentation": "Represents the debt instrument principal amount denomination for conversion into common stock.", "label": "Debt Instrument, Principal Amount Denomination for Conversion into Common Stock", "terseLabel": "Principal amount used for debt instrument conversion ratio" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentRepurchaseAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRepurchaseAmount", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Repurchase Amount", "terseLabel": "Debt redemption/repurchase price", "documentation": "Fair value amount of debt instrument that was repurchased." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentRepurchasedFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRepurchasedFaceAmount", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsConvertibleSeniorNotesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Repurchased Face Amount", "terseLabel": "Debt redeemed/repurchased", "documentation": "Face (par) amount of the original debt instrument that was repurchased." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesBalancesDetails", "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesDue2022ConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesFutureMinimumPaymentsDetails", "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureDebtInterestExpenseDetails", "http://www.ironwoodpharma.com/role/DisclosureDebtTables", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDerivativeAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": [ "r27", "r57", "r58", "r89", "r149", "r151", "r289", "r445", "r446", "r447", "r448", "r449", "r451", "r456", "r457", "r458", "r459", "r461", "r462", "r463", "r464", "r465", "r466", "r469", "r1026", "r1027", "r1028", "r1029", "r1030", "r1057", "r1228", "r1399", "r1401" ] }, "us-gaap_DebtInstrumentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentsAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesDue2022ConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDerivativeAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instruments [Abstract]", "terseLabel": "Debt" } } }, "auth_ref": [] }, "us-gaap_DeferredChargesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredChargesPolicyTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Deferred Charges, Policy [Policy Text Block]", "terseLabel": "Financing Costs", "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges." } } }, "auth_ref": [ "r252" ] }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFederalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesProvisionForBenefitFromIncomeTaxesTabularDisclosureDetails": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesProvisionForBenefitFromIncomeTaxesTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Federal Income Tax Expense (Benefit)", "terseLabel": "Federal", "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1230", "r1374", "r1377" ] }, "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesProvisionForBenefitFromIncomeTaxesTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]", "terseLabel": "Deferred taxes:" } } }, "auth_ref": [] }, "us-gaap_DeferredFinanceCostsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsGross", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Issuance Costs, Gross", "terseLabel": "Debt issuance costs, gross", "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r1399", "r1401" ] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Issuance Costs, Net", "terseLabel": "Debt issuance costs, net", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r1276", "r1398", "r1399", "r1401" ] }, "us-gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCumulativeEffectAdjustmentTabularDisclosureDetails", "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred tax assets", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": [ "r640", "r641" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesProvisionForBenefitFromIncomeTaxesTabularDisclosureDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesProvisionForBenefitFromIncomeTaxesAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesProvisionForBenefitFromIncomeTaxesTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred taxes", "totalLabel": "Total deferred taxes", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r10", "r202", "r1230" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesProvisionForBenefitFromIncomeTaxesAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesProvisionForBenefitFromIncomeTaxesTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Deferred Income Tax Expense (Benefit)" } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxLiabilities", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "irwd_DeferredTaxAssetsNetIncludingValuationAllowances", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Gross", "negatedTotalLabel": "Total deferred tax liabilities", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences." } } }, "auth_ref": [ "r102", "r103", "r173", "r665" ] }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxesAndTaxCredits", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Deferred Income Taxes and Tax Credits", "terseLabel": "Deferred income taxes", "documentation": "Amount of deferred income tax expense (benefit) and income tax credits." } } }, "auth_ref": [ "r131" ] }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesProvisionForBenefitFromIncomeTaxesTabularDisclosureDetails": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesProvisionForBenefitFromIncomeTaxesTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Deferred State and Local Income Tax Expense (Benefit)", "terseLabel": "State", "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1230", "r1374", "r1377" ] }, "irwd_DeferredTaxAssetsBasisDifferenceOnConvertibleNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "DeferredTaxAssetsBasisDifferenceOnConvertibleNotes", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Deferred Tax Assets, Basis Difference on Convertible Notes", "label": "Deferred Tax Assets, Basis Difference on Convertible Notes", "terseLabel": "Basis difference on Convertible Notes" } } }, "auth_ref": [] }, "irwd_DeferredTaxAssetsCapitalizedResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopment", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "The tax effect as of the balance sheet date of the amount of the estimated future tax deductions attributable to capitalized research and development related items which can only be realized if sufficient taxable income is generated in future periods to enable the deduction to be taken.", "label": "Deferred Tax Assets, Capitalized Research and Development", "terseLabel": "Capitalized research and development" } } }, "auth_ref": [] }, "irwd_DeferredTaxAssetsCollaborationAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "DeferredTaxAssetsCollaborationAgreement", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Deferred Tax Assets, Collaboration Agreement", "label": "Deferred Tax Assets, Collaboration Agreement", "terseLabel": "Basis difference on collaboration agreement for North America with AbbVie" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Goodwill and Intangible Assets", "terseLabel": "Intangible assets", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill." } } }, "auth_ref": [ "r1372" ] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "irwd_DeferredTaxAssetsNetIncludingValuationAllowances", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Gross", "totalLabel": "Total deferred tax assets", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r666" ] }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsLiabilitiesNet", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Net", "totalLabel": "Net deferred tax asset", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting." } } }, "auth_ref": [ "r1370" ] }, "us-gaap_DeferredTaxAssetsNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsNetAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Net [Abstract]", "terseLabel": "Deferred tax assets:" } } }, "auth_ref": [] }, "irwd_DeferredTaxAssetsNetIncludingValuationAllowances": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "DeferredTaxAssetsNetIncludingValuationAllowances", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails", "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesValuationAllowanceDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets Net Including Valuation Allowances", "terseLabel": "Net deferred tax assets", "totalLabel": "Net deferred tax assets" } } }, "auth_ref": [] }, "irwd_DeferredTaxAssetsOperatingLeases": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "DeferredTaxAssetsOperatingLeases", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Deferred Tax Assets, Operating Leases.", "label": "Deferred Tax Assets, Operating Leases", "terseLabel": "Operating lease liability" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": [ "r1372" ] }, "us-gaap_DeferredTaxAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOther", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Other", "terseLabel": "Other", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other." } } }, "auth_ref": [ "r1372" ] }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Tax Credit Carryforwards", "terseLabel": "Tax credit carryforwards", "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards." } } }, "auth_ref": [ "r1372" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost", "terseLabel": "Share-based compensation", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation." } } }, "auth_ref": [ "r1372" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals", "verboseLabel": "Accruals and reserves", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals." } } }, "auth_ref": [ "r1372" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails", "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesValuationAllowanceDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation allowance", "terseLabel": "Valuation allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r667" ] }, "us-gaap_DeferredTaxLiabilitiesNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesNetAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Net [Abstract]", "terseLabel": "Deferred tax liabilities:" } } }, "auth_ref": [] }, "irwd_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Deferred Tax Liabilities, Operating Lease, Right-of-use Assets", "label": "Deferred Tax Liabilities, Operating Lease, Right-of-use Assets", "negatedLabel": "Operating lease right-of-use assets" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "negatedLabel": "Fixed assets", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment." } } }, "auth_ref": [ "r1372" ] }, "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanActualReturnOnPlanAssets", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansChangeInFairValueOfPlanAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)", "terseLabel": "Return on plan assets excluding interest income", "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses." } } }, "auth_ref": [ "r518", "r1041" ] }, "us-gaap_DefinedBenefitPlanAdditionalInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAdditionalInformationAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansGeneralInformationDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Additional Information [Abstract]", "terseLabel": "General information" } } }, "auth_ref": [] }, "irwd_DefinedBenefitPlanAdministrationCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "DefinedBenefitPlanAdministrationCosts", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansNetPeriodicBenefitCostCreditDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansNetPeriodicBenefitCostCreditDetails" ], "lang": { "en-us": { "role": { "documentation": "Defined Benefit Plan, Administration Costs", "label": "Defined Benefit Plan, Administration Costs", "terseLabel": "Administration costs" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanAdministrationExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAdministrationExpenses", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansChangeInFairValueOfPlanAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Plan Assets, Administration Expense", "negatedLabel": "Administration expense", "documentation": "Amount of administration expense of defined benefit plan which decreases plan assets. Excludes plan administration expense paid by employer." } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAmortizationOfGainsLosses", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansNetPeriodicBenefitCostCreditDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansNetPeriodicBenefitCostCreditDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Amortization of Gain (Loss)", "negatedLabel": "Amortization of unrecognized actuarial gains/ (losses)", "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan." } } }, "auth_ref": [ "r505", "r543", "r569", "r1041", "r1042" ] }, "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansNetPeriodicBenefitCostCreditDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansNetPeriodicBenefitCostCreditDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)", "terseLabel": "Amortization prior service cost", "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan." } } }, "auth_ref": [ "r505", "r544", "r570", "r1041", "r1042" ] }, "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanAssetsTargetAllocationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssetsTargetAllocationsAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansAllocationOfPlanAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Plan Assets, Allocations [Abstract]", "terseLabel": "Allocation of Plan Assets, Percentage" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate", "terseLabel": "Discount rate (as a percent)", "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan." } } }, "auth_ref": [ "r550" ] }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets", "terseLabel": "Expected return on assets (as a percent)", "documentation": "Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan." } } }, "auth_ref": [ "r552", "r574" ] }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase", "terseLabel": "Expected rate of salary increase (as a percent)", "documentation": "Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan." } } }, "auth_ref": [ "r551" ] }, "us-gaap_DefinedBenefitPlanAssumptionsUsedInCalculationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssumptionsUsedInCalculationsAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Assumptions Used in Calculations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanBenefitObligation", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansFundedUnfundedStatusDetails": { "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansChangeInDefinedBenefitObligationDetails", "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansFundedUnfundedStatusDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Benefit Obligation", "negatedLabel": "Present value of defined benefit obligation", "negatedPeriodEndLabel": "Defined benefit obligation, ending balance", "negatedPeriodStartLabel": "Defined benefit obligation, beginning balance", "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan." } } }, "auth_ref": [ "r506" ] }, "irwd_DefinedBenefitPlanBenefitObligationBenefitsPaidDeposited": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaidDeposited", "crdr": "credit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansChangeInDefinedBenefitObligationDetails" ], "lang": { "en-us": { "role": { "documentation": "Defined Benefit Plan, Benefit Obligation, Benefits Paid (Deposited)", "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid (Deposited)", "negatedLabel": "Benefits (paid)/deposited" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansChangeInDefinedBenefitObligationDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant", "negatedLabel": "Contributions paid by employees", "documentation": "Amount of contributions received by defined benefit plan from participant which increase benefit obligation." } } }, "auth_ref": [ "r510" ] }, "us-gaap_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansChangeInDefinedBenefitObligationDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Remeasurement due to Settlement", "terseLabel": "Remeasurement (gain)/loss on defined benefit obligation", "documentation": "Amount of (increase) decrease to benefit obligation of defined benefit plan from remeasurement due to settlement. Excludes decrease to benefit obligation for settlement payment." } } }, "auth_ref": [ "r1282" ] }, "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansAllocationOfPlanAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Plan Assets, Category [Axis]", "documentation": "Information by defined benefit plan asset investment." } } }, "auth_ref": [ "r527", "r528", "r530", "r531", "r532", "r533", "r534", "r535", "r555", "r1039", "r1040", "r1041" ] }, "us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanChangeInBenefitObligationRollForward", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansChangeInDefinedBenefitObligationDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]", "terseLabel": "Defined Benefit Plan, Change in Benefit Obligation", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansChangeInFairValueOfPlanAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]", "terseLabel": "Change in Fair Value of Plan Assets", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanContributionsByEmployer": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanContributionsByEmployer", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansChangeInFairValueOfPlanAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer", "terseLabel": "Contributions paid by employer", "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets." } } }, "auth_ref": [ "r520", "r530", "r573", "r1039", "r1040", "r1041", "r1042" ] }, "us-gaap_DefinedBenefitPlanCurtailments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanCurtailments", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansChangeInDefinedBenefitObligationDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Curtailment", "terseLabel": "Curtailment", "documentation": "Amount of (increase) decrease in benefit obligation of defined benefit plan from event reducing expected years of future service of present employees or eliminating accrual of benefits for some or all future services of present employees." } } }, "auth_ref": [ "r508" ] }, "us-gaap_DefinedBenefitPlanDebtSecurityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanDebtSecurityMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansAllocationOfPlanAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Debt Security [Member]", "documentation": "Debt instrument issued by corporation, government and governmental agency, municipality, and other institution; in which defined benefit plan asset is invested." } } }, "auth_ref": [ "r1302" ] }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanDisclosureLineItems", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansAllocationOfPlanAssetsDetails", "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansFairValueOfPlanAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan Disclosure [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanEquitySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanEquitySecuritiesMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansAllocationOfPlanAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Equity Securities [Member]", "terseLabel": "Equities", "documentation": "Security representing ownership in corporation or other legal entity for which ownership is represented by share of stock, in which defined benefit plan asset is invested. Includes, but is not limited to, common stock, preferred stock, convertible security, stock right and stock warrant." } } }, "auth_ref": [ "r1039", "r1041" ] }, "us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Expected Future Benefit Payment [Abstract]", "terseLabel": "Defined Benefit Plan, Expected Future Benefit Payment" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanExpectedAmountsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedAmountsAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Expected Amounts [Abstract]" } } }, "auth_ref": [] }, "irwd_DefinedBenefitPlanExpectedFutureBenefitPaymentAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentAfterYearFour", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansFutureMinimumPaymentsDetails": { "parentTag": "irwd_DefinedBenefitPlanExpectedFutureBenefitPayments", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Defined Benefit Plan, Expected Future Benefit Payment, after Year Four", "label": "Defined Benefit Plan, Expected Future Benefit Payment, after Year Four", "terseLabel": "2029 and thereafter" } } }, "auth_ref": [] }, "irwd_DefinedBenefitPlanExpectedFutureBenefitPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "DefinedBenefitPlanExpectedFutureBenefitPayments", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansFutureMinimumPaymentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Defined Benefit Plan, Expected Future Benefit Payments", "label": "Defined Benefit Plan, Expected Future Benefit Payments", "totalLabel": "Total" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansFutureMinimumPaymentsDetails": { "parentTag": "irwd_DefinedBenefitPlanExpectedFutureBenefitPayments", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year One", "terseLabel": "2025", "documentation": "Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year." } } }, "auth_ref": [ "r537" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansFutureMinimumPaymentsDetails": { "parentTag": "irwd_DefinedBenefitPlanExpectedFutureBenefitPayments", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Four", "terseLabel": "2028", "documentation": "Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year." } } }, "auth_ref": [ "r537" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansFutureMinimumPaymentsDetails": { "parentTag": "irwd_DefinedBenefitPlanExpectedFutureBenefitPayments", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Three", "terseLabel": "2027", "documentation": "Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year." } } }, "auth_ref": [ "r537" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansFutureMinimumPaymentsDetails": { "parentTag": "irwd_DefinedBenefitPlanExpectedFutureBenefitPayments", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Two", "terseLabel": "2026", "documentation": "Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year." } } }, "auth_ref": [ "r537" ] }, "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansNetPeriodicBenefitCostCreditDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansNetPeriodicBenefitCostCreditDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets", "negatedLabel": "Expected return on plan assets", "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan." } } }, "auth_ref": [ "r505", "r542", "r568", "r1041", "r1042" ] }, "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanFairValueOfPlanAssets", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansFundedUnfundedStatusDetails": { "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansAllocationOfPlanAssetsDetails", "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansChangeInFairValueOfPlanAssetsDetails", "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansFairValueOfPlanAssetsDetails", "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansFundedUnfundedStatusDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Plan Assets, Amount", "periodEndLabel": "Fair value of plan assets, ending balance", "periodStartLabel": "Fair value of plan assets, beginning balance", "terseLabel": "Fair value of plan assets", "verboseLabel": "Plan assets", "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee." } } }, "auth_ref": [ "r517", "r528", "r530", "r531", "r1039", "r1040", "r1041" ] }, "us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation", "crdr": "credit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansChangeInDefinedBenefitObligationDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)", "negatedLabel": "Foreign currency exchange (gains)/loss", "documentation": "Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan." } } }, "auth_ref": [ "r512" ] }, "us-gaap_DefinedBenefitPlanFundedStatusOfPlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanFundedStatusOfPlan", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansFundedUnfundedStatusDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansFundedUnfundedStatusDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan", "totalLabel": "Net liability arising from defined benefit obligation", "documentation": "Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status." } } }, "auth_ref": [ "r504", "r526", "r1041" ] }, "us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanFundedStatusOfPlanAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansFundedUnfundedStatusDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan [Abstract]", "terseLabel": "Funded (unfunded) status" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanInformationAboutPlanAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanInformationAboutPlanAssetsAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansAllocationOfPlanAssetsDetails", "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansFairValueOfPlanAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Information about Plan Assets [Abstract]", "terseLabel": "Allocation of Plan Assets, Amount" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanInterestCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanInterestCost", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansNetPeriodicBenefitCostCreditDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansChangeInDefinedBenefitObligationDetails", "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansNetPeriodicBenefitCostCreditDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Interest Cost", "negatedLabel": "Interest expense on defined benefit obligation", "terseLabel": "Interest cost", "documentation": "Amount of cost recognized for passage of time related to defined benefit plan." } } }, "auth_ref": [ "r505", "r509", "r541", "r567", "r1041", "r1042" ] }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansNetPeriodicBenefitCostCreditDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansNetPeriodicBenefitCostCreditDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "totalLabel": "Total", "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan." } } }, "auth_ref": [ "r539", "r565", "r1041", "r1042" ] }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanNetPeriodicBenefitCostAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansNetPeriodicBenefitCostCreditDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]", "terseLabel": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansNetPeriodicBenefitCostCreditDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Excluding Service Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]", "terseLabel": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Excluding Service Cost, Statement of Income or Comprehensive Income", "documentation": "Indicates line item in statement of income or comprehensive income that includes components of net periodic benefit cost (credit), excluding service cost component, for defined benefit plan." } } }, "auth_ref": [ "r539", "r565" ] }, "irwd_DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDueToCurtailmentAndOther": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDueToCurtailmentAndOther", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansNetPeriodicBenefitCostCreditDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansNetPeriodicBenefitCostCreditDetails" ], "lang": { "en-us": { "role": { "documentation": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment and Other", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment and Other", "negatedLabel": "Curtailment and other" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanPlanAmendments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPlanAmendments", "crdr": "credit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansChangeInDefinedBenefitObligationDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment", "terseLabel": "Prior service (cost)/credit arising during financial year", "documentation": "Amount of increase (decrease) in benefit obligation of defined benefit plan from change in terms of existing plan or initiation of new plan." } } }, "auth_ref": [ "r514" ] }, "irwd_DefinedBenefitPlanPlanAssetsBenefitsPaidDeposited": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaidDeposited", "crdr": "credit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansChangeInFairValueOfPlanAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Defined Benefit Plan, Plan Assets, Benefits Paid (Deposited)", "label": "Defined Benefit Plan, Plan Assets, Benefits Paid (Deposited)", "negatedLabel": "Benefits (paid)/deposited" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansChangeInFairValueOfPlanAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Plan Assets, Contributions by Plan Participant", "terseLabel": "Contributions paid by employees", "documentation": "Amount of contributions received by defined benefit plan from participant which increases plan assets." } } }, "auth_ref": [ "r521" ] }, "us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansChangeInFairValueOfPlanAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)", "terseLabel": "Foreign currency exchange gains/(losses)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan." } } }, "auth_ref": [ "r519" ] }, "irwd_DefinedBenefitPlanPlanAssetsIncreaseDecreaseForActuarialGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "DefinedBenefitPlanPlanAssetsIncreaseDecreaseForActuarialGainLoss", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansChangeInFairValueOfPlanAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actuarial Gain (Loss)", "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actuarial Gain (Loss)", "terseLabel": "Actuarial gain/(loss) on plan assets" } } }, "auth_ref": [] }, "irwd_DefinedBenefitPlanPlanAssetsOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "DefinedBenefitPlanPlanAssetsOtherMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansAllocationOfPlanAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Defined Benefit Plan, Plan Assets, Other [Member]", "label": "Defined Benefit Plan, Plan Assets, Other [Member]", "terseLabel": "Other" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanRealEstateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanRealEstateMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansAllocationOfPlanAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Employee Benefit Plan, Real Estate [Member]", "terseLabel": "Real Estate", "documentation": "Property composed of building, land, and land improvement; in which employee benefit plan asset is invested." } } }, "auth_ref": [ "r1039", "r1041" ] }, "us-gaap_DefinedBenefitPlanRollForwardsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanRollForwardsAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansChangeInDefinedBenefitObligationDetails", "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansChangeInFairValueOfPlanAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Roll Forwards [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanServiceCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanServiceCost", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansNetPeriodicBenefitCostCreditDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansChangeInDefinedBenefitObligationDetails", "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansNetPeriodicBenefitCostCreditDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Service Cost", "negatedLabel": "Current service cost", "terseLabel": "Current service cost", "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan." } } }, "auth_ref": [ "r507", "r540", "r566", "r1041", "r1042" ] }, "us-gaap_DefinedBenefitPlanSponsorLocationExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanSponsorLocationExtensibleList", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansGeneralInformationDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Sponsor Location [Extensible Enumeration]", "terseLabel": "Defined Benefit Plan, Sponsor Location", "documentation": "Indicates location of employer sponsoring defined benefit plan designed to provide retirement benefits." } } }, "auth_ref": [ "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r550", "r551", "r552", "r553", "r555", "r558", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r574", "r1338" ] }, "us-gaap_DefinedBenefitPlanTypeExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanTypeExtensibleList", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansGeneralInformationDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Type [Extensible Enumeration]", "terseLabel": "Defined Benefit Plan, Type", "documentation": "Indicates type of defined benefit plan. Includes, but is not limited to, pension plan, other postretirement plan and special and contractual termination benefits payable upon retirement." } } }, "auth_ref": [ "r504", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r550", "r552", "r553", "r555", "r558", "r561", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574" ] }, "us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanWeightedAverageAssetAllocations", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansAllocationOfPlanAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Plan Assets, Actual Allocation, Percentage", "terseLabel": "Allocation of plan assets (as a percent)", "documentation": "Percentage of actual investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan." } } }, "auth_ref": [ "r1301" ] }, "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]", "terseLabel": "Principal Assumptions" } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanCostRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanCostRecognized", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedContributionRetirementPlansDetails" ], "lang": { "en-us": { "role": { "label": "Defined Contribution Plan, Cost", "terseLabel": "Compensation cost", "documentation": "Amount of cost for defined contribution plan." } } }, "auth_ref": [ "r577" ] }, "us-gaap_DefinedContributionPlanDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanDisclosureLineItems", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedContributionRetirementPlansDetails" ], "lang": { "en-us": { "role": { "label": "Defined Contribution Plan Disclosure [Line Items]", "verboseLabel": "Defined Contribution Plan", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r577" ] }, "irwd_DefinedContributionPlanEmployerMatchingContributionEligibleEmployeeContributionMaximum": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "DefinedContributionPlanEmployerMatchingContributionEligibleEmployeeContributionMaximum", "crdr": "credit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedContributionRetirementPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Defined Contribution Plan, Employer Matching Contribution, Eligible Employee Contribution, Maximum", "label": "Defined Contribution Plan, Employer Matching Contribution, Eligible Employee Contribution, Maximum", "terseLabel": "Matching contribution, annual employee eligible contribution limit, amount" } } }, "auth_ref": [] }, "irwd_DefinedContributionPlanEmployerMatchingContributionEmployeeContributionPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "DefinedContributionPlanEmployerMatchingContributionEmployeeContributionPercent", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedContributionRetirementPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of employee contributions for which the employer contributes a matching contribution to a defined contribution plan.", "label": "Defined Contribution Plan, Employer Matching Contribution Employee Contribution Percent", "terseLabel": "Matching contribution, percentage of employee contribution (as a percent)" } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedContributionRetirementPlansDetails" ], "lang": { "en-us": { "role": { "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay", "terseLabel": "Matching contribution, percent of employees' gross pay (as a percent)", "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedContributionRetirementPlansDetails" ], "lang": { "en-us": { "role": { "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match", "terseLabel": "Matching contribution, percent of match (as a percent)", "documentation": "Percentage employer matches of the employee's percentage contribution matched." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedContributionRetirementPlansDetails" ], "lang": { "en-us": { "role": { "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent", "terseLabel": "Employee contribution percentage per calendar year (as a percent)", "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanTable", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedContributionRetirementPlansDetails" ], "lang": { "en-us": { "role": { "label": "Defined Contribution Plan [Table]", "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans." } } }, "auth_ref": [ "r577" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Depreciation", "terseLabel": "Depreciation and amortization", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r10", "r50" ] }, "us-gaap_DepreciationAndAmortizationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAndAmortizationAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosurePropertyAndEquipmentDepreciationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Depreciation, Depletion and Amortization [Abstract]", "terseLabel": "Property and Equipment" } } }, "auth_ref": [] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosurePropertyAndEquipmentDepreciationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r10", "r333", "r345", "r361", "r1017", "r1018" ] }, "us-gaap_DerivativeCapPrice": { "xbrltype": "perUnitItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeCapPrice", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtCappedCallsWithRespectTo2024ConvertibleNotesAnd2026ConvertibleNotesDetails", "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsCappedCallsDetails" ], "lang": { "en-us": { "role": { "label": "Derivative, Cap Price", "terseLabel": "Cap price", "documentation": "The cap rate on a price risk derivative such as a cap or collar. A payment or receipt is triggered if the market rate exceeds the cap rate on the contract." } } }, "auth_ref": [] }, "us-gaap_DerivativesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativesPolicyTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Derivative Assets and Liabilities", "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities." } } }, "auth_ref": [ "r18", "r80", "r81", "r82", "r84", "r288", "r307" ] }, "us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DilutiveSecuritiesEffectOnBasicEarningsPerShareOther", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerShareComputationDetails": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerShareComputationDetails" ], "lang": { "en-us": { "role": { "label": "Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities", "terseLabel": "Add back interest expense, net of tax benefit, on assumed conversion of convertible notes", "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of dilutive convertible securities excluding adjustments related to ESOP convertible preferred stock, stock options, and restrictive stock units." } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsSummaryDetails" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r501", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1038" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsSummaryDetails" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r501", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1038" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsTables" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of revenue attributable to transactions from collaboration and license arrangements", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r1278" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlans" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Employee Stock Benefit Plans", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r587", "r592", "r623", "r624", "r626", "r1044" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisclosureTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureTextBlockAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities", "http://www.ironwoodpharma.com/role/DisclosureAcquisitions", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreements", "http://www.ironwoodpharma.com/role/DisclosureCommitmentsAndContingencies", "http://www.ironwoodpharma.com/role/DisclosureDebt", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlans", "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstruments", "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxes", "http://www.ironwoodpharma.com/role/DisclosureLeases", "http://www.ironwoodpharma.com/role/DisclosureNatureOfBusiness", "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerShare", "http://www.ironwoodpharma.com/role/DisclosurePropertyAndEquipment", "http://www.ironwoodpharma.com/role/DisclosureRetirementPlans", "http://www.ironwoodpharma.com/role/DisclosureSegmentReporting", "http://www.ironwoodpharma.com/role/DisclosureSelectedQuarterlyFinancialDataUnaudited", "http://www.ironwoodpharma.com/role/DisclosureStockholdersEquity", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "http://www.ironwoodpharma.com/role/DisclosureWorkforceReductionAndRestructuring" ], "lang": { "en-us": { "role": { "label": "Disclosure Text Block [Abstract]", "terseLabel": "Disclosure Text Block" } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r1090", "r1091", "r1114" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r1090", "r1091", "r1114", "r1157" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r1135" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_DomesticCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DomesticCountryMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails" ], "lang": { "en-us": { "role": { "label": "Domestic Tax Jurisdiction [Member]", "terseLabel": "Domestic Tax Jurisdiction", "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction." } } }, "auth_ref": [ "r644" ] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": [ "r1146" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerShareComputationDetails", "http://www.ironwoodpharma.com/role/DisclosureSelectedQuarterlyFinancialDataUnauditedDetails", "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "terseLabel": "Net income (loss) per share attributable to Ironwood Pharmaceuticals, Inc. stockholders - basic (in dollars per share)", "verboseLabel": "Net income (loss) per share - basic (in dollars per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r270", "r299", "r300", "r301", "r302", "r303", "r304", "r310", "r313", "r325", "r326", "r327", "r332", "r693", "r702", "r734", "r735", "r854", "r877", "r1009" ] }, "irwd_EarningsPerShareBasicExcludingCollaborativeArrangementsRevenueReduction": { "xbrltype": "perShareItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "EarningsPerShareBasicExcludingCollaborativeArrangementsRevenueReduction", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaGeneralInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Earnings Per Share, Basic, Excluding Collaborative Arrangements Revenue Reduction", "label": "Earnings Per Share, Basic, Excluding Collaborative Arrangements Revenue Reduction", "terseLabel": "Net income per share, excluding collaborative arrangements revenue reduction - basic (in dollars per share)" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerShareComputationDetails", "http://www.ironwoodpharma.com/role/DisclosureSelectedQuarterlyFinancialDataUnauditedDetails", "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "terseLabel": "Net income (loss) per share attributable to Ironwood Pharmaceuticals, Inc. stockholders - diluted (in dollars per share)", "verboseLabel": "Net income (loss) per share - diluted (in dollars per share)", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r270", "r299", "r300", "r301", "r302", "r303", "r304", "r313", "r325", "r326", "r327", "r332", "r693", "r702", "r734", "r735", "r854", "r877", "r1009" ] }, "us-gaap_EarningsPerShareDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDilutedAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerSharePotentiallyDilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted [Abstract]", "terseLabel": "Potentially dilutive securities" } } }, "auth_ref": [] }, "irwd_EarningsPerShareDilutedExcludingCollaborativeArrangementsRevenueReduction": { "xbrltype": "perShareItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "EarningsPerShareDilutedExcludingCollaborativeArrangementsRevenueReduction", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaGeneralInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Earnings Per Share, Diluted, Excluding Collaborative Arrangements Revenue Reduction", "label": "Earnings Per Share, Diluted, Excluding Collaborative Arrangements Revenue Reduction", "terseLabel": "Net income per share, excluding collaborative arrangements revenue reduction - diluted (in dollars per share)" } } }, "auth_ref": [] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Income (Loss) Per Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r39", "r40", "r329" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerShare" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Income (Loss) Per Share", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r309", "r328", "r330", "r331" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1397" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesFederalStatutoryRateDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]", "terseLabel": "Effective Income Tax Rate Reconciliation, Percent" } } }, "auth_ref": [] }, "irwd_EffectiveIncomeTaxRateReconciliationAcquisitionAccountingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "EffectiveIncomeTaxRateReconciliationAcquisitionAccountingAmount", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Acquisition Accounting, Amount", "label": "Effective Income Tax Rate Reconciliation, Acquisition Accounting, Amount", "terseLabel": "Acquisition accounting for VectivBio Acquisition" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesFederalStatutoryRateDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Federal statutory rate (as a percent)", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r285", "r644", "r680", "r1047" ] }, "irwd_EffectiveIncomeTaxRateReconciliationDisallowedTransactionCostsAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "EffectiveIncomeTaxRateReconciliationDisallowedTransactionCostsAmount", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Disallowed Transaction Costs, Amount", "label": "Effective Income Tax Rate Reconciliation, Disallowed Transaction Costs, Amount", "terseLabel": "Disallowed transaction costs" } } }, "auth_ref": [] }, "irwd_EffectiveIncomeTaxRateReconciliationExecutiveCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "EffectiveIncomeTaxRateReconciliationExecutiveCompensation", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation Executive Compensation.", "label": "Effective Income Tax Rate Reconciliation Executive Compensation", "terseLabel": "Executive compensation - Section 162(m)" } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTabularDisclosureDetails": { "parentTag": "irwd_AccruedExpensesAndOtherLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation and benefits", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r94" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansShareBasedCompensationExpenseAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansShareBasedCompensationExpenseTabularDisclosureDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansSummaryOfExpenseRecognizedByShareBasedCompensationArrangementDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Additional Disclosure [Abstract]", "terseLabel": "Employee Stock Benefit Plans" } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansShareBasedCompensationExpenseAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansShareBasedCompensationExpenseTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansUnrecognizedShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount [Abstract]", "terseLabel": "Unrecognized share-based compensation" } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansUnrecognizedShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "verboseLabel": "Weighted-average remaining recognition period", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r625" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansUnrecognizedShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized expense, net of estimated forfeitures, other than options", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r1366" ] }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansShareBasedCompensationExpenseTabularDisclosureDetails": { "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansShareBasedCompensationExpenseTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expense, Tax Benefit", "terseLabel": "Income tax benefit", "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement." } } }, "auth_ref": [ "r622" ] }, "us-gaap_EmployeeStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansStockBenefitPlansDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansSummaryOfExpenseRecognizedByShareBasedCompensationArrangementDetails" ], "lang": { "en-us": { "role": { "label": "Employee Stock [Member]", "terseLabel": "Employee Stock", "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansStockOptionsGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansSummaryOfExpenseRecognizedByShareBasedCompensationArrangementDetails", "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerShareComputationDetails", "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerSharePotentiallyDilutiveSecuritiesDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1088" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsNoncontrollingInterestDetails" ], "lang": { "en-us": { "role": { "label": "All Entities [Member]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1088" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r1088" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r1197" ] }, "dei_EntityListingParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingParValuePerShare", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Listing, Par Value Per Share", "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'." } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1088" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r1088" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r1088" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1088" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r1198" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": [ "r1140" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": [ "r1193" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": [ "r1193" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": [ "r1193" ] }, "us-gaap_EquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquipmentMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosurePropertyAndEquipmentTabularDisclosureDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Equipment [Member]", "terseLabel": "Laboratory equipment", "documentation": "Tangible personal property used to produce goods and services." } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r17", "r242", "r264", "r265", "r266", "r290", "r291", "r292", "r296", "r303", "r305", "r307", "r335", "r380", "r386", "r404", "r489", "r675", "r676", "r689", "r690", "r691", "r694", "r701", "r702", "r715", "r717", "r718", "r719", "r720", "r722", "r733", "r762", "r764", "r765", "r766", "r767", "r768", "r775", "r780", "r801", "r873", "r892", "r893", "r894", "r913", "r966" ] }, "irwd_EquityIncentivePlan2019Member": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "EquityIncentivePlan2019Member", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansStockBenefitPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "2019 Equity Incentive Plan [Member]", "label": "Equity Incentive Plan, 2019 [Member]", "terseLabel": "2019 Equity Plan" } } }, "auth_ref": [] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r1150" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r1107", "r1118", "r1128", "r1161" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r1104", "r1115", "r1125", "r1158" ] }, "irwd_EuropeAndOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "EuropeAndOtherMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsEuropeanAndOtherTerritoriesDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsSummaryDetails" ], "lang": { "en-us": { "role": { "documentation": "Europe and Other [Member]", "label": "Europe and Other", "terseLabel": "Europe and Other" } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r1156" ] }, "us-gaap_FairValueAdjustmentDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAdjustmentDisclosureAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsConvertibleSeniorNotesDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Adjustment Disclosure [Abstract]", "terseLabel": "Fair value disclosures" } } }, "auth_ref": [] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Fair Value Adjustment of Warrants", "terseLabel": "Change in fair value of note hedge warrants", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability." } } }, "auth_ref": [ "r1", "r10" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r737", "r738", "r751", "r1051" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r737", "r738", "r751", "r1051" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsConvertibleSeniorNotesDetails", "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails", "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansFairValueOfPlanAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r458", "r530", "r531", "r532", "r533", "r534", "r535", "r736", "r738", "r739", "r740", "r741", "r750", "r751", "r753", "r804", "r805", "r806", "r1027", "r1028", "r1039", "r1040", "r1041", "r1051", "r1053" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r737", "r738", "r739", "r741", "r1051", "r1392", "r1395" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstruments" ], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value of Financial Instruments", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r746", "r748", "r749", "r750", "r753", "r754", "r755", "r756", "r757", "r850", "r1051", "r1054" ] }, "us-gaap_FairValueInputsLevel12And3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel12And3Member", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsConvertibleSeniorNotesDetails", "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails", "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansFairValueOfPlanAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1, Level 2, and Level 3 [Member]", "documentation": "Fair value measurement input including quoted price in active market for identical asset or liability reporting entity can access at measurement date (level 1), input other than quoted price included within level 1 either directly or indirectly observable for asset or liability (level 2) and unobservable input reflecting entity's own assumption (level 3)." } } }, "auth_ref": [ "r1051", "r1303", "r1390", "r1394" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Fair Value, Inputs, Level 1", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r458", "r530", "r535", "r738", "r751", "r804", "r1039", "r1040", "r1041", "r1051" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsConvertibleSeniorNotesDetails", "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Fair Value, Inputs, Level 2", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r458", "r530", "r535", "r738", "r739", "r751", "r805", "r1027", "r1028", "r1039", "r1040", "r1041", "r1051" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansFairValueOfPlanAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Fair Value, Inputs, Level 3", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r458", "r530", "r531", "r532", "r533", "r534", "r535", "r738", "r739", "r740", "r741", "r751", "r806", "r1027", "r1028", "r1039", "r1040", "r1041", "r1051", "r1053" ] }, "us-gaap_FairValueInputsQuantitativeInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsQuantitativeInformationAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsGeneralInformationDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Abstract]", "terseLabel": "Fair Value of Financial Instruments" } } }, "auth_ref": [] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsConvertibleSeniorNotesDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r742", "r743", "r744", "r745", "r746", "r747" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsConvertibleSeniorNotesDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Disclosure of information about financial instrument liability measured at fair value on recurring basis using unobservable input." } } }, "auth_ref": [ "r742", "r743", "r744", "r745", "r746", "r747", "r752" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [ "r737", "r738", "r739", "r741", "r1051", "r1392", "r1395" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsConvertibleSeniorNotesDetails", "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails", "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansFairValueOfPlanAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r458", "r530", "r531", "r532", "r533", "r534", "r535", "r736", "r738", "r739", "r740", "r741", "r750", "r751", "r753", "r804", "r805", "r806", "r1027", "r1028", "r1039", "r1040", "r1041", "r1051", "r1053" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring basis", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r1051", "r1389", "r1390", "r1391", "r1392", "r1393", "r1395" ] }, "us-gaap_FederalFundsEffectiveSwapRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FederalFundsEffectiveSwapRateMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails" ], "lang": { "en-us": { "role": { "label": "Fed Funds Effective Rate Overnight Index Swap Rate [Member]", "terseLabel": "Fed Funds Effective Rate Overnight Index Swap Rate", "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg." } } }, "auth_ref": [ "r1385" ] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsFiniteLivedIntangibleAssetsDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Useful life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "2025", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r399", "r998", "r1025" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "2028", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r399", "r998", "r1025" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "2027", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r399", "r998", "r1025" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "2026", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r399", "r998", "r1025" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsFiniteLivedIntangibleAssetsDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesIntangibleAssetsDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPatentCostsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r390", "r392", "r393", "r394", "r396", "r397", "r400", "r401", "r815", "r819", "r998" ] }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]", "terseLabel": "Future annual amortization expense" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesIntangibleAssetsDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPatentCostsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r390", "r397", "r400", "r401", "r402", "r815", "r998", "r1025" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsFiniteLivedIntangibleAssetsDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesIntangibleAssetsDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPatentCostsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r390", "r392", "r393", "r394", "r396", "r397", "r400", "r401", "r998" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsFiniteLivedIntangibleAssetsDetails", "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Intangible assets, net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r815", "r1258" ] }, "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNetAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsFiniteLivedIntangibleAssetsDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net [Abstract]", "terseLabel": "Finite-Lived Intangible Assets, Net" } } }, "auth_ref": [] }, "us-gaap_FixedIncomeSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FixedIncomeSecuritiesMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansAllocationOfPlanAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Fixed Income Securities [Member]", "terseLabel": "Fixed Income", "documentation": "Investment that provides a return in the form of fixed periodic payments and eventual return of principal at maturity." } } }, "auth_ref": [ "r1041", "r1076", "r1077", "r1302" ] }, "us-gaap_ForeignCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCountryMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails" ], "lang": { "en-us": { "role": { "label": "Foreign Tax Jurisdiction [Member]", "terseLabel": "Foreign Tax Jurisdiction", "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile." } } }, "auth_ref": [ "r644", "r645" ] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency Translation", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": [ "r761" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r1111", "r1122", "r1132", "r1165" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r1111", "r1122", "r1132", "r1165" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r1111", "r1122", "r1132", "r1165" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r1111", "r1122", "r1132", "r1165" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r1111", "r1122", "r1132", "r1165" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": [ "r1145" ] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosurePropertyAndEquipmentTabularDisclosureDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and fixtures", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnDerivativeInstrumentsNetPretax", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfIncomeLoss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Derivative Instruments, Net, Pretax", "terseLabel": "Gain on derivatives", "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects." } } }, "auth_ref": [ "r83" ] }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSaleOfPropertyPlantEquipment", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Disposition of Property Plant Equipment", "negatedLabel": "Loss on disposal of property and equipment", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property." } } }, "auth_ref": [ "r10" ] }, "us-gaap_GranteeStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GranteeStatusAxis", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansRestrictedStockAwardsGeneralInformationDetails" ], "lang": { "en-us": { "role": { "label": "Grantee Status [Axis]", "documentation": "Information by status of recipient to whom award is granted." } } }, "auth_ref": [ "r588", "r590", "r593", "r594", "r595", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r617", "r618", "r619", "r620", "r621" ] }, "us-gaap_GranteeStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GranteeStatusDomain", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansRestrictedStockAwardsGeneralInformationDetails" ], "lang": { "en-us": { "role": { "label": "Grantee Status [Domain]", "documentation": "Status of recipient to whom award is granted." } } }, "auth_ref": [ "r588", "r590", "r593", "r594", "r595", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r617", "r618", "r619", "r620", "r621" ] }, "us-gaap_GuaranteeObligationsByNatureAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GuaranteeObligationsByNatureAxis", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Guarantor Obligations, Nature [Axis]", "documentation": "Information by nature of guarantee." } } }, "auth_ref": [ "r429", "r430", "r431", "r432" ] }, "us-gaap_GuaranteeObligationsCurrentCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GuaranteeObligationsCurrentCarryingValue", "crdr": "credit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Guarantor Obligations, Current Carrying Value", "terseLabel": "Liabilities recorded", "documentation": "The current carrying amount of the liability for the freestanding or embedded guarantor's obligations under the guarantee or each group of similar guarantees." } } }, "auth_ref": [ "r431" ] }, "us-gaap_GuaranteeObligationsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GuaranteeObligationsLineItems", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Guarantor Obligations [Line Items]", "terseLabel": "Guarantees", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r429", "r430", "r431", "r432" ] }, "us-gaap_GuaranteeObligationsNatureDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GuaranteeObligationsNatureDomain", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Guarantor Obligations, Nature [Domain]", "documentation": "Represents a description of the nature of the guarantee or each group of similar guarantees." } } }, "auth_ref": [ "r429", "r430", "r431", "r432" ] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r1090", "r1091", "r1114" ] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Impairment of Long-Lived Assets", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": [ "r0", "r138" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesComponentsOfIncomeBeforeIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesComponentsOfIncomeBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "terseLabel": "United States", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations." } } }, "auth_ref": [ "r284", "r643" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfIncomeLoss": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 }, "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesComponentsOfIncomeBeforeIncomeTaxesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesComponentsOfIncomeBeforeIncomeTaxesDetails", "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income (loss) before income taxes", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r115", "r179", "r183", "r855", "r869", "r1010", "r1017", "r1238", "r1240", "r1241", "r1242", "r1243" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesComponentsOfIncomeBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest [Abstract]", "terseLabel": "Income before income taxes" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesComponentsOfIncomeBeforeIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesComponentsOfIncomeBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "terseLabel": "Foreign", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile." } } }, "auth_ref": [ "r284", "r643" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsExpensesDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansShareBasedCompensationExpenseAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansShareBasedCompensationExpenseTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r405", "r411", "r417", "r743", "r747", "r752", "r887", "r889", "r951", "r998", "r1052", "r1423" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsExpensesDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansShareBasedCompensationExpenseAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansShareBasedCompensationExpenseTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r411", "r417", "r743", "r747", "r752", "r887", "r889", "r951", "r998", "r1052", "r1423" ] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Jurisdiction [Axis]", "documentation": "Information by income tax jurisdiction." } } }, "auth_ref": [ "r279", "r644", "r645", "r657", "r671", "r1047", "r1371" ] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Jurisdiction [Domain]", "documentation": "Income tax jurisdiction." } } }, "auth_ref": [ "r279", "r644", "r645", "r657", "r671", "r1047", "r1371" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxes" ], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r285", "r636", "r644", "r653", "r654", "r655", "r662", "r669", "r681", "r683", "r684", "r685", "r910", "r1047" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfIncomeLoss": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 2.0 }, "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesProvisionForBenefitFromIncomeTaxesTabularDisclosureDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesProvisionForBenefitFromIncomeTaxesAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesProvisionForBenefitFromIncomeTaxesTabularDisclosureDetails", "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails", "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit)", "negatedLabel": "Income tax expense", "terseLabel": "Income tax (benefit) expense", "totalLabel": "Income tax expense", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r189", "r205", "r306", "r307", "r333", "r346", "r361", "r642", "r644", "r682", "r878", "r1047" ] }, "irwd_IncomeTaxExpenseBenefitCash": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "IncomeTaxExpenseBenefitCash", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesProvisionForBenefitFromIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Income Tax Expense (Benefit), Cash", "label": "Income Tax Expense (Benefit), Cash", "terseLabel": "Income tax (benefit) expense, cash expense" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesProvisionForBenefitFromIncomeTaxesTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit), Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesProvisionForBenefitFromIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit), Continuing Operations, by Jurisdiction [Abstract]", "terseLabel": "Income Taxes" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]", "terseLabel": "Reconciliation of income taxes" } } }, "auth_ref": [] }, "irwd_IncomeTaxExpenseBenefitNonCash": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "IncomeTaxExpenseBenefitNonCash", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesProvisionForBenefitFromIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Income Tax Expense (Benefit), Non-cash", "label": "Income Tax Expense (Benefit), Non-cash", "terseLabel": "Income tax (benefit) expense, non-cash expense" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r263", "r638", "r639", "r662", "r663", "r668", "r673", "r907" ] }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount", "terseLabel": "Change in the valuation allowance", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r650", "r1047", "r1368" ] }, "irwd_IncomeTaxReconciliationChangeInEnactedStateAndLocalTaxRates": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "IncomeTaxReconciliationChangeInEnactedStateAndLocalTaxRates", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "documentation": "The portion of the difference between total income tax expense or benefit as reported in the Income Statement and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations, that is attributable to changes in the state and local income tax rates under enacted tax laws in the period.", "label": "Income Tax Reconciliation, Change in Enacted State and Local Tax Rates", "terseLabel": "Effect of change in state tax rate on deferred tax assets and deferred tax liabilities" } } }, "auth_ref": [] }, "irwd_IncomeTaxReconciliationExpiringNetOperatingLossesAndTaxCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "IncomeTaxReconciliationExpiringNetOperatingLossesAndTaxCredits", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "documentation": "The portion of the difference between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to expiring net operating losses and tax credits.", "label": "Income Tax Reconciliation, Expiring Net Operating Losses and Tax Credits", "terseLabel": "Expiring net operating losses and tax credits" } } }, "auth_ref": [] }, "irwd_IncomeTaxReconciliationFairMarketValuationOfNoteHedgeWarrantsAndConvertibleNoteHedges": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "IncomeTaxReconciliationFairMarketValuationOfNoteHedgeWarrantsAndConvertibleNoteHedges", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "documentation": "The portion of the difference between total income tax expense or benefit as reported in the Income Statement and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations, that is attributable to fair market valuation of note hedge warrants and convertible note hedges.", "label": "Income Tax Reconciliation, Fair Market Valuation of Note Hedge Warrants and Convertible Note Hedges", "terseLabel": "Fair market valuation of Note Hedge Warrants and Convertible Note Hedges" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount", "terseLabel": "Foreign tax rate differential", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)." } } }, "auth_ref": [ "r645", "r648", "r1047", "r1368" ] }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount", "terseLabel": "Income tax expense (benefit) using U.S. federal statutory rate", "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r644", "r1047" ] }, "us-gaap_IncomeTaxReconciliationNondeductibleExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationNondeductibleExpense", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount", "terseLabel": "Permanent differences", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses." } } }, "auth_ref": [ "r651", "r652", "r1368" ] }, "irwd_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCostWindfalls": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCostWindfalls", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible equity-based compensation costs windfalls.", "label": "Income Tax Reconciliation Nondeductible Expense, Share-based Compensation Cost, Windfalls", "negatedLabel": "Excess tax benefits" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationOtherAdjustments", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount", "terseLabel": "Other", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": [ "r1047", "r1368", "r1369" ] }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount", "terseLabel": "State income taxes, net of federal benefit", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)." } } }, "auth_ref": [ "r647", "r1047", "r1368" ] }, "us-gaap_IncomeTaxReconciliationTaxCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationTaxCredits", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount", "negatedLabel": "Tax credits", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits." } } }, "auth_ref": [ "r649", "r652", "r1368" ] }, "us-gaap_IncomeTaxUncertaintiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxUncertaintiesAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesAcquisitionsDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Uncertainties [Abstract]", "terseLabel": "Uncertain tax positions" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Income Taxes Paid, Net", "terseLabel": "Cash paid for income taxes", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": [ "r36", "r279", "r670", "r671" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued expenses", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r9" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable, net", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r9" ] }, "irwd_IncreaseDecreaseInAccruedResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "IncreaseDecreaseInAccruedResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "This element represents the net change in research and development expenses, which are accrued during the period, but not yet paid.", "label": "Increase (Decrease) in Accrued Research and Development Expense", "terseLabel": "Accrued research and development costs" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Operating lease liabilities", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r1208", "r1225" ] }, "irwd_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) in Operating Lease, Right-of-Use Asset", "label": "Increase (Decrease) in Operating Lease, Right-of-Use Asset", "negatedLabel": "Operating lease right-of-use assets" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherCurrentLiabilities", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Other Current Liabilities", "terseLabel": "Other liabilities", "documentation": "Amount of increase (decrease) in current liabilities classified as other." } } }, "auth_ref": [ "r1225" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Other Operating Assets", "negatedLabel": "Other assets", "documentation": "Amount of increase (decrease) in operating assets classified as other." } } }, "auth_ref": [ "r9" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r9" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity (Deficit)", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerShareComputationDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerShareComputationDetails" ], "lang": { "en-us": { "role": { "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities", "terseLabel": "Effect of dilutive securities, convertible notes", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method." } } }, "auth_ref": [ "r321", "r322", "r327" ] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerShareComputationDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerShareComputationDetails" ], "lang": { "en-us": { "role": { "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "terseLabel": "Effect of dilutive securities, share-based compensation", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r314", "r315", "r316", "r327", "r591" ] }, "us-gaap_IndemnificationGuaranteeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndemnificationGuaranteeMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Indemnification Agreement [Member]", "terseLabel": "Indemnification Agreement", "documentation": "An agreement (contract) that contingently requires the guarantor to make payments to the guaranteed party in compensation for that party's or parties' loss or injury attributable to specified events or actions, such as a patent infringement action against an entity that relied on certain representations as to ownership rights made by a software vendor." } } }, "auth_ref": [ "r1272" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": [ "r1111", "r1122", "r1132", "r1156", "r1165", "r1169", "r1177" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": [ "r1175" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r1092", "r1181" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r1092", "r1181" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r1092", "r1181" ] }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsFiniteLivedPolicy", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]", "terseLabel": "Intangible Assets", "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets." } } }, "auth_ref": [ "r811", "r812", "r813", "r815", "r1007", "r1252" ] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseDebt", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureDebtInterestExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtInterestExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Interest Expense, Debt", "totalLabel": "Total interest expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": [ "r123", "r464", "r474", "r1029", "r1030" ] }, "us-gaap_InterestExpenseDebtAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseDebtAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtInterestExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Interest Expense, Debt [Abstract]", "terseLabel": "Interest Expense" } } }, "auth_ref": [] }, "us-gaap_InterestExpenseDebtExcludingAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseDebtExcludingAmortization", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureDebtInterestExpenseDetails": { "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtInterestExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Interest Expense, Debt, Excluding Amortization", "terseLabel": "Contractual interest expense", "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs." } } }, "auth_ref": [ "r123", "r465", "r1029", "r1030" ] }, "irwd_InterestExpenseDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "InterestExpenseDebtTableTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of interest expense related to debt.", "label": "Interest Expense, Debt [Table Text Block]", "terseLabel": "Schedule of interest expense" } } }, "auth_ref": [] }, "irwd_InterestExpenseNoncashExpectedIncreaseDecreaseDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "InterestExpenseNoncashExpectedIncreaseDecreaseDuringPeriod", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCumulativeEffectAdjustmentAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Interest Expense, Noncash, Expected Increase (Decrease) During Period", "label": "Interest Expense, Noncash, Expected Increase (Decrease) During Period", "terseLabel": "Interest expense, noncash, expected increase (decrease) during period" } } }, "auth_ref": [] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfIncomeLoss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Interest Expense, Nonoperating", "negatedLabel": "Interest expense and other financing costs", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": [ "r344", "r1223" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r273", "r276", "r278" ] }, "us-gaap_InterestPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPayableCurrent", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTabularDisclosureDetails": { "parentTag": "irwd_AccruedExpensesAndOtherLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Interest Payable, Current", "terseLabel": "Accrued interest", "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r94" ] }, "us-gaap_InvestmentIncomeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeNet", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfIncomeLoss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Investment Income, Net", "terseLabel": "Interest and investment income", "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities." } } }, "auth_ref": [ "r120", "r121", "r123" ] }, "irwd_IronwoodPharmaceuticalsInc401KSavingsPlanMatchingContributions100PercentOnFirst3PercentAnd50PercentOnNext3Percent100PercentOnFirst3PercentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "IronwoodPharmaceuticalsInc401KSavingsPlanMatchingContributions100PercentOnFirst3PercentAnd50PercentOnNext3Percent100PercentOnFirst3PercentMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedContributionRetirementPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Ironwood Pharmaceuticals, Inc 401(k) Savings Plan, Matching Contributions, 100 Percent on First 3 Percent and 50 Percent on Next 3 Percent, 100 Percent on First 3 Percent [Member]", "label": "Ironwood Pharmaceuticals, Inc 401(k) Savings Plan, Matching Contributions, 100 Percent on First 3 Percent and 50 Percent on Next 3 Percent, 100 Percent on First 3 Percent", "terseLabel": "Ironwood Pharmaceuticals, Inc 401(k) Savings Plan, Matching Contributions, 100 Percent on First 3 Percent and 50 Percent on Next 3 Percent, 100 Percent on First 3 Percent" } } }, "auth_ref": [] }, "irwd_IronwoodPharmaceuticalsInc401KSavingsPlanMatchingContributions100PercentOnFirst3PercentAnd50PercentOnNext3Percent50PercentOnNext3PercentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "IronwoodPharmaceuticalsInc401KSavingsPlanMatchingContributions100PercentOnFirst3PercentAnd50PercentOnNext3Percent50PercentOnNext3PercentMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedContributionRetirementPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Ironwood Pharmaceuticals, Inc 401(k) Savings Plan, Matching Contributions, 100 Percent on First 3 Percent and 50 Percent on Next 3 Percent, 50 Percent on Next 3 Percent [Member]", "label": "Ironwood Pharmaceuticals, Inc 401(k) Savings Plan, Matching Contributions, 100 Percent on First 3 Percent and 50 Percent on Next 3 Percent, 50 Percent on Next 3 Percent", "terseLabel": "Ironwood Pharmaceuticals, Inc 401(k) Savings Plan, Matching Contributions, 100 Percent on First 3 Percent and 50 Percent on Next 3 Percent, 50 Percent on Next 3 Percent" } } }, "auth_ref": [] }, "irwd_IronwoodPharmaceuticalsInc401KSavingsPlanMatchingContributions100PercentOnFirst3PercentAnd50PercentOnNext3PercentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "IronwoodPharmaceuticalsInc401KSavingsPlanMatchingContributions100PercentOnFirst3PercentAnd50PercentOnNext3PercentMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedContributionRetirementPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Ironwood Pharmaceuticals, Inc 401(k) Savings Plan, Matching Contributions, 100 Percent on First 3 Percent and 50 Percent on Next 3 Percent [Member]", "label": "Ironwood Pharmaceuticals, Inc 401(k) Savings Plan, Matching Contributions, 100 Percent on First 3 Percent and 50 Percent on Next 3 Percent [Member]" } } }, "auth_ref": [] }, "irwd_IronwoodPharmaceuticalsInc401KSavingsPlanMatchingContributions75PercentOnFirst10000UpTo7500Member": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "IronwoodPharmaceuticalsInc401KSavingsPlanMatchingContributions75PercentOnFirst10000UpTo7500Member", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedContributionRetirementPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Ironwood Pharmaceuticals, Inc 401(k) Savings Plan, Matching Contributions, 75 Percent on First 10,000, up to 7,500", "label": "Ironwood Pharmaceuticals, Inc 401(k) Savings Plan, Matching Contributions, 75 Percent on First 10,000, up to 7,500 [Member]", "terseLabel": "Ironwood Pharmaceuticals, Inc 401(k) Savings Plan, Matching Contributions, 75 Percent on First $10,000, up to $7,500" } } }, "auth_ref": [] }, "irwd_IronwoodPharmaceuticalsInc401KSavingsPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "IronwoodPharmaceuticalsInc401KSavingsPlanMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedContributionRetirementPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Ironwood Pharmaceuticals, Inc 401(k) Savings Plan [Member]", "label": "Ironwood Pharmaceuticals, Inc 401(k) Savings Plan [Member]" } } }, "auth_ref": [] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureLeasesLeaseCostDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesLeaseCostDetails" ], "lang": { "en-us": { "role": { "label": "Lease, Cost", "totalLabel": "Total lease cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r787", "r1058" ] }, "us-gaap_LeaseCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesLeaseCostDetails" ], "lang": { "en-us": { "role": { "label": "Lease, Cost [Abstract]", "terseLabel": "Lease Cost" } } }, "auth_ref": [] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesTables" ], "lang": { "en-us": { "role": { "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of components of lease cost and supplemental cash flow information", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r1403" ] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosurePropertyAndEquipmentTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r137", "r794" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsNoncontrollingInterestDetails" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LesseeDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeDisclosureAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesSupplementalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lessee Disclosure [Abstract]", "terseLabel": "Operating Leases" } } }, "auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesLettersOfCreditDetails", "http://www.ironwoodpharma.com/role/DisclosureLeasesSummerStreetLeaseDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Leases", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r785", "r795" ] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionTable", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesLettersOfCreditDetails", "http://www.ironwoodpharma.com/role/DisclosureLeasesSummerStreetLeaseDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": [ "r785", "r795" ] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r784" ] }, "us-gaap_LesseeOperatingLeaseDescriptionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseDescriptionAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesSummerStreetLeaseDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Description [Abstract]", "terseLabel": "Operating Leases" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesSummerStreetLeaseDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]", "terseLabel": "Option to extend the term of the lease", "documentation": "Indicates (true false) whether lessee has option to extend operating lease." } } }, "auth_ref": [ "r786" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesTables" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "terseLabel": "Schedule of future minimum lease payments under non-cancelable operating leases", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r1404" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.ironwoodpharma.com/role/DisclosureLeasesOperatingLeaseObligationsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails", "http://www.ironwoodpharma.com/role/DisclosureLeasesOperatingLeaseObligationsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total future minimum lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r793" ] }, "irwd_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Liability, Payments, Due after Year Four", "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Four", "terseLabel": "2029 and thereafter" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r793" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2028", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r793" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r793" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r793" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureLeasesOperatingLeaseObligationsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesOperatingLeaseObligationsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: present value adjustment", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r793" ] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesSummerStreetLeaseDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Operating lease, renewal term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1402" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeases" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r779" ] }, "irwd_LetterOfCreditSubfacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "LetterOfCreditSubfacilityMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Letter of Credit Subfacility [Member]", "label": "Letter of Credit Subfacility [Member]", "terseLabel": "Letter of Credit Subfacility" } } }, "auth_ref": [] }, "us-gaap_LettersOfCreditOutstandingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LettersOfCreditOutstandingAmount", "crdr": "credit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesLettersOfCreditDetails" ], "lang": { "en-us": { "role": { "label": "Letters of Credit Outstanding, Amount", "terseLabel": "Letters of credit outstanding, amount", "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' deficit", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r111", "r178", "r865", "r1059", "r1229", "r1249", "r1396" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r95", "r248", "r283", "r375", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r706", "r709", "r710", "r760", "r1059", "r1273", "r1406", "r1407" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_LicenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LicenseMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsEuropeanAndOtherTerritoriesDetails" ], "lang": { "en-us": { "role": { "label": "License [Member]", "terseLabel": "License", "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark." } } }, "auth_ref": [ "r1279" ] }, "irwd_LineOfCreditAdditionalBorrowingCapacityThroughAccordionFeature": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "LineOfCreditAdditionalBorrowingCapacityThroughAccordionFeature", "crdr": "credit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Line of Credit, Additional Borrowing Capacity through Accordion Feature", "label": "Line of Credit, Additional Borrowing Capacity through Accordion Feature", "terseLabel": "Additional borrowing capacity" } } }, "auth_ref": [] }, "irwd_LineOfCreditFacilityAdditionalBorrowingCapacityPercentOfConsolidatedAdjustedEarningsBeforeInterestTaxDepreciationAndAmortization": { "xbrltype": "percentItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "LineOfCreditFacilityAdditionalBorrowingCapacityPercentOfConsolidatedAdjustedEarningsBeforeInterestTaxDepreciationAndAmortization", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "The additional borrowing capacity under line of credit, as percentage of consolidated adjusted earnings before interest tax depreciation and amortization.", "label": "Line of Credit Facility, Additional Borrowing Capacity, Percent of Consolidated Adjusted Earnings Before Interest Tax Depreciation and Amortization", "terseLabel": "Additional borrowing capacity, as percentage" } } }, "auth_ref": [] }, "irwd_LineOfCreditFacilityAdditionalBorrowingCapacityTrailingPeriodForConsolidatedAdjustedEarningsBeforeInterestTaxDepreciationAndAmortizationCalculation": { "xbrltype": "durationItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "LineOfCreditFacilityAdditionalBorrowingCapacityTrailingPeriodForConsolidatedAdjustedEarningsBeforeInterestTaxDepreciationAndAmortizationCalculation", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "The trailing period considered for calculation of consolidated adjusted earnings before interest, tax, depreciation and amortization.", "label": "Line of Credit Facility, Additional Borrowing Capacity, Trailing Period for Consolidated Adjusted Earnings Before Interest, Tax, Depreciation and Amortization Calculation", "terseLabel": "Additional borrowing capacity, trailing period" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityFrequencyOfCommitmentFeePayment": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityFrequencyOfCommitmentFeePayment", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Frequency of Commitment Fee Payment", "terseLabel": "Line of credit facility, frequency of commitment fee payment", "documentation": "Description of when the fee for available but unused credit capacity is required to be paid (for example, annually, quarterly, or monthly)." } } }, "auth_ref": [ "r92", "r99" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Line of credit facility, maximum borrowing capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r92", "r99" ] }, "irwd_LineOfCreditFacilityPledgeOfForeignSubsidiariesCapitalStockMaximumPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "LineOfCreditFacilityPledgeOfForeignSubsidiariesCapitalStockMaximumPercent", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "The maximum percentage of capital stock of foreign subsidiaries pledged under credit agreement.", "label": "Line of Credit Facility, Pledge of Foreign Subsidiaries Capital Stock, Maximum, Percent", "terseLabel": "Percentage of capital stock of foreign subsidiaries pledged (as a percent)" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "terseLabel": "Line of credit facility, unused capacity, commitment fee percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesBalancesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesFutureMinimumPaymentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesBalancesDetails", "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt", "totalLabel": "Net carrying amount", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r27", "r175", "r457", "r472", "r1027", "r1028", "r1057", "r1418" ] }, "us-gaap_LongTermDebtAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesBalancesDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Unclassified [Abstract]", "terseLabel": "Principal:" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtFairValue", "crdr": "credit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsConvertibleSeniorNotesDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Fair Value", "terseLabel": "Estimated fair value", "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission." } } }, "auth_ref": [ "r1389", "r1391", "r1392", "r1393" ] }, "irwd_LongTermDebtMaturitiesInterestPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "LongTermDebtMaturitiesInterestPayments", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesFutureMinimumPaymentsDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of interest to be paid on long-term debt.", "label": "Long-term Debt, Maturities, Interest Payments", "negatedLabel": "Less: amounts representing interest" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesFutureMinimumPaymentsDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2025", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r12", "r289", "r462" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesFutureMinimumPaymentsDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2026", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r12", "r289", "r462" ] }, "us-gaap_LongTermDebtTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtTerm", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesDue2022ConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Term", "terseLabel": "Debt instrument term", "documentation": "Period between issuance and maturity of long-term debt, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1391", "r1392", "r1393" ] }, "us-gaap_LongTermLineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermLineOfCredit", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Long-Term Line of Credit, Noncurrent", "terseLabel": "Revolving credit facility", "documentation": "The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r27", "r53", "r54" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesBalancesDetails", "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesDue2022ConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesFutureMinimumPaymentsDetails", "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureDebtInterestExpenseDetails", "http://www.ironwoodpharma.com/role/DisclosureDebtTables", "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsConvertibleSeniorNotesDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDerivativeAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r27", "r1262", "r1263", "r1264" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesBalancesDetails", "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesDue2022ConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesFutureMinimumPaymentsDetails", "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureDebtInterestExpenseDetails", "http://www.ironwoodpharma.com/role/DisclosureDebtTables", "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsConvertibleSeniorNotesDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDerivativeAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r27", "r55", "r1262", "r1263", "r1264" ] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "documentation": "Information by name or description of a single external customer or a group of external customers." } } }, "auth_ref": [ "r369", "r1034", "r1069", "r1073", "r1278", "r1422", "r1424", "r1425", "r1427", "r1428", "r1429", "r1430", "r1431", "r1432", "r1433", "r1434", "r1435", "r1436", "r1437", "r1438", "r1439", "r1440", "r1441", "r1442", "r1443", "r1444", "r1445", "r1446", "r1447", "r1448", "r1449", "r1450", "r1451" ] }, "us-gaap_MaturitiesOfLongTermDebtAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MaturitiesOfLongTermDebtAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Maturities of Long-Term Debt [Abstract]", "terseLabel": "Future minimum payments of Convertible senior notes" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTimeBasedRsusVestingDetails", "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedContributionRetirementPlansDetails", "http://www.ironwoodpharma.com/role/DisclosureWorkforceReductionAndRestructuringGeneralInformationDetails" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum", "documentation": "Upper limit of the provided range." } } }, "auth_ref": [ "r209", "r211", "r213", "r214", "r216", "r238", "r239", "r425", "r426", "r427", "r428", "r581", "r632", "r741", "r810", "r886", "r888", "r903", "r918", "r919", "r971", "r973", "r975", "r976", "r980", "r996", "r997", "r1024", "r1031", "r1043", "r1053", "r1054", "r1055", "r1056", "r1070", "r1275", "r1408", "r1409", "r1410", "r1411", "r1412", "r1413" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": [ "r1148" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": [ "r1148" ] }, "irwd_MeasurementPeriodMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "MeasurementPeriodMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to measurement period.", "label": "Measurement period" } } }, "auth_ref": [] }, "irwd_MilestonePaymentToBeReceivedByCompanyUponMilestoneAchievement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "MilestonePaymentToBeReceivedByCompanyUponMilestoneAchievement", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsChinaHongKongAndMacauDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount to be received by the company upon completion of milestone.", "label": "Milestone Payment to be Received by Company upon Milestone Achievement", "terseLabel": "Milestone payment to be received by company upon milestone achievement" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTimeBasedRsusVestingDetails", "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedContributionRetirementPlansDetails", "http://www.ironwoodpharma.com/role/DisclosureWorkforceReductionAndRestructuringGeneralInformationDetails" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum", "documentation": "Lower limit of the provided range." } } }, "auth_ref": [ "r209", "r211", "r213", "r214", "r216", "r238", "r239", "r425", "r426", "r427", "r428", "r581", "r632", "r741", "r810", "r886", "r888", "r903", "r918", "r919", "r971", "r973", "r975", "r976", "r980", "r996", "r997", "r1024", "r1031", "r1043", "r1053", "r1054", "r1055", "r1070", "r1275", "r1408", "r1409", "r1410", "r1411", "r1412", "r1413" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterest", "crdr": "credit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsNoncontrollingInterestDetails" ], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Noncontrolling Interest", "terseLabel": "Noncontrolling interests", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r110", "r177", "r283", "r375", "r435", "r437", "r438", "r439", "r442", "r443", "r760", "r864", "r929" ] }, "us-gaap_MinorityInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsNoncontrollingInterestDetails" ], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Noncontrolling Interest [Abstract]", "terseLabel": "Noncontrolling interests" } } }, "auth_ref": [] }, "us-gaap_MinorityInterestLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestLineItems", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsNoncontrollingInterestDetails" ], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest [Line Items]", "terseLabel": "Noncontrolling interests", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_MinorityInterestTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestTable", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsNoncontrollingInterestDetails" ], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest [Table]", "documentation": "Disclosure of information about noncontrolling interest, including, but not limited to, name of subsidiary, ownership percentage held by parent, ownership percentage held by noncontrolling owner, amount of noncontrolling interest and its location in statement of financial position, explanation of increase (decrease) in noncontrolling interest, noncontrolling interest share of net income (loss) of subsidiary and its location in statement of income, amount of noncontrolling interest represented by preferred stock, description and dividend requirement of preferred stock, and nature of noncontrolling interest." } } }, "auth_ref": [ "r73", "r76", "r110", "r116" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r1168" ] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Money Market Funds [Member]", "terseLabel": "Money market funds", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r1302" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r1176" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "documentation": "Single external customer or group of external customers." } } }, "auth_ref": [ "r369", "r1034", "r1069", "r1073", "r1278", "r1422", "r1424", "r1425", "r1427", "r1428", "r1429", "r1430", "r1431", "r1432", "r1433", "r1434", "r1435", "r1436", "r1437", "r1438", "r1439", "r1440", "r1441", "r1442", "r1443", "r1444", "r1445", "r1446", "r1447", "r1448", "r1449", "r1450", "r1451" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r1149" ] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NatureOfOperations", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNatureOfBusiness" ], "lang": { "en-us": { "role": { "label": "Nature of Operations [Text Block]", "terseLabel": "Nature of Business", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": [ "r191", "r206" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by (used in) financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r275" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r275" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r129", "r130", "r131" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerShareComputationDetails": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 1.0 }, "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfIncomeLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerShareComputationDetails", "http://www.ironwoodpharma.com/role/DisclosureSelectedQuarterlyFinancialDataUnauditedDetails", "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfIncomeLoss", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net income (loss) attributable to Ironwood Pharmaceuticals, Inc.", "verboseLabel": "Net income (loss) attributable to Ironwood Pharmaceuticals, Inc.", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r117", "r131", "r180", "r246", "r258", "r261", "r266", "r283", "r295", "r299", "r300", "r301", "r302", "r303", "r306", "r307", "r323", "r375", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r693", "r702", "r735", "r760", "r872", "r948", "r964", "r965", "r1084", "r1273" ] }, "us-gaap_NetIncomeLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Parent [Abstract]", "terseLabel": "Net income (loss)" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfIncomeLoss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerShareComputationDetails", "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "terseLabel": "Less: Net loss attributable to noncontrolling interests", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r78", "r164", "r258", "r261", "r303", "r306", "r307", "r871", "r1222" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerShareComputationDetails": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerShareComputationDetails" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Numerator used in computing net income (loss) per share - basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r271", "r299", "r300", "r301", "r302", "r310", "r311", "r324", "r327", "r702" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerShareComputationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerShareComputationDetails" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "totalLabel": "Numerator used in computing net income (loss) per share - diluted", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r271", "r312", "r317", "r318", "r319", "r320", "r324", "r327" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerShareComputationDetails" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]", "terseLabel": "Numerator:" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCumulativeEffectAdjustmentAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCumulativeEffectAdjustmentTabularDisclosureDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" ], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r240", "r241", "r242", "r243", "r244", "r245", "r293", "r295", "r296", "r297", "r298", "r301", "r308", "r332", "r370", "r371", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r403", "r404", "r412", "r675", "r676", "r677", "r678", "r679", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r724", "r725", "r726", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r758", "r759", "r772", "r775", "r778", "r796", "r797", "r798", "r799", "r800", "r801", "r816", "r817", "r818", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r905" ] }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCumulativeEffectAdjustmentAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCumulativeEffectAdjustmentTabularDisclosureDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update and Change in Accounting Principle [Table]", "documentation": "Disclosure of information about change in accounting principle or amendment to accounting standards or both. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards and other change in accounting principle." } } }, "auth_ref": [ "r37", "r240", "r241", "r242", "r243", "r244", "r245", "r293", "r295", "r296", "r297", "r298", "r301", "r308", "r332", "r370", "r371", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r403", "r404", "r412", "r675", "r676", "r677", "r678", "r679", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r724", "r725", "r726", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r758", "r759", "r772", "r775", "r778", "r796", "r797", "r798", "r799", "r800", "r801", "r816", "r817", "r818", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r905" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "New Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r1148" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r1111", "r1122", "r1132", "r1156", "r1165" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r1139" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r1138" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r1156" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r1176" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r1176" ] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Non-cash investing and financing activities" } } }, "auth_ref": [] }, "irwd_NoncontrollingInterestIncreaseDecreaseFromPurchaseOfSubsidiarySharesFromNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "NoncontrollingInterestIncreaseDecreaseFromPurchaseOfSubsidiarySharesFromNoncontrollingInterest", "crdr": "credit", "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Noncontrolling Interest, Increase (Decrease) from Purchase of Subsidiary Shares from Noncontrolling Interest", "label": "Noncontrolling Interest, Increase (Decrease) from Purchase of Subsidiary Shares from Noncontrolling Interest", "terseLabel": "Purchase of subsidiary shares from noncontrolling interests" } } }, "auth_ref": [] }, "us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestIncreaseFromBusinessCombination", "crdr": "credit", "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest, Increase from Business Combination", "terseLabel": "Noncontrolling interests on acquisition of VectivBio Holding AG", "documentation": "Amount of increase in noncontrolling interest from a business combination." } } }, "auth_ref": [ "r15", "r59", "r71" ] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestMember", "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest [Member]", "terseLabel": "Noncontrolling Interest", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r72", "r489", "r1231", "r1232", "r1233", "r1236", "r1453" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfIncomeLoss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSelectedQuarterlyFinancialDataUnauditedDetails", "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense)", "terseLabel": "Other income (expense), net", "totalLabel": "Other income (expense), net", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r122" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense):" } } }, "auth_ref": [] }, "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTables" ], "lang": { "en-us": { "role": { "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]", "terseLabel": "Summary of restricted stock activity", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares." } } }, "auth_ref": [ "r25" ] }, "srt_NorthAmericaMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NorthAmericaMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCollaborativeArrangementsRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaRoyaltyRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsSummaryDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "label": "North America [Member]", "terseLabel": "North America", "documentation": "Continent of North America." } } }, "auth_ref": [ "r1210", "r1211", "r1212", "r1213", "r1455", "r1456", "r1457", "r1458" ] }, "irwd_NoteHedgeWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "NoteHedgeWarrantsMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerSharePotentiallyDilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Note Hedge Warrants [Member]", "label": "Note Hedge Warrants [Member]", "terseLabel": "Note Hedge Warrants" } } }, "auth_ref": [] }, "irwd_NumberOfRemainingCommercialPeriodPerformanceObligations": { "xbrltype": "integerItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "NumberOfRemainingCommercialPeriodPerformanceObligations", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaGeneralInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of Remaining Commercial Period Performance Obligations.", "label": "Number of Remaining Commercial Period Performance Obligations", "terseLabel": "Remaining commercial-period performance obligations" } } }, "auth_ref": [] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfReportableSegments", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSegmentReportingDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentInformationDetails" ], "lang": { "en-us": { "role": { "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r1011", "r1022", "r1239" ] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfIncomeLoss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "Income (loss) from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r183", "r1010", "r1238", "r1240", "r1241", "r1242", "r1243" ] }, "us-gaap_OperatingIncomeLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLossAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Operating Income (Loss) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureLeasesLeaseCostDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesLeaseCostDetails", "http://www.ironwoodpharma.com/role/DisclosureLeasesSummerStreetLeaseDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Cost", "verboseLabel": "Operating lease cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r788", "r1058" ] }, "us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesOperatingLeaseObligationsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Gross Difference [Abstract]", "terseLabel": "Operating lease obligations" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]", "terseLabel": "Future Minimum Lease Payments" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureLeasesOperatingLeaseObligationsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesOperatingLeaseObligationsDetails", "http://www.ironwoodpharma.com/role/DisclosureLeasesSummerStreetLeaseDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability", "totalLabel": "Operating lease liabilities", "verboseLabel": "Operating lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r782" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureLeasesOperatingLeaseObligationsDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 }, "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesOperatingLeaseObligationsDetails", "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "negatedLabel": "Less: current portion of operating lease liabilities", "terseLabel": "Current portion of operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r782" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 }, "http://www.ironwoodpharma.com/role/DisclosureLeasesOperatingLeaseObligationsDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesOperatingLeaseObligationsDetails", "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease obligations, net of current portion", "verboseLabel": "Operating lease liabilities, net of current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r782" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesSupplementalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Payments", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r783", "r790" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesSummerStreetLeaseDetails", "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "verboseLabel": "Operating lease right-of-use assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r781" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesSummerStreetLeaseDetails", "http://www.ironwoodpharma.com/role/DisclosureLeasesSupplementalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate of operating leases (as a percent)", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r792", "r1058" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesSupplementalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term of operating leases", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r791", "r1058" ] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLossCarryforwards", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards", "totalLabel": "Net operating loss carryforwards", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r672" ] }, "irwd_OperatingLossCarryforwardsIndefinite": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "OperatingLossCarryforwardsIndefinite", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails": { "parentTag": "us-gaap_OperatingLossCarryforwards", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails" ], "lang": { "en-us": { "role": { "documentation": "Operating Loss Carryforwards, Indefinite", "label": "Operating Loss Carryforwards, Indefinite", "terseLabel": "Net operating loss carryforwards, indefinite" } } }, "auth_ref": [] }, "us-gaap_OperatingLossCarryforwardsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLossCarryforwardsLineItems", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards [Line Items]", "terseLabel": "Net operating loss carryforwards", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r672" ] }, "irwd_OperatingLossCarryforwardsSubjectToExpiration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "OperatingLossCarryforwardsSubjectToExpiration", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails": { "parentTag": "us-gaap_OperatingLossCarryforwards", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails" ], "lang": { "en-us": { "role": { "documentation": "Operating Loss Carryforwards, Subject to Expiration", "label": "Operating Loss Carryforwards, Subject to Expiration", "terseLabel": "Net operating loss carryforwards, subject to expiration" } } }, "auth_ref": [] }, "us-gaap_OperatingLossCarryforwardsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLossCarryforwardsTable", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards [Table]", "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization." } } }, "auth_ref": [ "r672" ] }, "us-gaap_OptionIndexedToIssuersEquityEquityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OptionIndexedToIssuersEquityEquityAxis", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtCappedCallsWithRespectTo2024ConvertibleNotesAnd2026ConvertibleNotesDetails", "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsCappedCallsDetails" ], "lang": { "en-us": { "role": { "label": "Option Indexed to Issuer's Equity [Axis]", "documentation": "Information by type of options indexed to an issuer's equity." } } }, "auth_ref": [ "r56", "r85", "r86", "r165" ] }, "us-gaap_OptionIndexedToIssuersEquityEquityTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OptionIndexedToIssuersEquityEquityTable", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtCappedCallsWithRespectTo2024ConvertibleNotesAnd2026ConvertibleNotesDetails", "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsCappedCallsDetails" ], "lang": { "en-us": { "role": { "label": "Option Indexed to Issuer's Equity, Equity [Table]", "documentation": "Disclosure of information about option contract issued and indexed to equity, classified as equity. Includes, but is not limited to, strike price, number of shares, indexed share, and settlement date." } } }, "auth_ref": [ "r56", "r85", "r86", "r165" ] }, "us-gaap_OptionIndexedToIssuersEquityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OptionIndexedToIssuersEquityLineItems", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtCappedCallsWithRespectTo2024ConvertibleNotesAnd2026ConvertibleNotesDetails", "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsCappedCallsDetails" ], "lang": { "en-us": { "role": { "label": "Option Indexed to Issuer's Equity [Line Items]", "terseLabel": "Capped Calls", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_OptionIndexedToIssuersEquityShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OptionIndexedToIssuersEquityShares", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtCappedCallsWithRespectTo2024ConvertibleNotesAnd2026ConvertibleNotesDetails", "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsCappedCallsDetails" ], "lang": { "en-us": { "role": { "label": "Option Indexed to Issuer's Equity, Shares", "terseLabel": "Number of shares covered by capped calls (in shares)", "documentation": "Maximum number of shares that could be issued to settle option contract indexed to equity." } } }, "auth_ref": [ "r166", "r167" ] }, "us-gaap_OptionIndexedToIssuersEquityStrikePrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OptionIndexedToIssuersEquityStrikePrice1", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtCappedCallsWithRespectTo2024ConvertibleNotesAnd2026ConvertibleNotesDetails", "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsCappedCallsDetails" ], "lang": { "en-us": { "role": { "label": "Option Indexed to Issuer's Equity, Strike Price", "terseLabel": "Strike price (in dollars per share)", "documentation": "Exercise or strike price stated in the contract for options indexed to the issuer's equity shares." } } }, "auth_ref": [ "r22", "r24" ] }, "us-gaap_OptionIndexedToIssuersEquityTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OptionIndexedToIssuersEquityTypeDomain", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtCappedCallsWithRespectTo2024ConvertibleNotesAnd2026ConvertibleNotesDetails", "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsCappedCallsDetails" ], "lang": { "en-us": { "role": { "label": "Option Indexed to Issuer's Equity, Type [Domain]", "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding." } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTabularDisclosureDetails": { "parentTag": "irwd_AccruedExpensesAndOtherLiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Other Accrued Liabilities, Current", "terseLabel": "Other", "verboseLabel": "Other accrued expenses", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r94" ] }, "irwd_OtherAccruedLiabilitiesCurrentUninvoicedVendorLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "OtherAccruedLiabilitiesCurrentUninvoicedVendorLiabilities", "crdr": "credit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Other Accrued Liabilities, Current, Uninvoiced Vendor Liabilities", "label": "Other Accrued Liabilities, Current, Uninvoiced Vendor Liabilities", "terseLabel": "Other accrued liabilities, uninvoiced vendor liabilities" } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Assets, Noncurrent", "terseLabel": "Other assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r252" ] }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostsCreditArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostsCreditArisingDuringPeriodNetOfTax", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansOtherComprehensiveIncomeLossDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Tax", "terseLabel": "Prior service (cost)/credit arising during financial year", "documentation": "Amount, after tax, of cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit)." } } }, "auth_ref": [ "r4", "r114", "r547" ] }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0, "order": 2.0 }, "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansOtherComprehensiveIncomeLossDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansOtherComprehensiveIncomeLossDetails", "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent", "negatedLabel": "Defined benefit pension plan", "totalLabel": "Expense (income) recognized in other comprehensive income", "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent." } } }, "auth_ref": [ "r4", "r5", "r16", "r113", "r114", "r163" ] }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent [Abstract]", "terseLabel": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Currency translation adjustment", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity." } } }, "auth_ref": [ "r8", "r16", "r163" ] }, "us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansOtherComprehensiveIncomeLossDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, after Tax", "negatedLabel": "Amortization prior service cost", "documentation": "Amount, after tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan." } } }, "auth_ref": [ "r7", "r114", "r257", "r547" ] }, "irwd_OtherComprehensiveIncomeLossDefinedBenefitPlanGainLossArisingDuringPeriodActuarialGainsLossesDemographicAssumptionsAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "OtherComprehensiveIncomeLossDefinedBenefitPlanGainLossArisingDuringPeriodActuarialGainsLossesDemographicAssumptionsAfterTax", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansOtherComprehensiveIncomeLossDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "documentation": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, Actuarial Gains (Losses), Demographic Assumptions, after Tax", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, Actuarial Gains (Losses), Demographic Assumptions, after Tax", "negatedLabel": "Actuarial (gains)/losses arising from demographic assumption" } } }, "auth_ref": [] }, "irwd_OtherComprehensiveIncomeLossDefinedBenefitPlanGainLossArisingDuringPeriodActuarialGainsLossesFinancialAssumptionsAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "OtherComprehensiveIncomeLossDefinedBenefitPlanGainLossArisingDuringPeriodActuarialGainsLossesFinancialAssumptionsAfterTax", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansOtherComprehensiveIncomeLossDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "documentation": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, Actuarial Gains (Losses), Financial Assumptions, after Tax", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, Actuarial Gains (Losses), Financial Assumptions, after Tax", "negatedLabel": "Actuarial (gains)/losses arising from financial assumptions" } } }, "auth_ref": [] }, "irwd_OtherComprehensiveIncomeLossDefinedBenefitPlanGainLossArisingDuringPeriodActuarialGainsLossesPlanExperienceAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "OtherComprehensiveIncomeLossDefinedBenefitPlanGainLossArisingDuringPeriodActuarialGainsLossesPlanExperienceAfterTax", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansOtherComprehensiveIncomeLossDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "documentation": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, Actuarial Gains (Losses), Plan Experience, after Tax", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, Actuarial Gains (Losses), Plan Experience, after Tax", "negatedLabel": "Actuarial (gains)/losses arising from plan experience" } } }, "auth_ref": [] }, "irwd_OtherComprehensiveIncomeLossDefinedBenefitPlanGainLossArisingDuringPeriodReturnOnPlanAssetsAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "OtherComprehensiveIncomeLossDefinedBenefitPlanGainLossArisingDuringPeriodReturnOnPlanAssetsAfterTax", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansOtherComprehensiveIncomeLossDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "documentation": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, Return on Plan Assets, after Tax", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, Return on Plan Assets, after Tax", "negatedLabel": "Return on plan assets excluding interest income" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other comprehensive income (loss), net of tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r17", "r26", "r259", "r262", "r267", "r303", "r762", "r763", "r768", "r851", "r873", "r1220", "r1221" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "totalLabel": "Total other comprehensive income (loss), net of tax", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r8", "r16", "r163", "r259", "r262", "r303" ] }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansOtherComprehensiveIncomeLossDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, after Tax", "terseLabel": "Amortization of unrecognized actuarial gains/(losses)", "documentation": "Amount, after tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan." } } }, "auth_ref": [ "r7", "r114", "r257", "r547" ] }, "irwd_OtherFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "OtherFinancingCosts", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureDebtInterestExpenseDetails": { "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtInterestExpenseDetails" ], "lang": { "en-us": { "role": { "documentation": "Other Financing Costs", "label": "Other Financing Costs", "terseLabel": "Other financing costs" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Liabilities, Noncurrent", "terseLabel": "Other liabilities", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r100" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfIncomeLoss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r124" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r1148" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r1109", "r1120", "r1130", "r1163" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r1112", "r1123", "r1133", "r1166" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r1112", "r1123", "r1133", "r1166" ] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipAxis", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsNoncontrollingInterestDetails" ], "lang": { "en-us": { "role": { "label": "Ownership [Axis]", "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment." } } }, "auth_ref": [] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipDomain", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsNoncontrollingInterestDetails" ], "lang": { "en-us": { "role": { "label": "Ownership [Domain]", "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment." } } }, "auth_ref": [] }, "us-gaap_ParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ParentMember", "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Parent [Member]", "terseLabel": "Ironwood Pharmaceuticals, Inc. stockholders' equity (deficit)", "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests." } } }, "auth_ref": [] }, "irwd_PatentCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "PatentCostsPolicyTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for patent and related costs.", "label": "Patent Costs [Policy Text Block]", "terseLabel": "Patent Costs" } } }, "auth_ref": [] }, "us-gaap_PatentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PatentsMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPatentCostsDetails" ], "lang": { "en-us": { "role": { "label": "Patents [Member]", "terseLabel": "Patents", "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law." } } }, "auth_ref": [ "r162", "r1253", "r1254", "r1255", "r1256", "r1257", "r1258", "r1259", "r1260" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r1137" ] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "irwd_PaymentMadeForInvestingInCappedCalls": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "PaymentMadeForInvestingInCappedCalls", "crdr": "credit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtCappedCallsWithRespectTo2024ConvertibleNotesAnd2026ConvertibleNotesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of payment made to counterparties to enter in to capped calls.", "label": "Payment Made for Investing in Capped Calls", "terseLabel": "Payment made to enter into Capped Calls" } } }, "auth_ref": [] }, "irwd_PaymentMadeForInvestingInCappedCallsPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "PaymentMadeForInvestingInCappedCallsPremium", "crdr": "credit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtCappedCallsWithRespectTo2024ConvertibleNotesAnd2026ConvertibleNotesDetails" ], "lang": { "en-us": { "role": { "documentation": "Payment Made for Investing in Capped Calls, Premium", "label": "Payment Made for Investing in Capped Calls, Premium", "terseLabel": "Payment made to enter into Capped Calls, premium" } } }, "auth_ref": [] }, "irwd_PaymentMadeForInvestingInCappedCallsTransactionCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "PaymentMadeForInvestingInCappedCallsTransactionCost", "crdr": "credit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtCappedCallsWithRespectTo2024ConvertibleNotesAnd2026ConvertibleNotesDetails" ], "lang": { "en-us": { "role": { "documentation": "Payment Made for Investing in Capped Calls, Transaction Cost", "label": "Payment Made for Investing in Capped Calls, Transaction Cost", "terseLabel": "Payment made to enter into Capped Calls, transaction cost" } } }, "auth_ref": [] }, "us-gaap_PaymentsForHedgeFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForHedgeFinancingActivities", "crdr": "credit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails" ], "lang": { "en-us": { "role": { "label": "Payments for Hedge, Financing Activities", "terseLabel": "Payments for convertible note hedges", "documentation": "The cash outflow for a financial contract that meets the hedge criteria as either cash flow hedge, fair value hedge or hedge of net investment in foreign operations." } } }, "auth_ref": [ "r277", "r1203" ] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Repurchases of common stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r127" ] }, "us-gaap_PaymentsForRestructuring": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRestructuring", "crdr": "credit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureWorkforceReductionAndRestructuringTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Payments for Restructuring", "negatedLabel": "Amounts paid", "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r416", "r1224" ] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments of Debt Issuance Costs", "negatedLabel": "Costs associated with revolving credit facility", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": [ "r33" ] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "negatedLabel": "Taxes paid related to net share settlement of share-based awards", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r272" ] }, "us-gaap_PaymentsToAcquireProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireProductiveAssets", "crdr": "credit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsGeneralInformationDetails" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Productive Assets", "terseLabel": "Aggregate consideration paid", "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets." } } }, "auth_ref": [ "r188", "r1381", "r1382", "r1383" ] }, "irwd_PaymentsToAcquireProductiveAssetsNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "PaymentsToAcquireProductiveAssetsNetOfCashAcquired", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Payments to Acquire Productive Assets, Net of Cash Acquired", "label": "Payments to Acquire Productive Assets, Net of Cash Acquired", "negatedLabel": "Acquisition of VectivBio Holding AG, net of cash acquired" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r126" ] }, "us-gaap_PaymentsToMinorityShareholders": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToMinorityShareholders", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsNoncontrollingInterestDetails", "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to Noncontrolling Interests", "negatedLabel": "Purchase of subsidiary shares from noncontrolling interests", "terseLabel": "Squeeze-out merger, cash paid", "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest." } } }, "auth_ref": [ "r32" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r1147" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r1147" ] }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlans" ], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Text Block]", "terseLabel": "Retirement Plans", "documentation": "The entire disclosure for retirement benefits." } } }, "auth_ref": [ "r503", "r527", "r529", "r535", "r554", "r556", "r557", "r558", "r559", "r560", "r575", "r576", "r577", "r1041" ] }, "us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementPlansPensionsPolicy", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Pension and Other Postretirement Plans, Pensions, Policy [Policy Text Block]", "terseLabel": "Defined Benefit Pension Obligations", "documentation": "Disclosure of accounting policy for pension plans. This accounting policy may address (1) the types of plans sponsored by the entity (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived." } } }, "auth_ref": [ "r13", "r14", "r19", "r65" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r1139" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r1156" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r1149" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r1138" ] }, "irwd_PercentageOfIncreaseInOperatingLeaseRent": { "xbrltype": "percentItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "PercentageOfIncreaseInOperatingLeaseRent", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesSummerStreetLeaseDetails" ], "lang": { "en-us": { "role": { "documentation": "Annual rent escalation in initial lease period and in renewal period.", "label": "Percentage of Increase in Operating Lease Rent", "terseLabel": "Annual rent escalation (as a percent)" } } }, "auth_ref": [] }, "irwd_PerformanceBasedRestrictedStockUnitsAbsoluteTotalShareholderReturnMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "PerformanceBasedRestrictedStockUnitsAbsoluteTotalShareholderReturnMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansPerformanceBasedRsusAssumptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Performance-based Restricted Stock Units, Absolute Total Shareholder Return [Member]", "label": "Performance-based Restricted Stock Units, Absolute Total Shareholder Return [Member]", "terseLabel": "Performance-based Restricted Stock Units, Absolute Total Shareholder Return" } } }, "auth_ref": [] }, "irwd_PerformanceBasedRestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "PerformanceBasedRestrictedStockUnitsMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansPerformanceBasedRsusActivityDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansPerformanceBasedRsusAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansPerformanceBasedRsusAssumptionsDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansPerformanceBasedRsusVestingDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansSummaryOfExpenseRecognizedByShareBasedCompensationArrangementDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTables", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansUnrecognizedShareBasedCompensationDetails", "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerShareComputationDetails", "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerSharePotentiallyDilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Performance-based Restricted Stock Units [Member]", "label": "Performance-based Restricted Stock Units [Member]", "terseLabel": "Performance-based Restricted Stock Units" } } }, "auth_ref": [] }, "irwd_PerformanceBasedRestrictedStockUnitsRelativeTotalShareholderReturnMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "PerformanceBasedRestrictedStockUnitsRelativeTotalShareholderReturnMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansPerformanceBasedRsusAssumptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Performance-based Restricted Stock Units, Relative Total Shareholder Return [Member]", "label": "Performance-based Restricted Stock Units, Relative Total Shareholder Return [Member]", "terseLabel": "Performance-based Restricted Stock Units, Relative Total Shareholder Return" } } }, "auth_ref": [] }, "us-gaap_PlanAssetCategoriesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanAssetCategoriesDomain", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansAllocationOfPlanAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Plan Assets, Category [Domain]", "documentation": "Defined benefit plan asset investment." } } }, "auth_ref": [ "r527", "r528", "r530", "r531", "r532", "r533", "r534", "r535", "r555", "r1039", "r1040", "r1041" ] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansStockBenefitPlansDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1340", "r1341", "r1342", "r1343", "r1344", "r1345", "r1346", "r1347", "r1348", "r1349", "r1350", "r1351", "r1352", "r1353", "r1354", "r1355", "r1356", "r1357", "r1358", "r1359", "r1360", "r1361", "r1362", "r1363", "r1364", "r1365" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansStockBenefitPlansDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1340", "r1341", "r1342", "r1343", "r1344", "r1345", "r1346", "r1347", "r1348", "r1349", "r1350", "r1351", "r1352", "r1353", "r1354", "r1355", "r1356", "r1357", "r1358", "r1359", "r1360", "r1361", "r1362", "r1363", "r1364", "r1365" ] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": [ "r1140" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": [ "r1196" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": [ "r1139" ] }, "us-gaap_PolicyTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyTextBlockAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Policy Text Block [Abstract]", "terseLabel": "Policy Text Blocks" } } }, "auth_ref": [] }, "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract]", "terseLabel": "Preferred stock" } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r104", "r476" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r104", "r927" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": [ "r104", "r476" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r104", "r927", "r946", "r1453", "r1454" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred stock, $0.001 par value, 75,000,000 shares authorized, no shares issued and outstanding", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r104", "r860", "r1059" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1219" ] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "terseLabel": "Reclassifications", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": [ "r1216" ] }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfLongTermDebt", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Long-Term Debt", "verboseLabel": "Net proceed received", "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer." } } }, "auth_ref": [ "r31", "r908" ] }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised", "terseLabel": "Proceeds from exercise of stock options and employee stock purchase plan", "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised." } } }, "auth_ref": [ "r6", "r23" ] }, "us-gaap_ProceedsFromLongTermLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromLongTermLinesOfCredit", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails", "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Long-Term Lines of Credit", "terseLabel": "Proceeds from revolving credit facility", "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer." } } }, "auth_ref": [ "r31" ] }, "us-gaap_ProceedsFromPaymentsToMinorityShareholdersAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromPaymentsToMinorityShareholdersAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsNoncontrollingInterestDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from (Payments to) Noncontrolling Interests [Abstract]", "terseLabel": "Noncontrolling interests" } } }, "auth_ref": [] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsChinaHongKongAndMacauDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsEuropeanAndOtherTerritoriesDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsJapanDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCollaborativeArrangementsRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCommercialEffortsDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaRoyaltyRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsOtherCollaborationAndLicenseAgreementsDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsSummaryDetails" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "documentation": "Information by product and service, or group of similar products and similar services." } } }, "auth_ref": [ "r218", "r219", "r220", "r221", "r222", "r223", "r236", "r365", "r814", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r1000", "r1032", "r1068", "r1070", "r1071", "r1074", "r1075", "r1214", "r1270", "r1271", "r1278", "r1422", "r1424", "r1425", "r1426", "r1427", "r1428", "r1429", "r1430", "r1431", "r1432", "r1433", "r1434", "r1435", "r1436", "r1437", "r1438", "r1439", "r1440", "r1441", "r1442", "r1443", "r1444", "r1445", "r1446", "r1447", "r1448", "r1449", "r1450", "r1451" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsChinaHongKongAndMacauDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsEuropeanAndOtherTerritoriesDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsJapanDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCollaborativeArrangementsRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCommercialEffortsDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaRoyaltyRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsOtherCollaborationAndLicenseAgreementsDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsSummaryDetails" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "documentation": "Product or service, or a group of similar products or similar services." } } }, "auth_ref": [ "r218", "r219", "r220", "r221", "r222", "r223", "r236", "r365", "r814", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r1000", "r1032", "r1068", "r1070", "r1071", "r1074", "r1075", "r1214", "r1270", "r1271", "r1278", "r1422", "r1424", "r1425", "r1426", "r1427", "r1428", "r1429", "r1430", "r1431", "r1432", "r1433", "r1434", "r1435", "r1436", "r1437", "r1438", "r1439", "r1440", "r1441", "r1442", "r1443", "r1444", "r1445", "r1446", "r1447", "r1448", "r1449", "r1450", "r1451" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfIncomeLoss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerShareComputationDetails", "http://www.ironwoodpharma.com/role/DisclosureSelectedQuarterlyFinancialDataUnauditedDetails", "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfIncomeLoss", "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss", "totalLabel": "Net income (loss)", "verboseLabel": "Net income (loss)", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r246", "r258", "r261", "r274", "r283", "r295", "r303", "r306", "r307", "r375", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r693", "r702", "r704", "r707", "r708", "r735", "r760", "r855", "r870", "r912", "r948", "r964", "r965", "r1049", "r1050", "r1085", "r1222", "r1273" ] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosurePropertyAndEquipmentTabularDisclosureDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r11", "r794" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosurePropertyAndEquipment" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r136", "r197", "r200", "r201" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosurePropertyAndEquipmentTabularDisclosureDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosurePropertyAndEquipmentTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment, gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r137", "r250", "r868" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosurePropertyAndEquipmentTabularDisclosureDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r794" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://www.ironwoodpharma.com/role/DisclosurePropertyAndEquipmentTabularDisclosureDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosurePropertyAndEquipmentTabularDisclosureDetails", "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r11", "r794", "r856", "r868", "r1059" ] }, "us-gaap_PropertyPlantAndEquipmentNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNetAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosurePropertyAndEquipmentTabularDisclosureDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Net [Abstract]", "terseLabel": "Property and Equipment" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r11", "r197", "r200", "r866" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosurePropertyAndEquipmentTables", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property and equipment", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r11" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosurePropertyAndEquipmentTabularDisclosureDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r137", "r794" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Estimated useful life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r1137" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r1137" ] }, "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "QuarterlyFinancialInformationDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Quarterly Financial Information Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_QuarterlyFinancialInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "QuarterlyFinancialInformationTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSelectedQuarterlyFinancialDataUnaudited" ], "lang": { "en-us": { "role": { "label": "Quarterly Financial Information [Text Block]", "terseLabel": "Selected Quarterly Financial Data (Unaudited)", "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information." } } }, "auth_ref": [ "r133", "r334" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTimeBasedRsusVestingDetails", "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedContributionRetirementPlansDetails", "http://www.ironwoodpharma.com/role/DisclosureWorkforceReductionAndRestructuringGeneralInformationDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r209", "r211", "r213", "r214", "r216", "r238", "r239", "r425", "r426", "r427", "r428", "r527", "r581", "r618", "r619", "r620", "r632", "r741", "r807", "r808", "r810", "r886", "r888", "r903", "r918", "r919", "r971", "r973", "r975", "r976", "r980", "r996", "r997", "r1024", "r1031", "r1043", "r1053", "r1054", "r1055", "r1056", "r1070", "r1078", "r1265", "r1275", "r1392", "r1409", "r1410", "r1411", "r1412", "r1413" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details", "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTimeBasedRsusVestingDetails", "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedContributionRetirementPlansDetails", "http://www.ironwoodpharma.com/role/DisclosureWorkforceReductionAndRestructuringGeneralInformationDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r209", "r211", "r213", "r214", "r216", "r238", "r239", "r425", "r426", "r427", "r428", "r527", "r581", "r618", "r619", "r620", "r632", "r741", "r807", "r808", "r810", "r886", "r888", "r903", "r918", "r919", "r971", "r973", "r975", "r976", "r980", "r996", "r997", "r1024", "r1031", "r1043", "r1053", "r1054", "r1055", "r1056", "r1070", "r1078", "r1265", "r1275", "r1392", "r1409", "r1410", "r1411", "r1412", "r1413" ] }, "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesUnrecognizedIncomeTaxBenefitsTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits [Roll Forward]", "terseLabel": "Unrecognized income tax benefits", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r1104", "r1115", "r1125", "r1158" ] }, "irwd_ReductionInCompanyWideWorkforceJanuary2025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "ReductionInCompanyWideWorkforceJanuary2025Member", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureWorkforceReductionAndRestructuringGeneralInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Reduction in Company-wide Workforce, January 2025 [Member]", "label": "Reduction in Company-wide Workforce, January 2025 [Member]", "terseLabel": "Reduction in Company-wide Workforce, January 2025" } } }, "auth_ref": [] }, "irwd_ReductionInHeadquarterBasedWorkforceApril2023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "ReductionInHeadquarterBasedWorkforceApril2023Member", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureWorkforceReductionAndRestructuringGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureWorkforceReductionAndRestructuringTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "documentation": "Reduction in Headquarter-based Workforce, April 2023 [Member]", "label": "Reduction in Headquarter-based Workforce, April 2023 [Member]", "terseLabel": "Reduction in Headquarter-based Workforce, April 2023" } } }, "auth_ref": [] }, "irwd_RemainingMilestonePaymentToBeReceivedByCompanyUponAmendmentToLicenseAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "RemainingMilestonePaymentToBeReceivedByCompanyUponAmendmentToLicenseAgreement", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsEuropeanAndOtherTerritoriesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of milestone payment to be received by the company upon amendment to the license agreement.", "label": "Remaining Milestone Payment to be Received by Company upon Amendment to License Agreement", "verboseLabel": "Remaining milestone payment due upon the amendment to the license agreement" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfConvertibleDebt", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Repayments of Convertible Debt", "negatedLabel": "Repayment of 2022 Convertible Notes", "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r128" ] }, "us-gaap_RepaymentsOfLongTermLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLongTermLinesOfCredit", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails", "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Repayments of Long-Term Lines of Credit", "negatedLabel": "Repayments of revolving credit facility", "terseLabel": "Repayments of revolving credit facility", "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer." } } }, "auth_ref": [ "r128" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsAccountsReceivableDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsChinaHongKongAndMacauDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsEuropeanAndOtherTerritoriesDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsJapanDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCollaborativeArrangementsRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCommercialEffortsDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaRoyaltyRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsOtherCollaborationAndLicenseAgreementsDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsSummaryDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsTables", "http://www.ironwoodpharma.com/role/DisclosureLeasesLettersOfCreditDetails", "http://www.ironwoodpharma.com/role/DisclosureLeasesSummerStreetLeaseDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "auth_ref": [ "r234", "r235", "r286", "r287", "r448", "r478", "r802", "r809", "r857", "r1004", "r1005" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfIncomeLoss": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsOtherCollaborationAndLicenseAgreementsDetails", "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense", "terseLabel": "Research and development", "verboseLabel": "Research and development expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r635", "r998", "r1017", "r1414" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsExpensesDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansShareBasedCompensationExpenseAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansShareBasedCompensationExpenseTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development Expense", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Costs", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r634" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r1105", "r1116", "r1126", "r1159" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r1106", "r1117", "r1127", "r1160" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r1113", "r1124", "r1134", "r1167" ] }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCash", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashDetails", "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "label": "Restricted Cash", "terseLabel": "Restricted cash", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r1217", "r1227", "r1415", "r1419" ] }, "us-gaap_RestrictedCashAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashDetails" ], "lang": { "en-us": { "role": { "label": "Restricted Cash [Abstract]", "terseLabel": "Restricted Cash" } } }, "auth_ref": [] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r249" ] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansRestrictedStockAwardsActivityDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansRestrictedStockAwardsAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansRestrictedStockAwardsGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansSummaryOfExpenseRecognizedByShareBasedCompensationArrangementDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansUnrecognizedShareBasedCompensationDetails", "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerShareComputationDetails" ], "lang": { "en-us": { "role": { "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r39" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansPerformanceBasedRsusActivityDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansPerformanceBasedRsusAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansPerformanceBasedRsusAssumptionsDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansPerformanceBasedRsusVestingDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansRestrictedStockUnitsDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansSummaryOfExpenseRecognizedByShareBasedCompensationArrangementDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTables", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTimeBasedRsusActivityDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTimeBasedRsusAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTimeBasedRsusVestingDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansUnrecognizedShareBasedCompensationDetails", "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerShareComputationDetails", "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerSharePotentiallyDilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units (RSUs)", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesAbstract", "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureWorkforceReductionAndRestructuring" ], "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Workforce Reduction and Restructuring", "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled." } } }, "auth_ref": [ "r413", "r414", "r416", "r419", "r424" ] }, "us-gaap_RestructuringAndRelatedCostExpectedCost1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostExpectedCost1", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureWorkforceReductionAndRestructuringGeneralInformationDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring and Related Cost, Expected Cost", "terseLabel": "Restructuring and related cost, expected cost", "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost." } } }, "auth_ref": [ "r415", "r418", "r421", "r423" ] }, "us-gaap_RestructuringAndRelatedCostExpectedCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostExpectedCostAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureWorkforceReductionAndRestructuringGeneralInformationDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring and Related Cost, Expected Cost [Abstract]", "terseLabel": "Restructuring and Related Cost, Expected Cost" } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureWorkforceReductionAndRestructuringGeneralInformationDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent", "terseLabel": "Restructuring and related cost, number of positions eliminated, period percent (as a percent)", "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)." } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedCostPositionsEliminatedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostPositionsEliminatedAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureWorkforceReductionAndRestructuringGeneralInformationDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring and Related Cost, Positions Eliminated [Abstract]", "terseLabel": "Workforce Reduction" } } }, "auth_ref": [] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCharges", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureWorkforceReductionAndRestructuringGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureWorkforceReductionAndRestructuringTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring Charges", "terseLabel": "Restructuring expenses", "verboseLabel": "Charges", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r10", "r420", "r421", "r1266" ] }, "us-gaap_RestructuringChargesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringChargesAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureWorkforceReductionAndRestructuringGeneralInformationDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring Charges [Abstract]", "terseLabel": "Restructuring Expenses" } } }, "auth_ref": [] }, "us-gaap_RestructuringChargesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringChargesMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsExpensesDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansShareBasedCompensationExpenseTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring Charges [Member]", "terseLabel": "Restructuring Charges", "documentation": "Primary financial statement caption in which the reported facts about restructuring charges have been included." } } }, "auth_ref": [ "r139", "r142" ] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveLineItems", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureWorkforceReductionAndRestructuringGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureWorkforceReductionAndRestructuringTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r415", "r416", "r417", "r418", "r421", "r422", "r423" ] }, "irwd_RestructuringExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "RestructuringExpenseBenefit", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfIncomeLoss": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "documentation": "Restructuring Expense (Benefit)", "label": "Restructuring Expense (Benefit)", "terseLabel": "Restructuring" } } }, "auth_ref": [] }, "us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureWorkforceReductionAndRestructuringGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureWorkforceReductionAndRestructuringTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]", "terseLabel": "Restructuring Charges, Statement of Income or Comprehensive Income", "documentation": "Indicates line item in statement of income or comprehensive income that includes restructuring charges." } } }, "auth_ref": [ "r1199", "r1200" ] }, "us-gaap_RestructuringPlanAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringPlanAxis", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureWorkforceReductionAndRestructuringGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureWorkforceReductionAndRestructuringTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring Plan [Axis]", "documentation": "Information by individual restructuring plan." } } }, "auth_ref": [] }, "us-gaap_RestructuringPlanDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringPlanDomain", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureWorkforceReductionAndRestructuringGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureWorkforceReductionAndRestructuringTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring Plan [Domain]", "documentation": "Identification of the individual restructuring plans." } } }, "auth_ref": [] }, "us-gaap_RestructuringReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserve", "crdr": "credit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureWorkforceReductionAndRestructuringTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring Reserve", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period", "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan." } } }, "auth_ref": [ "r416", "r422" ] }, "us-gaap_RestructuringReserveAccrualAdjustment1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveAccrualAdjustment1", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureWorkforceReductionAndRestructuringTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring Reserve, Accrual Adjustment", "terseLabel": "Adjustments", "documentation": "Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability." } } }, "auth_ref": [ "r416", "r422" ] }, "us-gaap_RestructuringReserveCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveCurrent", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTabularDisclosureDetails": { "parentTag": "irwd_AccruedExpensesAndOtherLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring Reserve, Current", "verboseLabel": "Accrued restructuring liabilities", "documentation": "Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset." } } }, "auth_ref": [ "r1218", "r1267", "r1268" ] }, "us-gaap_RestructuringReserveRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveRollForward", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureWorkforceReductionAndRestructuringTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring Reserve [Roll Forward]", "terseLabel": "Workforce Reduction", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_RestructuringSettlementAndImpairmentProvisions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringSettlementAndImpairmentProvisions", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureWorkforceReductionAndRestructuringGeneralInformationDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring, Settlement and Impairment Provisions", "terseLabel": "Restructuring expenses and adjustments, primarily comprised of employee severance, benefits and related costs", "documentation": "Amount of restructuring charges, remediation cost, and asset impairment loss." } } }, "auth_ref": [ "r118" ] }, "us-gaap_RestructuringSettlementAndImpairmentProvisionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringSettlementAndImpairmentProvisionsAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureWorkforceReductionAndRestructuringGeneralInformationDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring, Settlement and Impairment Provisions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCumulativeEffectAdjustmentTabularDisclosureDetails", "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit", "verboseLabel": "Retained earnings", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r108", "r152", "r863", "r896", "r901", "r909", "r928", "r1059" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "terseLabel": "Accumulated deficit", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r242", "r290", "r291", "r292", "r296", "r303", "r305", "r307", "r380", "r386", "r404", "r675", "r676", "r689", "r690", "r691", "r694", "r701", "r702", "r715", "r718", "r719", "r722", "r733", "r775", "r780", "r892", "r894", "r913", "r1453" ] }, "us-gaap_RetirementPlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanNameAxis", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansAllocationOfPlanAssetsDetails", "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansFairValueOfPlanAssetsDetails", "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedContributionRetirementPlansDetails" ], "lang": { "en-us": { "role": { "label": "Retirement Plan Name [Axis]", "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans." } } }, "auth_ref": [ "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r1043", "r1204", "r1280", "r1281", "r1282", "r1283", "r1284", "r1285", "r1286", "r1287", "r1288", "r1289", "r1290", "r1291", "r1292", "r1293", "r1294", "r1295", "r1296", "r1297", "r1298", "r1299", "r1300", "r1301", "r1302", "r1303", "r1304", "r1305", "r1306", "r1307", "r1308", "r1309", "r1310", "r1311", "r1312", "r1313", "r1314", "r1315", "r1316", "r1317", "r1318", "r1319", "r1320", "r1321", "r1322", "r1323", "r1324", "r1325", "r1326", "r1327", "r1328", "r1329", "r1330", "r1331", "r1332", "r1333", "r1334", "r1335", "r1336", "r1337", "r1338", "r1339" ] }, "us-gaap_RetirementPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanNameDomain", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansAllocationOfPlanAssetsDetails", "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansFairValueOfPlanAssetsDetails", "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedContributionRetirementPlansDetails" ], "lang": { "en-us": { "role": { "label": "Retirement Plan Name [Domain]", "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans." } } }, "auth_ref": [ "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r1043", "r1204", "r1280", "r1281", "r1282", "r1283", "r1284", "r1285", "r1286", "r1287", "r1288", "r1289", "r1290", "r1291", "r1292", "r1293", "r1294", "r1295", "r1296", "r1297", "r1298", "r1299", "r1300", "r1301", "r1302", "r1303", "r1304", "r1305", "r1306", "r1307", "r1308", "r1309", "r1310", "r1311", "r1312", "r1313", "r1314", "r1315", "r1316", "r1317", "r1318", "r1319", "r1320", "r1321", "r1322", "r1323", "r1324", "r1325", "r1326", "r1327", "r1328", "r1329", "r1330", "r1331", "r1332", "r1333", "r1334", "r1335", "r1336", "r1337", "r1338", "r1339" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfIncomeLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsChinaHongKongAndMacauDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsEuropeanAndOtherTerritoriesDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsJapanDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCollaborativeArrangementsRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCommercialEffortsDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaRoyaltyRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsOtherCollaborationAndLicenseAgreementsDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsSummaryDetails", "http://www.ironwoodpharma.com/role/DisclosureSelectedQuarterlyFinancialDataUnauditedDetails", "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenue", "verboseLabel": "Total revenues", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r181", "r182", "r333", "r342", "r343", "r357", "r361", "r365", "r367", "r369", "r500", "r501", "r814" ] }, "irwd_RevenueFromContractWithCustomerExcludingAssessedTaxReduction": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "RevenueFromContractWithCustomerExcludingAssessedTaxReduction", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaGeneralInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Revenue from Contract with Customer, Excluding Assessed Tax, Reduction", "label": "Revenue from Contract with Customer, Excluding Assessed Tax, Reduction", "terseLabel": "Revenue, reduction" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer Benchmark [Member]", "terseLabel": "Revenue from Contract with Customer Benchmark", "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r369", "r1205" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r207", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r999" ] }, "us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerProductAndServiceExtensibleList", "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]", "terseLabel": "Revenue from Contract with Customer, Product and Service", "documentation": "Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer." } } }, "auth_ref": [ "r1032" ] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCollaborativeArrangementsRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaRoyaltyRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsSummaryDetails", "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues:" } } }, "auth_ref": [] }, "irwd_RevolvingCreditAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "RevolvingCreditAgreementMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Revolving Credit Agreement [Member]", "label": "Revolving Credit Agreement [Member]", "terseLabel": "Revolving Credit Agreement" } } }, "auth_ref": [] }, "us-gaap_RoyaltyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RoyaltyMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsChinaHongKongAndMacauDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsEuropeanAndOtherTerritoriesDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsJapanDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCollaborativeArrangementsRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaRoyaltyRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsOtherCollaborationAndLicenseAgreementsDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsSummaryDetails" ], "lang": { "en-us": { "role": { "label": "Royalty [Member]", "terseLabel": "Royalty", "documentation": "Money for usage-based right to asset." } } }, "auth_ref": [ "r1279" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r1176" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r1176" ] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesRevenueNetMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" ], "lang": { "en-us": { "role": { "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r369", "r1205" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]", "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": [ "r237", "r308", "r586", "r1201", "r1235" ] }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsAccountsReceivableDetails" ], "lang": { "en-us": { "role": { "label": "Accounts and Financing Receivables [Table]", "documentation": "Disclosure of information about accounts and financing receivables. Includes, but is not limited to, amount of receivable and allowance for credit loss." } } }, "auth_ref": [ "r106", "r112", "r373", "r1247" ] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued expenses and other current liabilities", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]", "documentation": "Disclosure of information about acquired finite-lived intangible asset by major class." } } }, "auth_ref": [ "r392", "r393", "r394", "r396", "r998" ] }, "us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAllocationOfPlanAssetsTableTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Allocation of Plan Assets [Table Text Block]", "terseLabel": "Schedule of the allocation of plan assets", "documentation": "Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans. This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall." } } }, "auth_ref": [ "r156" ] }, "us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of amounts recognized in other comprehensive income", "documentation": "Tabular disclosure of the net gain (loss) and net prior service cost or credit recognized in other comprehensive income (loss) for the period for pension plans and/or other employee benefit plans, and reclassification adjustments of other comprehensive income (loss) for the period, as those amounts, including amortization of the net transition asset or obligation, are recognized as components of net periodic benefit cost." } } }, "auth_ref": [ "r153" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerSharePotentiallyDilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": [ "r39" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerShareTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of potentially dilutive securities that have been excluded from computation of diluted weighted average shares outstanding", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r39" ] }, "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAssumptionsUsedTableTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansTables" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Assumptions [Table Text Block]", "terseLabel": "Schedule of principal assumptions used for the purpose of the actuarial valuations", "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate." } } }, "auth_ref": [ "r549" ] }, "us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Changes in Fair Value of Plan Assets [Table Text Block]", "terseLabel": "Schedule of movements in the fair value of plan assets", "documentation": "Tabular disclosure of the reconciliation of beginning and ending balances of the fair value of plan assets of pension plans and/or other employee benefit plans showing separately, if applicable, the effects during the period attributable to each of the following: actual return on plan assets, foreign currency exchange rate changes, contributions by the employer, contributions by plan participants, benefits paid, business combinations, divestitures, and settlements." } } }, "auth_ref": [ "r155" ] }, "us-gaap_ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Changes in Projected Benefit Obligations [Table Text Block]", "terseLabel": "Schedule of movements in the present value of the defined benefit obligation", "documentation": "Tabular disclosure of the change in the benefit obligation of pension plans and/or other employee benefit plans from the beginning to the end of the period, showing separately, if applicable, the effects of the following: service cost, interest cost, contributions by plan participants, actuarial gains and losses, foreign currency exchange rate changes, benefits paid, plan amendments, business combinations, divestitures, curtailments, settlements, and special and contractual termination benefits." } } }, "auth_ref": [ "r154" ] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsChinaHongKongAndMacauDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsEuropeanAndOtherTerritoriesDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsJapanDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCollaborativeArrangementsRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCommercialEffortsDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaRoyaltyRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsOtherCollaborationAndLicenseAgreementsDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsTables", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r703" ] }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]", "terseLabel": "Summary of expense recognized for share-based compensation arrangements", "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit." } } }, "auth_ref": [ "r68" ] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of the components of the provision for (benefit from) income taxes", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r1373" ] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtTableTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Schedule of outstanding convertible senior notes", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of components of deferred tax assets and liabilities", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r1370" ] }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansAllocationOfPlanAssetsDetails", "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansFairValueOfPlanAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan [Table]", "documentation": "Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r13", "r61", "r62", "r63", "r64" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerShareTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of computation of basic and diluted net loss per common share", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r1237" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Reconciliation of income taxes from continuing operations computed using U.S. federal statutory rate to that reflected in operations", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r646", "r1047", "r1368" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansShareBasedCompensationExpenseAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansShareBasedCompensationExpenseTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r68" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Share-based compensation expense reflected in the condensed consolidated statements of operations", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r68" ] }, "us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfExpectedBenefitPaymentsTableTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Expected Benefit Payments [Table Text Block]", "terseLabel": "Schedule of future expected benefit payments", "documentation": "Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter." } } }, "auth_ref": [ "r157" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of assets and liabilities measured at fair value on a recurring basis", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r1389", "r1390" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesIntangibleAssetsDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPatentCostsDetails" ], "lang": { "en-us": { "role": { "label": "Intangible Asset, Finite-Lived [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset." } } }, "auth_ref": [ "r390", "r397", "r400", "r401", "r402", "r815", "r998", "r1025" ] }, "us-gaap_ScheduleOfGuaranteeObligationsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGuaranteeObligationsTable", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Guarantor Obligation [Table]", "documentation": "Disclosure of information about guarantor obligation by guarantee or group of guarantees. Includes, but is not limited to, nature, terms, origin, and purpose of guarantee, triggering event, maximum exposure, and amount of obligation. Excludes product warranty." } } }, "auth_ref": [ "r429", "r430", "r431", "r432" ] }, "irwd_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignAndComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignAndComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions and the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Income Before Income Tax Domestic and Foreign and Components of Income Tax Expense Benefit [Table Text Block]", "terseLabel": "Schedule of the components of income before income taxes" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "terseLabel": "Schedule of future minimum payments details of debt", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": [ "r12" ] }, "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNetBenefitCostsTableTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Net Benefit Costs [Table Text Block]", "terseLabel": "Schedule of amounts recognized through profit or loss", "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments." } } }, "auth_ref": [ "r158" ] }, "us-gaap_ScheduleOfNetFundedStatusTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNetFundedStatusTableTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Net Funded Status [Table Text Block]", "terseLabel": "Schedule of amounts included in the consolidated statements of financial position", "documentation": "Tabular disclosure of net funded status of pension plans and/or other employee benefit plans." } } }, "auth_ref": [ "r60" ] }, "us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update and Change in Accounting Principle [Table Text Block]", "terseLabel": "Schedule of ASU 2020-06 cumulative-effect adjustment", "documentation": "Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items." } } }, "auth_ref": [ "r37", "r38", "r41", "r42", "r1384" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosurePropertyAndEquipmentTabularDisclosureDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r11", "r794" ] }, "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSelectedQuarterlyFinancialDataUnauditedTables" ], "lang": { "en-us": { "role": { "label": "Quarterly Financial Information [Table Text Block]", "terseLabel": "Selected Quarterly Financial Data (Unaudited)", "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data." } } }, "auth_ref": [ "r190" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureWorkforceReductionAndRestructuringGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureWorkforceReductionAndRestructuringTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring Cost [Table]", "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve." } } }, "auth_ref": [ "r415", "r416", "r417", "r418", "r421", "r422", "r423" ] }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureWorkforceReductionAndRestructuringTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "terseLabel": "Schedule of accrued liabilities activity recorded in connection with the reductions in workforce and related restructuring activities", "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period." } } }, "auth_ref": [ "r52", "r141" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansPerformanceBasedRsusActivityDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansPerformanceBasedRsusAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansPerformanceBasedRsusAssumptionsDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansPerformanceBasedRsusVestingDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansRestrictedStockAwardsActivityDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansRestrictedStockAwardsAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansRestrictedStockAwardsGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansRestrictedStockUnitsDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansStockBenefitPlansDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansStockOptionsGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansSummaryOfExpenseRecognizedByShareBasedCompensationArrangementDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTables", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTimeBasedRsusActivityDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTimeBasedRsusAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTimeBasedRsusVestingDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansUnrecognizedShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r588", "r590", "r593", "r594", "r595", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r617", "r618", "r619", "r620", "r621" ] }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Summary of RSU activity", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [ "r159" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of stock option activity", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r20", "r21", "r159" ] }, "irwd_ScheduleOfShareBasedPaymentAwardPerformanceBasedRestrictedStockUnitsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "ScheduleOfShareBasedPaymentAwardPerformanceBasedRestrictedStockUnitsValuationAssumptionsTableTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of valuation assumptions for performance-based restricted stock units.", "label": "Schedule of Share-based Payment Award, Performance-based Restricted Stock Units, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of weighted-average assumptions used to estimate the fair value of Relative TSR PSUs and Absolute TSR PSUs" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost [Table Text Block]", "terseLabel": "Schedule of unrecognized share-based compensation expense, net of estimated forfeitures by type of awards and weighted-average period", "documentation": "Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r161" ] }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]", "terseLabel": "Summary of changes in the unrecognized tax benefits", "documentation": "Tabular disclosure of the change in unrecognized tax benefits." } } }, "auth_ref": [ "r658", "r1046" ] }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "terseLabel": "Schedule of percentages of revenue and accounts receivable recognized from significant customers", "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth_ref": [ "r43", "r44", "r45", "r46", "r87", "r168" ] }, "us-gaap_SecuredDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredDebtMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureDebtInterestExpenseDetails", "http://www.ironwoodpharma.com/role/DisclosureDebtTables" ], "lang": { "en-us": { "role": { "label": "Secured Debt [Member]", "terseLabel": "Secured Debt", "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets." } } }, "auth_ref": [] }, "irwd_SecuredOvernightFinancingRateSofrAdjustedTermSecuredMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "SecuredOvernightFinancingRateSofrAdjustedTermSecuredMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Secured Overnight Financing Rate (SOFR), Adjusted Term Secured [Member]", "label": "Secured Overnight Financing Rate (SOFR), Adjusted Term Secured [Member]", "terseLabel": "Secured Overnight Financing Rate (SOFR), Adjusted Term Secured" } } }, "auth_ref": [] }, "us-gaap_SecuredOvernightFinancingRateSofrMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredOvernightFinancingRateSofrMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails" ], "lang": { "en-us": { "role": { "label": "Secured Overnight Financing Rate (SOFR) [Member]", "documentation": "Interest rate at which bank can borrow U.S. dollar overnight while posting U.S. Treasury bond as collateral." } } }, "auth_ref": [ "r1385" ] }, "irwd_SecuredOvernightFinancingRateSofrOneMonthAdjustedTermMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "SecuredOvernightFinancingRateSofrOneMonthAdjustedTermMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Secured Overnight Financing Rate (SOFR), One-month Adjusted Term [Member]", "label": "Secured Overnight Financing Rate (SOFR), One-month Adjusted Term [Member]", "terseLabel": "Secured Overnight Financing Rate (SOFR), One-month Adjusted Term" } } }, "auth_ref": [] }, "irwd_SecuredRevolvingCreditFacilityAmendmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "SecuredRevolvingCreditFacilityAmendmentMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Secured Revolving Credit Facility, Amendment [Member]", "label": "Secured Revolving Credit Facility, Amendment [Member]", "terseLabel": "Secured Revolving Credit Facility, Amendment" } } }, "auth_ref": [] }, "irwd_SecuredRevolvingCreditFacilityInitialMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "SecuredRevolvingCreditFacilityInitialMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Secured Revolving Credit Facility, Initial [Member]", "label": "Secured Revolving Credit Facility, Initial [Member]", "terseLabel": "Secured Revolving Credit Facility, Initial" } } }, "auth_ref": [] }, "irwd_SecuredRevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "SecuredRevolvingCreditFacilityMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Secured Revolving Credit Facility [Member]", "label": "Secured Revolving Credit Facility [Member]", "terseLabel": "Secured Revolving Credit Facility" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1087" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r1089" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsEuropeanAndOtherTerritoriesDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCollaborativeArrangementsRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCommercialEffortsDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaRoyaltyRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsSummaryDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "documentation": "Geographical area." } } }, "auth_ref": [ "r210", "r212", "r215", "r217", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r367", "r368", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r915", "r916", "r917", "r972", "r974", "r977", "r981", "r984", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r1001", "r1033", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1072", "r1078", "r1278", "r1422", "r1424", "r1425", "r1427", "r1428", "r1429", "r1430", "r1431", "r1432", "r1433", "r1434", "r1435", "r1436", "r1437", "r1438", "r1439", "r1440", "r1441", "r1442", "r1443", "r1444", "r1445", "r1446", "r1447", "r1448", "r1449", "r1450", "r1451" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSegmentReportingDetails" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]", "terseLabel": "Segment Reporting, CODM, Individual Title and Position or Group Name", "documentation": "Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting." } } }, "auth_ref": [ "r340", "r1016", "r1023" ] }, "us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSegmentReportingDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentInformationDetails" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]", "terseLabel": "Segment information", "verboseLabel": "Segment Reporting" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSegmentReporting" ], "lang": { "en-us": { "role": { "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Reporting", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r184", "r333", "r336", "r337", "r338", "r339", "r341", "r347", "r348", "r349", "r359", "r360", "r361", "r362", "r363", "r365", "r366", "r369", "r1011", "r1014", "r1015", "r1017", "r1019", "r1021", "r1022" ] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment Information", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r364", "r367", "r1012", "r1013", "r1020" ] }, "us-gaap_SelectedQuarterlyFinancialInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SelectedQuarterlyFinancialInformationAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSelectedQuarterlyFinancialDataUnauditedDetails" ], "lang": { "en-us": { "role": { "label": "Selected Quarterly Financial Information [Abstract]", "terseLabel": "Selected Quarterly Financial Data" } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfIncomeLoss": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCommercialEffortsDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPatentCostsDetails", "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r119" ] }, "us-gaap_SellingGeneralAndAdministrativeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpenseAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPatentCostsDetails" ], "lang": { "en-us": { "role": { "label": "Selling, General and Administrative Expense [Abstract]", "terseLabel": "Patent Costs" } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsExpensesDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansShareBasedCompensationExpenseAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansShareBasedCompensationExpenseTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, General and Administrative Expenses", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]", "terseLabel": "Selling, General and Administrative Expenses", "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption." } } }, "auth_ref": [ "r1367" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r9" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansPerformanceBasedRsusVestingDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansRestrictedStockAwardsGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansRestrictedStockUnitsDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansStockBenefitPlansDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansStockOptionsGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTimeBasedRsusVestingDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Additional General Disclosures [Abstract]", "terseLabel": "Stock Benefit Plans" } } }, "auth_ref": [] }, "irwd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansStockBenefitPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the offering period under the equity-based compensation plan.", "label": "Share Based Compensation Arrangement by Share Based Payment Award, Award Offering Period", "terseLabel": "Offering period" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansPerformanceBasedRsusVestingDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansRestrictedStockAwardsGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansStockOptionsGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTimeBasedRsusVestingDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "verboseLabel": "Vesting period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r1044" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansPerformanceBasedRsusAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansRestrictedStockAwardsAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTimeBasedRsusAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]", "terseLabel": "Employee Stock Benefit Plans" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansPerformanceBasedRsusActivityDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansRestrictedStockAwardsActivityDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTimeBasedRsusActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited (in shares)", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r610" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansPerformanceBasedRsusActivityDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansRestrictedStockAwardsActivityDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTimeBasedRsusActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited (in dollars per share)", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r610" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansPerformanceBasedRsusActivityDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansRestrictedStockAwardsActivityDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTimeBasedRsusActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r608" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansPerformanceBasedRsusActivityDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansPerformanceBasedRsusAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansRestrictedStockAwardsActivityDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansRestrictedStockAwardsAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTimeBasedRsusActivityDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTimeBasedRsusAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (in dollars per share)", "verboseLabel": "Weighted-average grant date fair value (in dollars per share)", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r608" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansPerformanceBasedRsusActivityDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansRestrictedStockAwardsActivityDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTimeBasedRsusActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Outstanding at the end of the period (in shares)", "periodStartLabel": "Outstanding at the beginning of the period (in shares)", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r605", "r606" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansPerformanceBasedRsusActivityDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansRestrictedStockAwardsActivityDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTimeBasedRsusActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Number of Shares", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansPerformanceBasedRsusActivityDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansRestrictedStockAwardsActivityDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTimeBasedRsusActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Outstanding at the end of the period (in dollars per share)", "periodStartLabel": "Outstanding at the beginning of the period (in dollars per share)", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r605", "r606" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansPerformanceBasedRsusActivityDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansPerformanceBasedRsusAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansRestrictedStockAwardsActivityDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansRestrictedStockAwardsAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTimeBasedRsusActivityDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTimeBasedRsusAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted-Average Grant Date Fair Value" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansPerformanceBasedRsusActivityDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansRestrictedStockAwardsActivityDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTimeBasedRsusActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested and released (in shares)", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r609" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansPerformanceBasedRsusAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansRestrictedStockAwardsAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTimeBasedRsusAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "terseLabel": "Vested in period, total fair value", "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash." } } }, "auth_ref": [ "r612" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansPerformanceBasedRsusActivityDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansRestrictedStockAwardsActivityDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTimeBasedRsusActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested and released (in dollars per share)", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r609" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansPerformanceBasedRsusAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]", "terseLabel": "Weighted-average assumptions used to estimate fair value" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansPerformanceBasedRsusAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield (as a percent)", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r619" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansPerformanceBasedRsusAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility (as a percent)", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r618" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansPerformanceBasedRsusAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate (as a percent)", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r620" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansPerformanceBasedRsusActivityDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansPerformanceBasedRsusAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansPerformanceBasedRsusAssumptionsDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansPerformanceBasedRsusVestingDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansRestrictedStockAwardsActivityDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansRestrictedStockAwardsAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansRestrictedStockAwardsGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansRestrictedStockUnitsDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansStockBenefitPlansDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansStockOptionsGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansSummaryOfExpenseRecognizedByShareBasedCompensationArrangementDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTables", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTimeBasedRsusActivityDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTimeBasedRsusAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTimeBasedRsusVestingDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansUnrecognizedShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r588", "r590", "r593", "r594", "r595", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r617", "r618", "r619", "r620", "r621" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansStockBenefitPlansDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "terseLabel": "Shares reserved for issuance (in shares)", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r1045" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansStockBenefitPlansDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "terseLabel": "Shares available for future grant (in shares)", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r66" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansStockOptionsActivityDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansStockOptionsTotalIntrinsicValueDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Stock options" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "verboseLabel": "Number of Shares - Exercisable (in shares)", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r599" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "verboseLabel": "Weighted-Average Exercise Price - Exercisable (in dollars per share)", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r599" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansStockOptionsTotalIntrinsicValueDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Total intrinsic value of options exercised", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": [ "r612" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "negatedLabel": "Cancelled (in shares)", "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired." } } }, "auth_ref": [ "r1346" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Cancelled (in dollars per share)", "documentation": "Weighted average price of options that were either forfeited or expired." } } }, "auth_ref": [ "r1346" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value - Outstanding", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r66" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding at the end of the period (in shares)", "periodStartLabel": "Outstanding at the beginning of the period (in shares)", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r597", "r598" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of Shares", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding at the end of the period (in dollars per share)", "periodStartLabel": "Outstanding at the beginning of the period (in dollars per share)", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r597", "r598" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted-Average Exercise Price" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest [Abstract]", "terseLabel": "Vested or expected to vest" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "verboseLabel": "Number of Shares (in shares)", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r613" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "verboseLabel": "Weighted-Average Exercise Price (in dollars per share)", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r613" ] }, "irwd_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdNumberOfAdditionalSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdNumberOfAdditionalSharesAvailableForGrant", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansStockBenefitPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the threshold number of additional shares available for future grant under the equity-based compensation plan.", "label": "Share Based Compensation Arrangement by Share Based Payment Award, Threshold Number of Additional Shares Available for Grant", "terseLabel": "Threshold number of additional shares available for future grant (in shares)" } } }, "auth_ref": [] }, "irwd_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentageOfAdditionalSharesAvailableForGrant": { "xbrltype": "percentItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentageOfAdditionalSharesAvailableForGrant", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansStockBenefitPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the percentage to be used for the threshold number of additional shares available for future grant under the equity-based compensation plan, expressed as a percentage of common stock outstanding on the last day of the immediately preceding fiscal year.", "label": "Share Based Compensation Arrangement by Share Based Payment Award, Threshold Percentage of Additional Shares Available for Grant", "terseLabel": "Percentage for the threshold number of additional shares available for future grant, expressed as percentage of common stock outstanding on the last day of the immediately preceding fiscal year (as a percent)" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansPerformanceBasedRsusActivityDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansPerformanceBasedRsusAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansPerformanceBasedRsusAssumptionsDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansPerformanceBasedRsusVestingDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansRestrictedStockAwardsActivityDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansRestrictedStockAwardsAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansRestrictedStockAwardsGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansRestrictedStockUnitsDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansStockBenefitPlansDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansStockOptionsGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansSummaryOfExpenseRecognizedByShareBasedCompensationArrangementDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTables", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTimeBasedRsusActivityDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTimeBasedRsusAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTimeBasedRsusVestingDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansUnrecognizedShareBasedCompensationDetails", "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerShareComputationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r593", "r594", "r595", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r617", "r618", "r619", "r620", "r621" ] }, "irwd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageCommonStockFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageCommonStockFairValue", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansPerformanceBasedRsusAssumptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the weighted average fair value of common stock.", "label": "Share Based Compensation Arrangements by Share Based Payment Award, Fair Value Assumptions, Weighted Average Common Stock, Fair Value", "terseLabel": "Fair value of common stock (in dollars per share)" } } }, "auth_ref": [] }, "irwd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNumberOfSharesPerOptionExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNumberOfSharesPerOptionExercised", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "documentation": "Right to receive this specified number of shares of common stock per restricted stock unit.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Number Of Shares Per Option Exercised", "terseLabel": "Right to number of shares of common stock per RSU (in shares)" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in dollars per share)", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r602" ] }, "irwd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTerm", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansStockOptionsGeneralInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "The period of time, from the grant date until the time at which the share-based [option] award expires.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options Expiration Term", "terseLabel": "Expiration period" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Policy Text Block]", "terseLabel": "Share-Based Compensation Expense", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r587", "r596", "r615", "r616", "r617", "r618", "r621", "r627", "r628", "r629", "r630" ] }, "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedPaymentArrangementNonemployeeMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansRestrictedStockAwardsGeneralInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonemployee [Member]", "terseLabel": "Share-Based Payment Arrangement, Nonemployee", "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires." } } }, "auth_ref": [ "r588", "r593", "r594", "r595", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r617", "r618", "r619", "r620", "r621" ] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharePrice", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsNoncontrollingInterestDetails" ], "lang": { "en-us": { "role": { "label": "Share Price", "terseLabel": "Share price (in dollars per share)", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "irwd_ShareRepurchasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "ShareRepurchasesPolicyTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for share repurchases.", "label": "Share Repurchases [Policy Text Block]", "terseLabel": "Share Repurchases" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansPerformanceBasedRsusAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r617" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Contractual Life - Exercisable", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r66" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Contractual Life - Outstanding", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r160" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "verboseLabel": "Weighted Average Contractual Life", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r613" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansStockBenefitPlansDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent", "terseLabel": "Purchase price as a percentage of fair market value of a share of common stock on the first or last day of an offering period (as a percent)", "documentation": "Purchase price of common stock expressed as a percentage of its fair value." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsNoncontrollingInterestDetails" ], "lang": { "en-us": { "role": { "label": "Shares, Outstanding", "terseLabel": "Shares outstanding (in shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermLeaseCost", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureLeasesLeaseCostDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesLeaseCostDetails" ], "lang": { "en-us": { "role": { "label": "Short-Term Lease, Cost", "terseLabel": "Short-term lease cost", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": [ "r789", "r1058" ] }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosurePropertyAndEquipmentTabularDisclosureDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Software and Software Development Costs [Member]", "terseLabel": "Software", "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use." } } }, "auth_ref": [] }, "us-gaap_StateAndLocalJurisdictionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StateAndLocalJurisdictionMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails" ], "lang": { "en-us": { "role": { "label": "State and Local Jurisdiction [Member]", "terseLabel": "State", "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax." } } }, "auth_ref": [ "r644" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r17", "r105", "r109", "r110", "r242", "r264", "r265", "r266", "r290", "r291", "r292", "r296", "r303", "r305", "r307", "r335", "r380", "r386", "r404", "r489", "r675", "r676", "r689", "r690", "r691", "r694", "r701", "r702", "r715", "r717", "r718", "r719", "r720", "r722", "r733", "r762", "r764", "r765", "r766", "r767", "r768", "r775", "r780", "r801", "r873", "r892", "r893", "r894", "r913", "r966" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsEuropeanAndOtherTerritoriesDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCollaborativeArrangementsRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCommercialEffortsDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaRoyaltyRevenueDetails", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsSummaryDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "documentation": "Information by geographical components." } } }, "auth_ref": [ "r210", "r212", "r215", "r217", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r367", "r368", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r915", "r916", "r917", "r972", "r974", "r977", "r981", "r984", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r1001", "r1033", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1072", "r1078", "r1278", "r1422", "r1424", "r1425", "r1427", "r1428", "r1429", "r1430", "r1431", "r1432", "r1433", "r1434", "r1435", "r1436", "r1437", "r1438", "r1439", "r1440", "r1441", "r1442", "r1443", "r1444", "r1445", "r1446", "r1447", "r1448", "r1449", "r1450", "r1451" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerShareComputationDetails", "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r290", "r291", "r292", "r335", "r780", "r814", "r906", "r914", "r920", "r921", "r922", "r923", "r924", "r925", "r927", "r930", "r931", "r932", "r933", "r934", "r936", "r937", "r938", "r939", "r941", "r942", "r943", "r944", "r945", "r947", "r949", "r950", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r966", "r1079" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesDue2024AndConvertibleSeniorNotesDue2026Details" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": [ "r237", "r308", "r586", "r1201", "r1202", "r1235" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerShareComputationDetails", "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r290", "r291", "r292", "r335", "r372", "r780", "r814", "r906", "r914", "r920", "r921", "r922", "r923", "r924", "r925", "r927", "r930", "r931", "r932", "r933", "r934", "r936", "r937", "r938", "r939", "r941", "r942", "r943", "r944", "r945", "r947", "r949", "r950", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r966", "r1079" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r1108", "r1119", "r1129", "r1162" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "irwd_StockAwardMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "StockAwardMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansSummaryOfExpenseRecognizedByShareBasedCompensationArrangementDetails" ], "lang": { "en-us": { "role": { "documentation": "Stock Awards [Member]", "label": "Stock Awards [Member]", "terseLabel": "Stock Awards" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of common stock related to share-based awards and employee stock purchase plan (in shares)", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r17", "r104", "r105", "r152" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised (in shares)", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r17", "r104", "r105", "r152", "r602" ] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of common stock related to share-based awards and employee stock purchase plan", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r67", "r104", "r105", "r152" ] }, "irwd_StockOptionExerciseProceedsReceivableInOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "StockOptionExerciseProceedsReceivableInOtherCurrentAssets", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Stock Option Exercise Proceeds Receivable in Other Current Assets", "label": "Stock Option Exercise Proceeds Receivable in Other Current Assets", "terseLabel": "Stock option exercise proceeds receivable in other current assets" } } }, "auth_ref": [] }, "irwd_StockOptionsAndRestrictedStockUnitsAcquireeAcceleratedUponChangeInControlMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "StockOptionsAndRestrictedStockUnitsAcquireeAcceleratedUponChangeInControlMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansSummaryOfExpenseRecognizedByShareBasedCompensationArrangementDetails" ], "lang": { "en-us": { "role": { "documentation": "Stock Options and Restricted Stock Units, Acquiree, Accelerated upon Change in Control [Member]", "label": "Stock Options and Restricted Stock Units, Acquiree, Accelerated upon Change in Control [Member]", "terseLabel": "Stock Options and Restricted Stock Units, Acquiree, Accelerated upon Change in Control" } } }, "auth_ref": [] }, "srt_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureStockholdersEquityStockRepurchaseProgramDetails" ], "lang": { "en-us": { "role": { "label": "Share Repurchase Program, Authorized, Amount", "terseLabel": "Stock repurchase program, authorized amount", "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": [ "r1277" ] }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedAndRetiredDuringPeriodShares", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureStockholdersEquityStockRepurchaseProgramDetails", "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Repurchased and Retired During Period, Shares", "negatedLabel": "Repurchases of common stock (in shares)", "terseLabel": "Common stock repurchased and retired (in shares)", "documentation": "Number of shares that have been repurchased and retired during the period." } } }, "auth_ref": [ "r17", "r104", "r105", "r152" ] }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedAndRetiredDuringPeriodValue", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureStockholdersEquityStockRepurchaseProgramDetails", "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Repurchased and Retired During Period, Value", "negatedLabel": "Repurchases of common stock", "terseLabel": "Common stock repurchased and retired", "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital)." } } }, "auth_ref": [ "r17", "r104", "r105", "r152" ] }, "irwd_StockRepurchasedAndRetiredDuringPeriodWeightedAveragePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "StockRepurchasedAndRetiredDuringPeriodWeightedAveragePrice", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureStockholdersEquityStockRepurchaseProgramDetails" ], "lang": { "en-us": { "role": { "documentation": "Stock Repurchased and Retired During Period, Weighted-average Price", "label": "Stock Repurchased and Retired During Period, Weighted-average Price", "terseLabel": "Common stock repurchased and retired, weighted-average price (in dollars per share)" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent", "totalLabel": "Total stockholders' deficit", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r105", "r109", "r110", "r135", "r929", "r946", "r967", "r968", "r1059", "r1086", "r1229", "r1249", "r1396", "r1453" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent [Abstract]", "terseLabel": "Stockholders' deficit:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r72", "r73", "r77", "r242", "r243", "r265", "r290", "r291", "r292", "r296", "r303", "r305", "r380", "r386", "r404", "r489", "r675", "r676", "r689", "r690", "r691", "r694", "r701", "r702", "r715", "r717", "r718", "r719", "r720", "r722", "r733", "r762", "r764", "r768", "r778", "r801", "r893", "r894", "r911", "r929", "r946", "r967", "r968", "r982", "r1085", "r1229", "r1249", "r1396", "r1453" ] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity [Text Block]", "terseLabel": "Stockholders' Equity", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r148", "r282", "r475", "r477", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r723", "r969", "r970", "r983" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureWorkforceReductionAndRestructuringGeneralInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r769", "r803" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureWorkforceReductionAndRestructuringGeneralInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r769", "r803" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureWorkforceReductionAndRestructuringGeneralInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r769", "r803" ] }, "us-gaap_SubsequentEventsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsPolicyPolicyTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Subsequent Events, Policy [Policy Text Block]", "terseLabel": "Subsequent Events", "documentation": "Disclosure of accounting policy for reporting subsequent events." } } }, "auth_ref": [] }, "irwd_SummerStreetLeaseAndVehicleLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "SummerStreetLeaseAndVehicleLeaseMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesLettersOfCreditDetails" ], "lang": { "en-us": { "role": { "documentation": "Summer Street Lease and Vehicle Lease [Member]", "label": "Summer Street Lease and Vehicle Lease [Member]", "terseLabel": "Summer Street Lease and Vehicle Lease" } } }, "auth_ref": [] }, "irwd_SummerStreetLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "SummerStreetLeaseMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureLeasesSummerStreetLeaseDetails" ], "lang": { "en-us": { "role": { "documentation": "Summer Street Lease [Member]", "label": "Summer Street Lease [Member]", "terseLabel": "Summer Street Lease" } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental cash flow disclosure:" } } }, "auth_ref": [] }, "irwd_SwitzerlandBasicPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "SwitzerlandBasicPlanMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansAllocationOfPlanAssetsDetails", "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansDefinedBenefitRetirementPlansFairValueOfPlanAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Switzerland Basic Plan [Member]", "label": "Switzerland Basic Plan [Member]", "terseLabel": "Switzerland Basic Plan" } } }, "auth_ref": [] }, "us-gaap_TableTextBlock": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TableTextBlock", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables", "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsTables", "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsTables", "http://www.ironwoodpharma.com/role/DisclosureDebtTables", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTables", "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsTables", "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesTables", "http://www.ironwoodpharma.com/role/DisclosureLeasesTables", "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerShareTables", "http://www.ironwoodpharma.com/role/DisclosurePropertyAndEquipmentTables", "http://www.ironwoodpharma.com/role/DisclosureRetirementPlansTables", "http://www.ironwoodpharma.com/role/DisclosureSelectedQuarterlyFinancialDataUnauditedTables", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "http://www.ironwoodpharma.com/role/DisclosureWorkforceReductionAndRestructuringTables" ], "lang": { "en-us": { "role": { "label": "Table Text Block [Abstract]", "terseLabel": "Table Text Blocks" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r1155" ] }, "irwd_TaxCreditCarryforwardAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "TaxCreditCarryforwardAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardsDetails" ], "lang": { "en-us": { "role": { "documentation": "Tax Credit Carryforward [Abstract]", "label": "Tax Credit Carryforward [Abstract]", "terseLabel": "Tax credit carryforward" } } }, "auth_ref": [] }, "us-gaap_TaxCreditCarryforwardAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxCreditCarryforwardAmount", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardsDetails" ], "lang": { "en-us": { "role": { "label": "Tax Credit Carryforward, Amount", "terseLabel": "Tax credit carryforward", "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r672" ] }, "irwd_ThresholdPercentageOfCollateralizedValue": { "xbrltype": "percentItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "ThresholdPercentageOfCollateralizedValue", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsGeneralInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "The percentage of threshold collateralized value.", "label": "Threshold Percentage of Collateralized Value", "verboseLabel": "Threshold percentage of collateralized value (as a percent)" } } }, "auth_ref": [] }, "irwd_TimeBasedRestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "TimeBasedRestrictedStockUnitsMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansSummaryOfExpenseRecognizedByShareBasedCompensationArrangementDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTables", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTimeBasedRsusActivityDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTimeBasedRsusAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansTimeBasedRsusVestingDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansUnrecognizedShareBasedCompensationDetails", "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerShareComputationDetails", "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerSharePotentiallyDilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Time-based Restricted Stock Units [Member]", "label": "Time-based Restricted Stock Units [Member]", "terseLabel": "Time-based Restricted Stock Units" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r1147" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r1154" ] }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable [Policy Text Block]", "terseLabel": "Accounts Receivable", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": [ "r185", "r186", "r187", "r1245", "r1246", "r1248" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r1175" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r1177" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.ironwoodpharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r1178" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [ "r1179" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": [ "r1179" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r1177" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r1177" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r1180" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": [ "r1178" ] }, "us-gaap_TypeOfAdoptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfAdoptionMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCumulativeEffectAdjustmentAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCumulativeEffectAdjustmentTabularDisclosureDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update [Domain]", "documentation": "Amendment to accounting standards." } } }, "auth_ref": [ "r240", "r241", "r242", "r243", "r244", "r245", "r295", "r296", "r297", "r298", "r308", "r370", "r371", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r403", "r404", "r412", "r675", "r676", "r677", "r678", "r679", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r724", "r725", "r726", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r758", "r759", "r772", "r775", "r778", "r796", "r797", "r798", "r799", "r800", "r801", "r816", "r817", "r818", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureCollaborationLicenseAndOtherAgreementsNorthAmericaCommercialEffortsDetails", "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "U.S." } } }, "auth_ref": [] }, "us-gaap_USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USTreasurySecuritiesMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "US Treasury Securities [Member]", "terseLabel": "U.S. Treasury securities", "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)." } } }, "auth_ref": [ "r1008", "r1039", "r1041", "r1051", "r1416" ] }, "us-gaap_UnamortizedDebtIssuanceExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnamortizedDebtIssuanceExpense", "crdr": "debit", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesBalancesDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 1.0 }, "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesFutureMinimumPaymentsDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesBalancesDetails", "http://www.ironwoodpharma.com/role/DisclosureDebtConvertibleSeniorNotesFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Unamortized Debt Issuance Expense", "negatedLabel": "Less: unamortized debt issuance costs", "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset." } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r1174" ] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesUnrecognizedIncomeTaxBenefitsAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesUnrecognizedIncomeTaxBenefitsTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits", "periodEndLabel": "Balance at the end of the period", "periodStartLabel": "Balance at the beginning of the period", "terseLabel": "Unrecognized tax benefits", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r637", "r658", "r1046" ] }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesUnrecognizedIncomeTaxBenefitsTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "negatedLabel": "Decreases for tax positions in prior periods", "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns." } } }, "auth_ref": [ "r659", "r1046" ] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "crdr": "credit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesUnrecognizedIncomeTaxBenefitsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Accrued interest and penalties related to uncertain tax positions", "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return." } } }, "auth_ref": [ "r656", "r1046" ] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesUnrecognizedIncomeTaxBenefitsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued [Abstract]", "terseLabel": "Unrecognized tax benefits" } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense", "crdr": "debit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesUnrecognizedIncomeTaxBenefitsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense", "terseLabel": "Interest and penalties related to uncertain tax positions", "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return." } } }, "auth_ref": [ "r656", "r1046" ] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesUnrecognizedIncomeTaxBenefitsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense [Abstract]", "terseLabel": "Unrecognized tax benefits" } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition", "crdr": "credit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesAcquisitionsDetails", "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesUnrecognizedIncomeTaxBenefitsTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits, Increase Resulting from Acquisition", "terseLabel": "Increases for tax positions assumed in VectivBio Acquisition", "verboseLabel": "Uncertain tax position, increases for acquisitions", "documentation": "Amount of increase in unrecognized tax benefits resulting from acquisitions." } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "crdr": "credit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesUnrecognizedIncomeTaxBenefitsTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "terseLabel": "Increases based on tax positions related to the current period", "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return." } } }, "auth_ref": [ "r660", "r1046" ] }, "irwd_UnrecognizedTaxBenefitsReserveForUncertainTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "UnrecognizedTaxBenefitsReserveForUncertainTaxPositions", "crdr": "credit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesUnrecognizedIncomeTaxBenefitsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Unrecognized Tax Benefits, Reserve for Uncertain Tax Positions", "label": "Unrecognized Tax Benefits, Reserve for Uncertain Tax Positions", "terseLabel": "Reserves for uncertain tax positions recorded in other liabilities" } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "crdr": "credit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesUnrecognizedIncomeTaxBenefitsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Amount of unrecognized tax benefits that, if recognized, would affect effective tax rate", "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate." } } }, "auth_ref": [ "r661", "r1046" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r47", "r48", "r49", "r193", "r195", "r198", "r199" ] }, "us-gaap_ValuationAllowanceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowanceAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesValuationAllowanceDetails" ], "lang": { "en-us": { "role": { "label": "Valuation Allowance [Abstract]", "terseLabel": "Income Taxes" } } }, "auth_ref": [] }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "crdr": "credit", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesValuationAllowanceDetails" ], "lang": { "en-us": { "role": { "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "terseLabel": "(Decrease) increase in valuation allowance", "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset." } } }, "auth_ref": [ "r664" ] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateAxis", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails" ], "lang": { "en-us": { "role": { "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateDomain", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureDebtGeneralInformationDetails" ], "lang": { "en-us": { "role": { "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "irwd_VectivbioAcquisitionRelatedWorkforceReductionsJune2023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "VectivbioAcquisitionRelatedWorkforceReductionsJune2023Member", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureWorkforceReductionAndRestructuringGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureWorkforceReductionAndRestructuringTabularDisclosureDetails" ], "lang": { "en-us": { "role": { "documentation": "VectivBio Acquisition-related Workforce Reductions, June 2023 [Member]", "label": "VectivBio Acquisition-related Workforce Reductions, June 2023 [Member]", "terseLabel": "VectivBio Acquisition-related Workforce Reductions, June 2023" } } }, "auth_ref": [] }, "irwd_VectivbioHoldingAgAndItsSubsidiariesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ironwoodpharma.com/20241231", "localname": "VectivbioHoldingAgAndItsSubsidiariesMember", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsAcquiredInProcessResearchAndDevelopmentDetails", "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsExpensesDetails", "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsGeneralInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsNoncontrollingInterestDetails", "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsTotalConsiderationPaidAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureAcquisitionsTotalConsiderationPaidTabularDisclosureDetails", "http://www.ironwoodpharma.com/role/DisclosureEmployeeStockBenefitPlansShareBasedCompensationExpenseAdditionalInformationDetails", "http://www.ironwoodpharma.com/role/DisclosureIncomeTaxesAcquisitionsDetails" ], "lang": { "en-us": { "role": { "documentation": "VectivBio Holding AG and its Subsidiaries [Member]", "label": "VectivBio Holding AG and its Subsidiaries [Member]", "terseLabel": "VectivBio Holding AG and its subsidiaries" } } }, "auth_ref": [] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": [ "r1143" ] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerShareComputationDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]", "terseLabel": "Effect of dilutive securities:" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerShareComputationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerShareComputationDetails", "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average shares used in computing net income (loss) per share attributable to Ironwood Pharmaceuticals, Inc. stockholders - diluted (in shares)", "totalLabel": "Weighted average number of common shares outstanding used in computing net income (loss) per share - diluted (in shares)", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r312", "r327" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerShareComputationDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerShareComputationDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerShareComputationDetails", "http://www.ironwoodpharma.com/role/StatementConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average shares used in computing net income (loss) per share attributable to Ironwood Pharmaceuticals, Inc. stockholders - basic (in shares)", "verboseLabel": "Weighted average number of common shares outstanding used in computing net income (loss) per share - basic (in shares)", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r310", "r327" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract", "presentation": [ "http://www.ironwoodpharma.com/role/DisclosureNetIncomeLossPerShareComputationDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]", "terseLabel": "Denominator:" } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": [ "r1141" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "13", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(j)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-15" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "30", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481097/715-30-50-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(2)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "80", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-2" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481648/480-10-50-2" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)(2)", "SubTopic": "40", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Subparagraph": "(c)", "Paragraph": "2", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "270", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-12" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "270", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-13" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-13" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-14" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "55", "Paragraph": "63", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-63" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "70", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-21" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "40", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-4" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "40", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "270", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/270/tableOfContent" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "460", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/460/tableOfContent" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Subparagraph": "(a)", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Subparagraph": "(b)", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Subparagraph": "(d)(5)", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Subparagraph": "(f)", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Subparagraph": "(h)", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(i)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-3" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r175": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r176": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r177": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r178": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r179": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r180": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r181": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r182": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r183": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r184": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r185": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B" }, "r186": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-15" }, "r187": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-6" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "326", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-3" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "326", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-3" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/808/tableOfContent" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column C", "Footnote": "5", "Publisher": "SEC" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column C", "Footnote": "4", "Publisher": "SEC" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(a)", "Footnote": "4", "Publisher": "SEC" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(b)", "Footnote": "4", "Publisher": "SEC" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column C", "Footnote": "2", "Publisher": "SEC" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column F", "Footnote": "7", "Publisher": "SEC" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column A", "Publisher": "SEC" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column B", "Publisher": "SEC" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column C", "Publisher": "SEC" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column D", "Publisher": "SEC" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column E", "Publisher": "SEC" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column F", "Publisher": "SEC" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column B", "Publisher": "SEC" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column C", "Publisher": "SEC" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column D", "Publisher": "SEC" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column E", "Publisher": "SEC" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column F", "Publisher": "SEC" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column G", "Publisher": "SEC" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column H", "Publisher": "SEC" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column I", "Publisher": "SEC" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Paragraph": "Column A", "Footnote": "4", "Publisher": "SEC" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "4", "Subsection": "08", "Paragraph": "m", "Subparagraph": "(1)(iii)", "Publisher": "SEC" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "4", "Subsection": "08", "Paragraph": "m", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 11", "Section": "L", "Publisher": "SEC" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 11", "Section": "M", "Paragraph": "Question 2", "Publisher": "SEC" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 4", "Publisher": "SEC" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-17A" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-27" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(n))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-6" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-42" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1B" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "36", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-2" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/420/tableOfContent" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/715/tableOfContent" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-3A" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(10)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(9)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(o)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(p)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-8" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.1.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-5" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/830/tableOfContent" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r802": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r807": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r808": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r810": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r811": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1" }, "r812": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1" }, "r813": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-4" }, "r814": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r815": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r816": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r817": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r818": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r819": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r820": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r821": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r822": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r823": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r824": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r825": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r826": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r827": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r828": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r829": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r830": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r831": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r832": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r833": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r834": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r835": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r836": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r837": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r838": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r839": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r840": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r841": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r842": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r843": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r844": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r845": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r846": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r847": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r848": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r849": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r850": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r851": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r852": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r853": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r854": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r855": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r856": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r857": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r858": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r859": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r860": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r861": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r862": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r863": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r864": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r865": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r866": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r867": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r868": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r869": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r870": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r871": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r872": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r873": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r874": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r875": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r876": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r877": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r878": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r879": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r880": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r881": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r882": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r883": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r884": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r885": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r886": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r887": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r888": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r889": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r890": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r891": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r892": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r893": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r894": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r895": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r896": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r897": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r898": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r899": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r900": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r901": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r902": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r903": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r904": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r905": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3" }, "r906": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r907": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r908": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r909": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r910": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r911": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r912": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r913": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r914": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r915": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r916": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r917": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r918": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r919": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r920": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r921": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r922": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r923": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r924": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r925": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r926": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r927": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r928": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r929": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r930": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r931": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r932": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r933": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r934": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r935": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r936": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r937": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r938": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r939": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r940": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r941": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r942": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r943": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r944": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r945": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r946": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r947": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r948": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r949": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r950": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r951": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r952": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r953": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r954": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r955": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r956": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r957": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r958": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r959": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r960": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r961": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r962": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r963": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r964": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r965": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r966": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r967": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r968": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r969": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r970": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r971": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r972": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r973": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r974": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r975": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r976": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r977": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r978": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r979": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r980": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r981": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r982": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3" }, "r983": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r984": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r985": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479196/954-310-45-1" }, "r986": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r987": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r988": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r989": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r990": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r991": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r992": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r993": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r994": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r995": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r996": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r997": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r998": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r999": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r1000": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r1001": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r1002": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r1003": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r1004": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r1005": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r1006": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r1007": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r1008": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1009": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r1010": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r1011": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1012": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1013": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1014": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1015": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1016": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1017": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r1018": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r1019": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r1020": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r1021": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r1022": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r1023": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r1024": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r1025": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r1026": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1027": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r1028": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r1029": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r1030": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r1031": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r1032": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1033": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1034": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1035": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1036": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1037": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1038": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1039": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1040": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1041": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r1042": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-18" }, "r1043": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r1044": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1045": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1046": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "217", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217" }, "r1047": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r1048": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479908/805-50-55-1" }, "r1049": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r1050": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r1051": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r1052": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r1053": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r1054": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1055": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1056": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1057": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r1058": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r1059": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r1060": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r1061": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r1062": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r1063": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r1064": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r1065": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r1066": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r1067": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r1068": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r1069": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r1070": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r1071": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1072": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1073": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1074": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r1075": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r1076": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r1077": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1078": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r1079": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r1080": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1081": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1082": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1083": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1084": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r1085": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r1086": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r1087": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1088": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r1089": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r1090": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r1091": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r1092": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r1093": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K" }, "r1094": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1" }, "r1095": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r1096": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r1097": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r1098": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "2" }, "r1099": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "1" }, "r1100": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2" }, "r1101": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r1102": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "ii" }, "r1103": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "iii" }, "r1104": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r1105": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r1106": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r1107": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r1108": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r1109": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r1110": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r1111": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r1112": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r1113": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r1114": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r1115": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r1116": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r1117": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r1118": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r1119": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r1120": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r1121": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r1122": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r1123": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r1124": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r1125": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r1126": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r1127": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r1128": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r1129": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r1130": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r1131": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r1132": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r1133": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r1134": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r1135": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r1136": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r1137": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r1138": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r1139": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r1140": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r1141": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r1142": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r1143": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r1144": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r1145": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r1146": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r1147": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r1148": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r1149": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r1150": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r1151": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r1152": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r1153": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r1154": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r1155": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r1156": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r1157": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r1158": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r1159": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r1160": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r1161": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r1162": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r1163": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r1164": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r1165": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r1166": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r1167": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r1168": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r1169": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r1170": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r1171": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r1172": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r1173": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r1174": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r1175": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r1176": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r1177": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r1178": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r1179": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r1180": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r1181": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r1182": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106" }, "r1183": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1" }, "r1184": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r1185": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r1186": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r1187": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "2" }, "r1188": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "1" }, "r1189": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2" }, "r1190": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r1191": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "ii" }, "r1192": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "iii" }, "r1193": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r1194": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r1195": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r1196": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r1197": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r1198": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r1199": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r1200": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r1201": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r1202": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r1203": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r1204": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1205": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r1206": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r1207": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r1208": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r1209": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r1210": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column A", "Subparagraph": "(ii)", "Footnote": "2", "Publisher": "SEC" }, "r1211": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r1212": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(b)", "Footnote": "1", "Publisher": "SEC" }, "r1213": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r1214": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r1215": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r1216": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1" }, "r1217": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1218": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1219": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1220": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r1221": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r1222": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r1223": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1224": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r1225": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1226": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1227": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r1228": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1229": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1230": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1231": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r1232": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r1233": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r1234": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-6" }, "r1235": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r1236": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r1237": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r1238": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r1239": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r1240": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r1241": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1242": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1243": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1244": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r1245": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r1246": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r1247": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "40", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481628/310-20-40-7" }, "r1248": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1" }, "r1249": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1250": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r1251": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r1252": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r1253": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r1254": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1255": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1256": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1257": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1258": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1259": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1260": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1261": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r1262": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1263": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1264": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1265": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1266": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3" }, "r1267": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r1268": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r1269": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r1270": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1271": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r1272": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r1273": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1274": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1275": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1276": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r1277": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r1278": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r1279": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1280": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1281": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1282": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(10)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1283": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1284": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1285": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1286": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1287": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1288": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1289": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1290": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(9)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1291": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1292": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1293": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1294": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1295": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1296": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1297": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1298": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1299": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1300": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1301": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1302": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1303": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1304": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1305": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1306": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1307": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1308": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1309": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1310": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1311": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1312": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1313": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1314": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1315": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1316": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1317": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1318": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1319": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1320": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1321": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1322": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1323": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1324": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1325": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1326": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1327": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2" }, "r1328": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r1329": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r1330": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1331": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1332": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1333": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1334": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1335": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1336": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1337": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1338": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1339": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-8" }, "r1340": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1341": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1342": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1343": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1344": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1345": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1346": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1347": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1348": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1349": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1350": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1351": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1352": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1353": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1354": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1355": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1356": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1357": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1358": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1359": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1360": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1361": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1362": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1363": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1364": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1365": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1366": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1367": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "SubTopic": "35", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1" }, "r1368": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r1369": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r1370": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r1371": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r1372": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6" }, "r1373": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r1374": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r1375": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r1376": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r1377": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r1378": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r1379": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r1380": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3" }, "r1381": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1" }, "r1382": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1" }, "r1383": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2" }, "r1384": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r1385": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480682/815-20-25-6A" }, "r1386": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1387": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1388": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1389": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1390": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1391": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1392": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1393": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1394": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1395": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r1396": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1397": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1398": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r1399": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1400": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r1401": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1402": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1403": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r1404": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r1405": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r1406": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1407": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1408": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1409": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1410": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1411": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1412": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1413": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1414": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r1415": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r1416": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r1417": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1418": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1419": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1420": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1421": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1422": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1423": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1424": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1425": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1426": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1427": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1428": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1429": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1430": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1431": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1432": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1433": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1434": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1435": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1436": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1437": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1438": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1439": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1440": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1441": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1442": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1443": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1444": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1445": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1446": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1447": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1448": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1449": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1450": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1451": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1452": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1453": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1454": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1455": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1456": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1457": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1458": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" } } }